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ABSTRACT 
 In the brain, chemical signaling molecules transfer information from cell-to-cell to 
modulate mood, behavior, and physiological functions like metabolism and circadian rhythm. 
The research presented in this dissertation is focused on characterizing a specific class of 
signaling molecules, endogenous signaling peptides. Despite being gene products, this class of 
signaling molecules is complex and diverse. Cell to cell signaling peptides are differentially 
processed, modified, and distributed depending on time and spatial location. The detection of the 
peptide complement in a biological sample is an analytical challenge due to the broad range of 
concentrations and diverse chemical properties of endogenous peptides. The presence of other 
classes of molecules, like salts and lipids, add to sample complexity and further complicates the 
characterization of signaling peptides. 
 The ability to characterize endogenous peptides is dependent on the selection of 
appropriate, information-rich tools. In this dissertation, a set of mass spectrometry approaches 
coupled with optimized liquid chromatography separations and appropriate sample preparation 
were successfully utilized to measure chemical information for peptides in biological samples. 
Multiple MS platforms, each with distinct advantages and limitations, were utilized for 
identification and quantitation. To gain insight into the role of signaling peptides in a specific 
behavior, relative quantitation measurements with MS were performed in a non-targeted 
approach. Specifically, measurements were made for peptide level changes in the hippocampus 
and amygdala of mice to study the extinction of conditioned place preference (CPP) for cocaine 
in mice that have access to a running wheel after CPP training. MS measurements have yielded 
both known and novel candidate peptides that show relative abundance changes with exercise 
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and context re-exposure, which yields insight into the biochemical mechanisms driving the 
observed extinguishment of CPP with running.  
Successful MS measurements of endogenous peptide measurements are dependent on 
appropriate and optimized sample preparation procedures. An optimized sampling procedure was 
developed and applied to detect the novel peptide alarin in the supernatant of a transfected cell 
line. While a synthetic version of the peptide spiked into the medium was detected by MS, the 
endogenous form of the peptide expressed by the cell line could not be unambiguously 
identified. Additionally, MS measurements were employed to evaluate the effects of different 
sample handling treatments on the detection of peptides in the mouse striatum and hypothalamus. 
The results of this preliminary study indicate for the sample treatments used, each has its 
limitations and the selection of an appropriate sample treatment in biological studies is 
dependent on the study goals and resources. 
 This demonstrates the capabilities of mass spectrometric approaches to investigate 
peptide identities and dynamics, which can be utilized to enhance our understanding of the role 
of peptides in cell-to-cell signaling in the nervous system.  
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CHAPTER 1 
INTRODUCTION AND THESIS OVERVIEW 
 
1.1 Motivation 
 Despite significant research on the subject, the human brain remains one of big mysteries 
in science and to understand it is one of the greatest challenges in medicine. Contributing to its 
complexity is the complex brain connectome, where individual neurons in the brain can have 
connections with many other neurons and different cell types that number from hundreds to 
thousands. One way to ease the analysis of neural circuitry and communication is to use 
simplified models to measure isolated aspects. While connections are important, the sea of 
chemicals bathing the neurons also changes their properties. Of particular interest are the 
extracellular molecules involved in cell-to-cell communication. A diverse set of cell to cell 
signaling molecules is used in the brain to transfer information from cell to cell, globally change 
the properties of cells, and by these actions, modulate mood, behavior, and physiological state. In 
the Sweedler laboratory, a suite of analytical tools have been developed and utilized to measure 
spatial, temporal, and chemical information for signaling molecules and deduce their roles in 
different biological functions or behaviors. The analytical tools employed include mass 
spectrometry, electrophysiology, nuclear magnetic resonance spectroscopy, fluorescence, and 
separations. Studies of numerous neurochemical pathways have been performed in a variety of 
model organisms ranging in complexity from single cells1, 2 to invertebrates3-6 to the mammalian 
nervous system.7-9  
 The research presented in this dissertation is focused on the characterization of a 
particular class of biomolecules known as cell to cell signaling peptides. For structural 
 2 
 
identification and relative quantitation measurements of endogenous peptides in a variety of 
samples, mass spectrometry approaches were selected, evaluated, and applied. Multiple 
instruments and sampling approaches were utilized to answer fundamental questions about the 
presence, processing, and dynamics of cell to cell signaling peptides in the central nervous 
system.  
 
1.2 Target Molecule: Endogenous Signaling Peptides 
 Signaling peptides are small protein derived molecules that act as cell-to-cell signaling 
molecules in the brain and spinal cord, and are the most complicated class of signaling 
molecules. As signaling molecules, they integrate the functions of the brain with the systems of 
the body and can act as neurohormones, neurotransmitters, or neuromodulators.10 To improve 
understanding of specific functions and behaviors, it is important to be able to detect and identify 
signaling peptides in the appropriate brain regions. The detection of these molecules in the brain 
presents a unique analytical challenge due to their low endogenous concentrations, broad 
dynamic range, and diverse chemical properties.11 Even with the large amounts of genetic 
information that is being generated by sequencing technologies, the bioactive form of a signaling 
peptide is difficult to predict. With classical signaling peptides, often referred to as neuropeptides 
and hormones, bioactive peptides are generated by enzymatic cleavages of larger precursor 
molecules known as prohormones and after cleavage, may undergo a variety of post-translational 
modifications (PTMs), as diagramed in Figure 1.1.12, 13 PTMs can be difficult to predict from 
genomic information alone, but are an essential element for peptide function as the inclusion of 
PTMs can provide resistance to enzyme degradation and regulate the binding affinity to 
receptors.14 Non-classical signaling peptides derived from non-prohormone proteins have also 
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been uncovered.15 As the enzymes present and prohormone processing is specific to a particular 
brain region, structural elucidation for the final bioactive product requires measurement an 
information rich approach, like mass spectrometry (MS).11 The MS-based sub-discipline that 
focuses on the comprehensive analysis of the peptide content of an organism, tissue, or cell is 
referred to as peptidomics.14, 16, 17 
 
1.3 Instrumentation: Mass Spectrometry 
Mass spectrometry (MS) is a measurement tool that measures the mass-to-charge ratio 
(m/z) of ions in the gas phase. For a wide range of compounds, MS can provide information 
about molecular weight, elemental composition, and structural information. MS has been utilized 
in the study of peptides to measure chemical information that does not require pre-selection of a 
target molecule and is capable of analyzing the composition of a complex sample. The three 
main components of a mass spectrometer are the ion source, mass analyzer, and detector. The 
detector works by transforming signals from ions into electrical signal that can be processed as a 
current or voltage by a computer. The different ion sources and mass analyzers used in the 
studies included in this dissertation are described in detail below. The selection of the 
appropriate instrumental platform is sample and study dependent. Therefore, included in the 
descriptions below are the advantages and limitations of the different MS components and the 
considerations that are important for a successful peptidomics experiment.  
1.3.1 Ion Sources 
 The ion source is the starting point in mass spectrometric analysis where gaseous analyte 
ions are formed. The application of mass spectrometry to thermally delicate biochemical species 
became viable with the introduction of “soft” ionization sources in the late 1980s. In the studies 
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presented in this dissertation, two types of these soft ionization sources were used: matrix-
assisted laser desorption/ionization (MALDI) and electrospray ionization (ESI). The first 
ionization technique, MALDI, was first described nearly simultaneously in 1988 by two research 
groups.18, 19 For MALDI, the analyte is mixed with an organic matrix, which strongly absorbs 
ultraviolet (UV) radiation and the mixture is deposited on a metal plate. Common MALDI 
matrices for studying peptides and proteins include α-cyano-4-hydroxy cinnamic acid (CHCA), 
2.5-dihydroxybenzoic acid (DHB), and sinapinic acid (SA). The sample plate is placed in a 
vacuum chamber and irradiated with a pulsed UV laser beam. When irradiated with the laser 
beam, the matrix and analyte are desorbed and ionized, creating an ion plume that is directed into 
the mass analyzer. In MALDI, charge can be imparted to the analyte through protonation, 
deprotonation, or the formation of adducts.  
The second ionization technique utilized in the studies presented in this dissertation is 
ESI. Developed around the same time as MALDI, ESI was described by Fenn and co-workers in 
1989.20 Rather than being mixed with an organic matrix, the analyte is dissolved in liquid 
solution, typically water mixed with volatile organic compounds, such as acetonitrile or 
methanol. The liquid is forced through a capillary, to which a high voltage is applied and as the 
solution exits the tip of the charged capillary, coloumbic repulsion forces the solution into small 
droplets. A dry gas is then used to aid in the evaporation of the solvent molecules and charge is 
transferred to the analyte of interest. Electric field differences then direct the ions into the mass 
spectrometer. Multiply charged ions are often observed with ESI, with the number of charges 
dependent on the chemical properties of the analyte as well as the solvent used. Peptides and 
proteins are typically dissolved in acidic, aqueous solutions and the acidic conditions lead to the 
protonation of all available basic sites (the N-terminal amine group and basic side groups of 
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lysine, arginine, and histidine residues). Since it is a continuous ionization technique, ESI is 
readily coupled to separation techniques like liquid chromatography (LC) or capillary 
electrophoresis for direct sample introduction.  
Sensitivity enhancements with electrospray ionization can be made by reducing the 
diameter of the spray needle and lowering the flow rate. A variant of ESI, termed nanospray 
ionization, uses a typical flow rate of 20 nL/min through a 5µm inner diameter needle to yield 
sensitivity enhancements of up to 500-fold compared to conventional ESI.21 Fewer ions are being 
ionized simultaneously and therefore, more are being detected by the mass spectrometer. The 
primary disadvantages of nanospray ionization are difficulties in set-up, maintenance, and a lack 
of robustness and reproducibility. In most nanospray sources, a microscope and XYZ stage is 
needed to manipulate and align the needle with the MS source, making conditions difficult to 
reproduce across experiments. Additionally, the small dimensions of the spray needle make it 
more susceptible to clogs and less robust than conventional spray needles. Our experiments 
utilized a variant of low-flow electrospray, termed captive spray ionization, which operates at 
flow rates of 250 nL/min to 50 μL/min, which are between those used for nanospray and ESI. 
Captive spray ionization is designed to enhance sensitivity by using the vacuum of MS to pull in 
gas around the spray tip to desolvate and funnel ions to the MS interface.22, 23 The commercial 
CaptiveSpray source produced by Bruker (Bremen, Germany) is a plug-and-play design that 
connects directly to the MS inlet capillary, eliminating the need for the XYZ adjustable stages to 
align the sprayer commonly seen with nanospray sources. A schematic of the commercial source 
is included in Figure 1.2. The easy and consistent set-up makes the Captivespray source an 
important component for reproducible MS analysis for quantitative measurements. 
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While both MALDI and ESI are used in peptidomic experiments, each has distinct 
advantages and disadvantages. An advantage of MALDI when analyzing biological samples is 
the high tolerance for contaminants, such as salts and detergents. Salts and detergents can 
interfere with the spraying process and impact the ions produced with ESI. Its tolerance for some 
contaminants allows MALDI to be utilized for the direct analysis of tissue extracts without extra 
sample processing or LC separation. In addition, MALDI is fast and utilizes only a small portion 
of the sample, allowing for re-analysis of the sample as needed. In contrast to ESI, MALDI 
typically produces singly charged ions, which eases the interpretation of spectra from complex 
samples. There are limitations that must be considered when utilizing MALDI compared to ESI 
to study peptides in complex biological samples. First, MALDI is susceptible to signal 
suppression due to competition among analytes for charge and certain high-abundance analytes 
being ionized more easily. Signal suppression is a real concern in highly complex samples, 
where abundant analytes can generate intense MS signals and overwhelm the signals of low 
concentration analytes. The signal suppression seen with MALDI is less prominent in ESI and 
reduced further with LC separation prior to ionization. Another consideration with MALDI 
analysis of peptides is that the quality of the MS spectra can be significantly influenced by the 
sample-matrix preparation procedures, which should be optimized and controlled to get 
reproducible results.24 ESI is not dependent on crystallization and is more reproducible. A third 
limitation for MALDI, but not ESI, that must be considered is that small molecular weight 
compounds are difficult to characterize in MALDI due to the interference of matrix ions.  
1.3.2 Mass Analyzers 
The mass analyzer is the component of the mass spectrometer that measures the m/z ratio 
of ions by separating the ions in time or space. Each mass analyzer has distinct advantages in 
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terms of scan speed, sensitivity, resolution, and mass accuracy. Three mass analyzer 
configurations were utilized in the experiments described in this dissertation. a time-of-flight 
(TOF) analyzer, an ion trap (IT) analyzer, and a hybrid quadrupole-time-of-flight (QTOF) 
analyzer.  
Mass analyzers can be separated into two classes: beam type analyzers or trapping 
analyzers. The TOF and QTOF used in our experiments are beam type mass analyzers. The TOF 
mass analyzer separates ions in space by initially imparting a set amount of kinetic energy to ions 
by accelerating them through an electric field and allowing them to travel a set distance in a 
field-free region, referred to as the flight tube. In the field-free region, the ion travels at a 
velocity that is inversely proportional to its m/z. The instrument measures how long it takes a 
particular ion to traverse the length of the flight tube and from that, calculates its velocity and 
ultimately, m/z. In principle, this mass analyzer has an unlimited m/z range. To control for the 
variation in initial velocities of ions imparted by the vaporization and ionization process and 
improve mass resolution, a reflectron is used to focus ions with the same m/z but different 
velocities and reflect them back along the original flight path, effectively creating a longer flight 
tube.25 Since analysis requires ions be introduced in pulses, TOF analyzers are well suited for use 
with MALDI. In the QTOF instrument, ions pass through a quadrupole analyzer before being 
accelerated into the flight tube of the orthogonal TOF analyzer. The operating principle behind 
the quadrupole analyzer is to apply radiofrequency (rf) and direct current (dc) voltages to the 
rods of the quadrupole to create an electric field gradient through which only select m/z will pass. 
With the QTOF instrument, the quadrupole acts as a focusing device in MS mode and it is used 
to select ions for fragmentation in tandem MS mode.  
 8 
 
 While there are a few types of trapping mass analyzers, the analyzer in our instrument is 
a 3D quadrupole IT. This analyzer works by selectively trapping ions by applying rf and dc 
voltages to a set of electrodes to create a potential well. The trapped ions are then released by 
changing the applied potentials. Compared to the TOF mass analyzer, the ion trap has a 
relatively low mass accuracy and low resolution. However, the IT has high sensitivity and is an 
excellent platform for performing tandem MS.  
1.3.3 Tandem MS Fragmentation 
In tandem MS or MS/MS, a select ion (or ions) of interest is subjected to fragmentation 
prior to mass analysis. Tandem MS is an invaluable tool for determining the primary structure 
(amino acid sequence) of a peptide and its PTMs. The peptide backbone can fragment at multiple 
sites: Cα-C, N-C, or N- Cα, which creates six types of fragment ions. Series of ions are created by 
fragmentation along the length of the peptide and labeled by whether the charge is retained at the 
N- or C-terminal. The fragmentation nomenclature depicted in Figure 1.3 is used to designate 
where the peptide backbone was cleaved. The mass difference between consecutive ions in a 
series is used to determine consecutive amino acid identities, except for the isobaric residues 
leucine and isoleucine, in the peptide sequence. Two dissociation mechanisms were utilized for 
peptide fragmentation and sequencing in this dissertation, collision induced dissociation (CID) 
and electron-transfer dissociation (ETD). 
In CID, an ion (termed the parent ion), after mass selection, is accelerated into multiple 
collisions with inert gas atoms (e.g., He, Ar) in the collision cell. The kinetic energy of those 
collisions is transformed into vibrational energy in the peptide ion and is released through 
fragmentation events. In low energy CID (below 100 eV), used in our QTOF and IT instruments, 
fragmentation occurs at the peptide bond linking amino acids to create b and y series ions and 
 9 
 
small neutral losses.26 In ETD, rather than collide with an inert gas atom, fragmentation is 
induced by transferring electrons to charged peptide ions. In our IT instrument, radical anions of 
fluoranthene are generated by chemical ionization and introduced into the IT, where the electron 
transfer to the peptide ions occurs in the gas phase. The addition of an electron destabilizes the 
peptide ion and fragmentation occurs between the N-Cα bond to create c and z series ions. ETD 
is a gentler fragmentation method and works well for sequencing large, highly charged peptides 
and for the identification of weakly bonded post-translation modifications.27, 28 
 
1.4 Instrumentation: Liquid Chromatography 
 The complexity of biological samples and the wide dynamic range of peptides complicate 
peptidomic investigations. While direct analysis of samples with MS is possible, fractionation 
via liquid chromatography (LC) is often used prior to MS detection to enhance the 
characterization of peptides in complex biological samples. LC separations are accomplished 
through partitioning of analytes between mobile (liquid) and stationary phases. In the studies 
presented in this dissertation, reverse phase (RP) LC separations were used to separate analytes 
based on hydrophobicity and reduce the complexity of peptide extracts from tissue samples and 
cell culture medium. RPLC is often employed for separations with biological samples because 
the sample solution and mobile phase are aqueous. Endogenous peptides are typically 
hydrophilic in nature, which makes them soluble in water, but they are also hydrophobic enough 
to interact with the stationary phase, which is typically C18, in the column.29, 30 Adsorbed 
peptides are eluted from the column with a gradient of polar to non-polar solutions.  
The selection of the appropriate mobile phase conditions is critical to the success of the 
separation of peptides in a biological sample. The typical organic, non-polar solutions used in 
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RPLC peptide analysis are methanol (MeOH) and acetonitrile (ACN). While the relatively 
higher hydrophilicity and hydrogen bonding capabilities of MeOH compared to ACN, make it 
useful for peptide analysis and ionization for mass spectrometric analysis, water/MeOH mixtures 
have a higher viscosity and require higher operating pressures to drive the solution through the 
column and therefore, ACN is more common.31 LC systems can be directly coupled to a mass 
spectrometer to analyze peptides as they are eluted. To aid in the downstream analysis of 
peptides via positive mode MS, a small percentage of acid such as acetic acid (AA) or formic 
acid (FA) is added to the mobile phase to lower the pH and promote protonation of analyte 
molecules. The addition of AA or FA also aids in the separation of charged analytes on a RP 
column by suppressing the ionization of silanol groups in the silica support material. For 
negative mode MS, mobile phase solutions can be made basic by adding ammonium acetate or 
ammonium formate. Other additives, termed ion pairing agents, can also be added to mobile 
phases to improve the resolution of RPLC separations. Charged molecules will not be retained 
on the RP column, so an ion pairing agent is added to interact with charged molecules and form 
complexes, which have a higher affinity for the stationary phase through a hydrophobic element 
included in the ion pairing agent. Since the primary analysis of peptides is performed in acidic 
conditions, the ion pairing agents used are trifluoroacetic acid (TFA) and heptafluorobutyric acid 
(HFBA), which interact and increase the retention of positively-charged peptides on the RP 
column. HFBA contains a larger hydrophobic moiety compared to TFA and the use of the 
different agents can change the elution behavior of analytes in an LC separation.32 A limitation to 
the use of ion pairing agents in LC for peptidomic studies is the possibility of ion suppression 
created with the complexing of charged analytes with ion pairing agents that can lead to them not 
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being detected in MS.33 Because of this limitation, ion pairing reagents were often used only in 
LC separations not coupled to a mass spectrometer. 
 
1.5 Samples: Model Organisms 
 To gain insight into the complex workings of the brain and nervous system, selecting an 
appropriate biological model is a crucial step. Many neurochemical pathways are conserved 
across metazoan and therefore, simpler models are often used to provide more straightforward 
answers to fundamental and complex questions in neuroscience. Several model organisms have 
been involved in genomic and proteomic sequencing efforts, which aids in research and 
understanding of these organisms.  
1.5.1 Mus musculus 
 Mouse, mus musculus, is a common model organism used in laboratory research to 
characterize biological and chemical properties of mammalian systems and act as a precursor or 
substitute for research in human subjects. The high degree of homology between mice and 
humans make it a key model for studying behavior and disease mechanisms. Mice are small, 
relatively easy to maintain, and reproduce quickly. Since mice are such a common laboratory 
research tool, they are well understood and can be genetically manipulated and inbred to yield 
genetically identical strains for accurate and repeatable experiments. Additionally, a lot of 
research has been dedicated to understanding the anatomy and function of different regions of 
the mouse brain.34, 35 The projects described in this dissertation utilize isolated whole brain 
regions or biopsy punches from specific brain regions for studies of peptide dynamics. While the 
mouse is an invaluable resource for understanding brain chemistry, direct translation to the 
human brain, especially with behavior, is difficult due to species differences.36 
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1.5.2 Immortalized Cell Lines 
Immortalized cell lines are a population of cells isolated from a complex organism that 
due to a mutation, proliferates indefinitely in vitro. Immortalized cell lines are widely used as a 
simple model for more complex biological systems, such as the biochemistry of human cells. 
These cell lines are a cost effective and non-invasive way to measure the role of biomolecules in 
a simplified system. In chapter 5, cells from an immortalized keratinocyte cell line, HaCaT 
(human, adult, low calcium, high temperature), were used to measure peptide processing and 
expression. This cell line was the first permanent cell line from adult human skin that exhibits 
normal differentiation and has been widely used for studies of skin biology and differentiation.37, 
38 While immortalized cell lines originate from a well-known tissue type, the mutation that 
allows them to grow indefinitely may change the biology of the cells and must be considered in 
any analysis. 
 
1.6 Thesis and Research Overview 
 The work presented in this dissertation presents new applications of mass spectrometry to 
the identification and quantitation of endogenous peptides in complex biological samples. 
Chapter 2 presents an overview of MS-based quantitation approaches that can be used in the 
study of peptide dynamics, examining peptide level shifts with temporal and physiological 
changes. Some of these approaches were utilized in later chapters. 
Chapters 3 and 4 describe the used of MS-based quantitation to measure peptide changes 
in the hippocampus (Chapter 3) and the amygdala (Chapter 4) of mice used in a conditioned 
place preference (CPP) experiment. These studies were inspired by previous work done by 
collaborators in the Rhodes laboratory, which discovered wheel running leads to the extinction of 
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CPP for cocaine.39 Chapter 3 examines the utility of combining a label-free quantitation 
approach with MALDI MS detection with a well-studied isotopic labeling quantitation approach. 
In the hippocampus, the combination of the two approaches yielded the detection and 
identification of the decrease in several myelin basic protein-derived peptides in mice that had 
access to a running wheel compared to sedentary mice. In Chapter 4, the same isotopic labeling 
approach was used to identify peptide changes in the amygdala of runner and sedentary mice re-
exposed to a context they had been previously trained to associate with cocaine compared to a 
control context. Distinct sets of peptide changes were found with context re-exposure in the 
runner mice and in the sedentary animals.  
 Chapter 5 describes the effort to identify a specific peptide, alarin that has been 
implicated in cell-to-cell signaling. We developed sampling protocols and MS-based approaches 
to detect alarin in a complex culture medium and from overexpressing human keratinocyte cells 
transfected with the alarin prohormone. While a few putative alarin-related peptides were 
detected, an unambiguous identification was not possible. 
 Chapter 6 investigates how different sample collection and processing procedures affect 
the peptides measured by mass spectrometry. In this chapter, four different sampling treatments 
are applied prior to peptide extraction from two different mouse brain regions: the hypothalamus 
and the striatum. The different sample treatments include: no heating or perfusion, perfusion 
with saline and DHB, heating of the head with a commercial microwave, or perfusion with 
physiological saline followed by microwave heating. Similar to Chapter 3, a label-free 
quantitation method with MALDI MS detection was utilized to measure peptide profiles from 
individual animals and compare relative amounts between treatment groups. In addition, 
differential isotopic labeling with LC-ESI-MS detection was used to verify and explore further 
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the differences in peptides detected in the striatum with the different sample treatments. Overall, 
we discovered that heating the tissue with a commercial microwave lead to a higher variation in 
the peptide profiles partly due to the fact that the amount of heating was difficult to control. The 
results of this chapter indicate that proper sampling can lead to better detection of known 
signaling peptides and that the appropriate sampling approach must be selected based on 
research goals and resources. 
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1.8 Figures 
 
 
 
Figure 1.1 Cartoon representation of classical neuropeptide processing steps. In the first stage, 
the signaling region is cleaved from the pre-prohormone during translation. Following 
translation, processing enzymes cleave the prohormone into smaller peptides. The peptides may 
then undergo further post-translational modifications (such as phosphorylation (P) or amidation) 
to create a bioactive signaling molecule.  
 
 
 
 
Figure 1.2 Schematic of the CaptiveSpray ion source. Adapted from www.Bruker.com 
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Figure 1.3 Nomenclature of fragment ions produced in tandem mass spectrometry. 
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CHAPTER 2 
QUANTITATION OF ENDOGENOUS PEPTIDES USING  
MASS SPECTROMETRY-BASED METHODS 
 
2.1 Notes and Acknowledgments 
 This chapter presents recent progress, advancements and applications in mass 
spectrometry-based quantitation of endogenous peptides from complex biological samples. The 
chapter is adapted from the invited review article “Quantitation of Endogenous Peptides using 
Mass Spectrometry Methods” published in Current Opinion in Chemical Biology 17, 801-808 
(2013) with coauthors Elena V Romanova and Jonathan V Sweedler reproduced here with 
permission from Elsevier.1 I would also like to acknowledge Stephanie Baker for her assistance 
in the manuscript preparation. This chapter helps to create context for the work presented in 
subsequent chapters by summarizing the challenges in quantitative peptidomics and highlights 
research conducted in our laboratory and by others in this field. This work was supported by 
Award Number P30 DA018310 from the National Institute on Drug Abuse and by National 
Science Foundation Division of Chemistry under grant CHE-11-11705 (with co-funding from 
the Division of Biological Infrastructure). The content is solely the responsibility of the authors 
and does not necessarily represent the official views of the award agencies. 
 
2.2 Introduction 
Endogenous peptides play important roles in regulating biological processes, via cell-to-
cell communication as peptide hormones and neuropeptides. Mass spectrometry (MS) has 
emerged as a useful analytical tool for the study of endogenous peptides because it has the ability 
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to deduce structural information for peptides present in a sample without prior knowledge. The 
MS-based sub-discipline that focuses on the comprehensive analysis of the peptide content of an 
organism, tissue, or cell is referred to as peptidomics.2-4 While oftentimes the emphasis of 
peptidomic experiments is exploratory, to find and identify hundreds of peptides from a sample, 
quantitative peptidomic studies are becoming more common since changes in peptide dynamics 
in different physiological states can yield insight into the peptide’s functions. Quantitative 
measurements with MS are not straightforward due to differences in sampling, heterogeneity in 
ionization, and unpredictable suppression effects that can arise when working with a complex 
mixture.5 To be able to utilize MS for peptide quantitation, different strategies have been 
implemented, which can be broadly categorized as absolute quantitation approaches and relative 
quantitation approaches. In the study of endogenous peptides, relative quantitation approaches 
have been applied more often since they can be used to characterize the levels of several peptides 
simultaneously. Most of the absolute quantitation applications described below were targeted for 
one or a few specific peptides, making it a specialized, rather than global technique. 
 
2.3 Absolute Quantitation of Endogenous Peptides via Mass Spectrometry 
Studies of peptide function may require information on the absolute amount or 
concentration of a specific bioactive molecule. With MS, absolute quantitation experiments are 
typically performed with the addition of an internal reference standard, which is typically the 
target peptide synthesized with heavy stable isotopes.6 The requirement of a customized 
reference standard limits this approach for targeted analysis of known peptides in well-
characterized physiological functions. Examples utilizing an isotopically labeled reference 
standard for absolute peptide quantitation include: measuring met-enkephalin and beta-endorphin 
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levels in the human pituitary,7 detecting and quantifying neurotensin in human brain tissue 
samples,8 measuring enkephalins in the dialysate of rat brain,9 and determining the concentration 
of nematode pheromones in Caenorhabditis elegans worm bodies and the liquid culture 
medium.10 
Multiple reaction monitoring (MRM) is another strategy for absolute peptide quantitation 
that measures the amount of a peptide based on the number of fragmentation events detected. 
Similar to absolute peptide quantitation methods with an internal standard, MRM requires prior 
knowledge of the target molecule, but it does not require peptide standards with heavy stable 
isotopes. When looking for changes in a specific peptide, MRM with a triple-quadrupole MS 
offers high sensitivity, high specificity, and fast analysis. Examples of specific endogenous 
peptides quantified using MRM include alpha- and gamma-endorphins in rat brain11 and alpha 
melanocyte stimulating hormone in mouse pituitary.12 Due to its high sensitivity and high 
specificity, MRM has also found utility in detecting and quantifying neuropeptides in 
microdialysates.13-15 
 
2.4 Chemical Labeling of Endogenous Peptides for Relative Quantitation 
 Label-based methods of peptide quantitation rely on the introduction of heavy stable 
isotopes (e.g. 2H, 13C, 15N, or 18O) to cause a predictable mass shift that allows for the 
discrimination of labeled and unlabeled species in the mass spectrometer. The ideal isotopic label 
would react with a group common to all peptides, have a large enough mass difference between 
heavy and light species to be able to resolve labeled compounds in MS, and not interfere with 
MS detection; additionally, isotopically-labeled peptides should coelute on LC.16-18 Labeling 
methods for quantitative analysis of peptides can be categorized as either in vivo metabolic 
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labeling or in vitro chemical labeling. Figure 2.1 illustrates the common isotope labeling 
strategies used in MS-based quantitative peptidomics. In the related field of quantitative 
proteomics, there are additional enzymatic methods that will introduce 18O onto the C-terminal 
of peptides generated by the proteolytic digestion of protein precursors in 18O-labeled water.19 
However, this methodology is not readily applicable to the study of endogenous peptides because 
analysis is performed without enzymatic digestion. The appropriate method of label 
incorporation is dependent on the sample to be analyzed; some of the advantages and limitations 
for each approach are highlighted in Figure 2.1(a).  
2.4.1 In vivo Metabolic Labeling 
With in vivo metabolic labeling, the label is incorporated by introducing an isotopically 
enriched element (amino acids, salts) to the growth media for the labeling of cells or to the diet 
for the labeling of whole animals.20-22 An example of this technique for the study of endogenous 
peptides is presented in Che et al.23 where metabolic labeling was used to investigate production 
of peptide hormones in cell culture. The major advantage of in vivo metabolic labeling compared 
to chemical labeling is that it is less vulnerable to variability introduced by differences in sample 
handling because the isotopic tag is incorporated prior to sample preparation. A limitation to this 
method is that successful incorporation of a stable isotope through metabolic labeling is 
expensive and time consuming when applied to the study of complex organisms, in which the 
metabolic incorporation of the tag can require weeks depending on growth rate. A detailed 
review of the progress and considerations in metabolic-labeling of model organisms has been 
presented by Gouw et al.24 While metabolic labeling has emerged as a valuable technique for 
quantitative proteomics with cell lines and simpler organisms, its difficult adaption for more 
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complex model animals makes its use limited in the study of endogenous peptides dynamics 
associated with changes in behavior or physiological state. 
2.4.2 In vitro Chemical Labeling 
 In contrast to in vivo metabolic labeling of peptides, in vitro chemical labeling is fast and 
since it is performed after tissue harvest, applicable to any sample. Chemical labeling can also be 
accomplished via numerous routes by modifying reactive sites with isotopic tags (Figure 2.1(b)). 
While relative quantitation with metabolic labeling is limited to only two states, labeled and 
unlabeled, chemical labeling tags have been designed with multiple isoforms that allow for 
multiplexed analysis of more than two peptide samples.18, 25 Relative quantitation can be 
performed in two ways: measuring the relative MS signal detected for labeled peaks of a known 
mass difference or using isobaric tags and measuring the relative signals of reporter ions detected 
after fragmentation via tandem MS. The real disadvantage to the chemical labeling techniques is 
the possibility of artifacts introduced by differences in sample handling when comparing two or 
more samples. However, a distinct advantage is that the likelihood of systematic errors is limited 
by measuring all samples in the same MS or LC-MS experiment. 
 Historically, one of the first chemical labels used for MS-based relative quantitation was 
isotope coded affinity tags (ICAT), introduced in 1999.26 The components of an ICAT reagent 
include a thiol-reactive group to specifically react with cysteine residues in the peptide or 
protein, a linker that contains “light” or “heavy” isotopes, and a biotin moiety for affinity 
capture. While this label has found wide use in the field of quantitative proteomics, its use for 
quantitative peptidomics is not recommended because cysteine is a relatively rare residue and not 
found in most endogenous peptides.5 
 24 
 
 Rather than tagging a rare amino acid like cysteine, the chemical tags commonly used for 
quantitative peptidomics react with primary amine groups such as the N-terminus of a peptide 
and internal lysine side chains. Inexpensive commercial reagents that can be used to tag amine 
groups include isotopically light and heavy forms of acetic anhydride, succinic anhydride, and 
formaldehyde. With each of these labels, relative amounts of peptides in two or more samples 
are measured by looking at the MS signals detected for differentially labeled peptides. While 
acetic anhydride was one of the first of these reagents to be tested, its utility is limited because 
light and heavy labeled peptides do not completely coelute from LC due to deuterium isotopic 
effects.27 In contrast, peptides labeled with deuterated and non-deuterated succinic anhydride do 
co-elute with reverse phase LC. Labeling with succinic anhydride and deuterated or heavy 
succinic anhydride has been used in our laboratory to measure neuropeptide level changes in 
behaviorally distinct honey bees,28 and characterize the role of processing enzymes in the non-
classical processing of spinal cord peptides29 and in the production of amidated peptides in mice 
under genetic and dietary manipulations.30 Peptide pairs labeled via reductive amination of 
primary amines by deuterated and non-deuterated formaldehyde also show minimum isotope 
effects and co-elute with reverse phase LC.31 The Li laboratory has utilized formaldehyde 
labeling in several studies of peptide dynamics in crustaceans.32-34 One limitation to the use of 
these commercially available labeling reagents is that the free amine groups are transformed into 
amides and therefore, unless there is another spot on the peptide to accept a positive charge, the 
peptide will not be detected in positive mode MS.35  
To retain a site that can accept a positive charge after reaction with the primary amine 
groups, the trimethylammonium butyrate (TMAB) isotopic tags incorporates a quaternary amine 
in the label. This reagent was first described by Zhang et al.36 and is easily synthesized in 
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multiple isotopic forms.18 TMAB-based tags have been used extensively in quantitative 
peptidomics, especially in the study of neuropeptides. The tags have been used to investigate the 
role of processing enzymes, prohormone convertase 1/337 and carboxypeptidase E38 in 
neuropeptide biosynthesis and to measure changes in relative peptide levels in the brain after the 
administration of different drugs of abuse.39, 40 A limitation with TMAB-based tags and any of 
the chemical labels that are used in the mass-difference approach for quantitation is the increased 
spectral complexity in MS mode compared to isobaric reagents, especially when the tags are 
used in multiplexed quantitative peptidomic experiments.  
The isobaric tags that utilize tandem MS for relative quantitation by derivatizing primary 
amine groups are: isobaric tags for relative and absolute quantitation (iTRAQ) and tandem mass 
tags (TMT). Labeling with these reagents produces labeled peptides with identical mass and 
chromatographic properties, but unique m/z ions in tandem MS.41, 42 Our laboratory has 
demonstrated that iTRAQ reagents can be used for small volume samples of individual neurons 
from the model organism, Aplysia californica to measure relative peptide levels in single cells.43 
There are a few limitations to using these tags for relative quantitation that must be considered 
when performing quantitative peptidomics experiments. The first disadvantage with iTRAQ or 
TMT tags compared to other labeling reagents is that they are expensive and difficult to 
synthesize. To address the issue of cost, N,N-dimethyl leucine tagging agents were developed as 
a less expensive alternative for isobaric labeling and tandem MS-based quantitation.44, 45 This 
tagging agent was used in the Li laboratory to quantify neuropeptide expression changes in the 
different stages of development of the lobster, Homarus americanus.46 A second limitation with 
tandem mass tags is quantitation requires tandem mass spectra, which are typically produced for 
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only the most abundant peptides species detected in MS mode and missing for low abundance 
peptides. 
 An alternative method to the chemical tags described above is incorporation of metal-
chelate complexes for relative quantitation. Similar to ICAT tags, the first metal-coded affinity 
tags (MeCAT) were used to derivatize cysteine groups via thiol chemistry,47, 48 but the chemistry 
has been adapted to labeling amine groups.49, 50 As with the other chemical labeling techniques, 
the relative quantitation of a peptide is measured by the ratio of differently labeled species 
detected by MS. Unique with MeCAT labeling compared to other techniques is the ability to 
perform absolute quantitation by quantifying the amount of rare earth metal ions detected by 
elemental analysis with inductively-coupled plasma (ICP)-MS.51, 52 Thus far, this technique has 
been applied to quantify extreme peptide changes, such as in enzymatic reactions,50, 53 and 
therefore, more testing is needed to determine if it is suitable for detecting the subtle alterations 
found in physiological peptide dynamics. 
 
2.5 Label-Free Relative Quantitation of Endogenous Peptides 
Label-free approaches for quantitative analysis have found utility in the study of 
endogenous peptides. A significant advantage to label-free approaches compared to chemical 
labeling quantitation strategies is that there is no limit to the number of samples or conditions 
that can be compared. These methods are better suited for small volume samples that are less 
suitable for derivatization with labeling agents and can extend to peptides with posttranslational 
modifications, such as N-terminal acetylation, that would prevent them from reacting with 
chemical labels. Label-free methods also have a higher dynamic range for quantitation and are 
therefore, better suited for detecting large variations in peptide levels than chemical labeling 
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methods.35 The major challenge with label-free approaches is that individual samples are 
analyzed in separate MS or LC-MS experiments, making the approach more susceptible to 
systematic errors than the chemical labeling techniques due to variations in sample preparation, 
sample injection, and analyte ionization. Reproducible MS and LC-MS analysis with rigorous 
statistical analysis, discussed further below, are critical for the success of label-free quantitation 
of peptides.54, 55 Figure 2.2 presents a diagram of the two major approaches used for label-fee 
quantitation with MS: feature-based-intensity methods and spectral counting methods.  
In the feature-intensity-based method, the measured peak intensity or peak area for a 
particular peptide is compared across MS analyses to measure the relative peptide amount in the 
different samples. This approach is based on the assumption that within the linear range of the 
detector, the detected ion intensity or area corresponds to peptide concentration. A peak intensity 
comparison of peptides detected using matrix-assisted laser desorption/ionization (MALDI) MS 
between sample groups has been used by our laboratory to investigate changes in peptide 
dynamics with alterations in behavioral phenotype.56, 57 Integrated peak intensities were also used 
to find endogenous peptides that change in the suprachiasmatic nucleus of rats at different times 
of day to investigate their role in circadian rhythm.58 
The second common label-free MS quantitation method, spectral counting, is where the 
relative peptide amount is inferred by the number of MS/MS spectra generated for that particular 
species. The spectral counting method is based on the assumption that a high abundance peptide 
will be selected for fragmentation more often and produce more tandem MS spectra than one of 
lower concentration and the number of observed fragmentation spectra is therefore proportional 
to the relative amount of the peptide. This strategy has been applied to examine endogenous 
peptide changes in the brains of rats59, 60 and Japanese quails.61 The spectral counting method 
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does have limitations, especially with peptides at concentration extremes. Very low abundance 
peptides often go undetected with data-dependent acquisition and high abundance peptides can 
have imprecise quantitation due to saturation of spectral counts as a consequence of deficiencies 
in the ion-trapping capacity and ion efficiency of the mass spectrometer.35 
 
2.6 Challenges that Drive New Developments in Quantitative Peptidomics 
 Although mass spectrometry is a useful technique for studying peptides, there are a 
multitude of global parameters that can affect measurement accuracy in quantitative experiments, 
ranging from biased sampling to the quality of the MS data acquired and how to efficiently 
analyze the data with mathematical tools. Quantitative peptidomics experiments remain difficult 
and time-consuming and these challenges have sparked methodological and technical advances 
that are discussed below.  
2.6.1 Considerations in Sampling 
Endogenous peptides are a unique class of molecules that exhibit low endogenous 
concentrations, a broad dynamic range, and wide-ranging chemical properties. These qualities 
make the comprehensive detection and identification of endogenous peptides in a sample almost 
impossible. Complete peptide detection and identification are currently limited by both sampling 
and detection. Extraction of all peptides from a tissue sample remains elusive and MS 
measurements are complicated by heterogeneity in ionization and unpredictable ionization 
suppression effects that can arise when working with a complex mixture.   
To use quantitative analysis of peptides in a diagnostic manner to find potential 
biomarkers, the sample analyzed should mirror the in vivo state of the tissue. A complication in 
neuropeptide detection is the post-mortem degradation of abundant proteins in tissue samples. 
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Protein fragmentation by proteases and other enzymes changes the composition of the peptidome 
and signals from fragments can overwhelm that of low concentration peptides in MS. Several 
methods have been introduced to halt the action of protein-modifying enzymes through heat 
treatment. Snap-freezing, heat denaturation with a conventional microwave and submersion of 
the tissue in boiling water are fairly inexpensive methods for protein stabilization that can 
applied after sacrifice.62, 63 However, for reliable quantitative measurements, the treatment of 
tissue must be standardized and reproducible. Technology introduced by Svensson et al.64 
combines heat and pressure under vacuum to heat tissue rapidly and uniformly with an 
automated instrument. The peptide profile for a tissue sample using this technology is 
comparable to tissue collected with animal sacrifice by focused microwave irradiation, which is 
thought to closest reflect the in vivo peptidome. The heat denaturation of enzymes preserves 
post-translational modifications as well as preventing the degradation of abundant proteins. This 
technology is advantageous for quantitative measurements compared to the other methods 
described where homogenous heating of the tissue is difficult to control. 
While peptidomics studies aim to identify all peptides in a sample, the variety of lengths 
and hydrophobicities of neuropeptides has led to a low identification rate due to complications in 
sampling. In mass-limited samples, such as individual cells or defined brain nuclei, few peptides 
are abundant enough to exceed the detection limits of current MS technologies. A tissue extract 
is the typical sample, but an extraction solution that can both extract and preserve the 
neuropeptides with their wide range of hydrophobicities has yet to be found. To try and address 
the range of hydrophobicities, many sampling procedures include multiple extraction steps with 
both aqueous and organic solutions. Yet, many neuropeptides that are known to be in a given 
brain region are not detected in a given study. One factor that is likely leading to low 
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identification rates of peptides is the dilution and loss of peptides during multi-step extraction 
methods. To address incomplete mixing and dilution with multi step extraction procedures, 
Zhang et al.65 introduced an approach termed mixing on column to try and maximize extraction 
efficiency for LC applications. In this approach, peptides are extracted from tissue samples in 
both aqueous and organic conditions.  The extraction solutions are kept separate until they are 
loaded onto a trap column, where they were mixed prior to analysis using LC-MS. This 
extraction technique showed an increase in detected peptides compared to the more common 
acetic acid extraction and when the organic and aqueous extraction solutions are mixed prior to 
analysis.65 An alternative extraction method introduced by our laboratory, uses 2,5-
dihydroxybenzoic acid (DHB), a commonly used matrix for matrix-assisted laser 
desorption/ionization (MALDI) MS, for one-step extraction of signal peptides from tissue 
samples.66 This extraction technique is both easy and reproducible, but that ease is limited to 
MALDI MS applications since removing the DHB prior to LC analysis involves extra clean-up 
and separation prior to analysis. However, capillary electrophoresis with DHB as the background 
electrolyte has been used to fractionate peptides from these extracts for further MS analysis.67  
2.6.2 Considerations in Data Analysis for Quantitative Peptidomics 
 Even with the best possible sampling and extraction strategies, tissue extracts are 
inherently complex and heterogeneous. To date, the major bottleneck in quantitative peptidomic 
experiments is in the analysis of the data collected. Quantitative measurements of complex 
biological samples by MS requires the ability to resolve overlapping isotopic peak patterns to 
identify different molecular species of the same nominal mass as well as accurate mass 
measurement to improve identification confidence and limit search space for faster data 
processing. The advent of instruments with increasingly high mass-resolving power allowed 
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hundreds and even thousands of peptide components determined in an individual experiment. 
High resolution instruments have made the signal processing and peak picking tasks simpler than 
they were with low resolution instruments, but high resolution mass spectrometers also generate 
gigabytes of complex data, which perpetuates the demand for robust data processing tools. 
The data processing for label-free quantification strategies is markedly more complicated 
than those incorporating stable isotopic labels because peptide measurements are made across 
different LC-MS runs. Reviews on the important stages and considerations for data processing 
and statistical analysis for label-free quantitative peptidomics are presented in Nahnsen et al55 
and Christin et al.68 The main processing steps for label-free quantitation include signal 
processing, feature finding, and spectral alignment. Alignment of LC-MS runs is especially 
critical to accurate quantitative measurements with feature-based-methods. While the hope is a 
peptide’s elution time on LC and ionization behavior remains consistent between measurements, 
changes in the retention time parameter can become large and are hard to predict across analyses. 
To address shifts in retention time, several algorithmic approaches have been used.55, 69 A 
discussion of the different metrics used for alignment as well as critique of different methods can 
be found in Lange et al.69 After the peptide features are aligned, the next critical computational 
step in label-free quantitative peptidomics experiments is normalization, which accounts for 
variability in intensity signals due to systematic errors.70 Kultima et al.71 compared 10 different 
normalization metrics and found that a linear regression with a correction for the analysis order 
performed best for their peptidomics data sets. However, software packages for label-free 
quantitation typically contain a limited set of normalization methods, which must be considered 
when choosing an analysis program. A review by Cappadona et al. 72 details that and other 
factors that must be considered in selecting an appropriate software package for quantitative 
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analysis. Critiques of current commercial and open source software packages for labeled and 
label-free quantitation with MS are also available.73-75 
 
2.7 Conclusions and Future Perspectives 
 Mass spectrometry has revolutionized the way important biomolecules are analyzed and 
characterized. MS technology brings molecular characterization to a new level of confidence and 
allows for inquiry across disciplinary boundaries, as evidenced by the advent of several “omics” 
technologies. Numerous MS-based quantitation strategies have been applied in the study of 
endogenous peptides in specialized applications in fundamental research. These techniques are 
well-developed enough to be also utilized in clinical applications like biomarker discovery and 
the development of peptide therapeutics. Each method provides its own advantages and 
limitations, and the selection of the appropriate technique is study-dependent. Due to the 
growing popularity and availability of high resolution mass spectrometers, a shift toward use of 
the more versatile and cost-effective label-free strategies for peptide quantitation is expected. 
Continued progress is needed in creating sensitive and reliable methods for absolute quantitation, 
and on the development of robust and user-friendly statistical tools for the assessment and 
reporting of quantitative data.  
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2.9 Figures 
 
 
Figure 2.1 Diagram of the mass spectrometry-based strategies for quantitation of peptides with stable 
isotopic labeling methods. (a) Routes of isotope introduction, highlighting the advantages and limitations 
of each method as it is applied to the study of endogenous peptides. (b) Overview of select popular 
chemical labeling methods. Figure is adapted from Romanova et al.1 with permission from Elsevier © 
2013. Key: ICAT – isotope-coded affinity tag; DOTA – 1,4,7,10-tetraazacyclododecane-N,N’,N’’,N’’’-
tetraacetic acid (metal –coded affinity tag); iTRAQ-isobaric tags for relative or absolute quantitation; 
TMT – tandem mass tags; TMAB – trimethylammoniumbutyryl-based tags; IT-MS – ion trap mass 
spectrometer; MALDI-TOF – matrix-assisted laser desorption/ionization time-of-flight mass spectrometer 
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Figure 2.2 Diagram of label-free quantitation strategies. Figure is adapted from Romanova et al.1 with 
permission from Elsevier © 2013. 
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CHAPTER 3 
COMBINING MS-BASED QUANTITATION METHODS TO MEASURE PEPTIDE 
CHANGES WITH EXERCISE 
 
3.1 Notes and Acknowledgments 
The data presented in this chapter focuses on mass spectrometry-based quantitative 
peptidomics in the dentate gyrus of the hippocampus of mice used in a conditioned place 
preference experiment. This chapter is adapted from amanuscript in preparation co-authored by 
Martina L. Mustroph, Elena V. Romanova, Bruce R. Southey, Justin S. Rhodes, and Jonathan V. 
Sweedler. My contribution to this work was designing and performing MS-related experiments, 
followed by data analysis and interpretation. Justin Rhodes and Jonathan Sweedler initiated this 
project and provided useful advice throughout. Martina L. Mustroph raised the animals, 
performed the behavioral studies essential to the experiment, collected tissue samples for 
peptidomics work, and aided in the MALDI MS analysis of individual samples. Members of the 
Rhodes laboratory assisted with animal care and dissection. Elena V. Romanova provided 
guidance in designing the experiments and advice throughout the study. Bruce R Southey was a 
great help in statistical analysis of the data. The project was supported by the National Institute 
on Drug Abuse under Award no. P30DA018310. The content of this chapter is solely the 
responsibility of the authors and does not necessarily represent the official views of NIDA or the 
National Institutes of Health. 
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3.2 Introduction 
Understanding the biochemical changes that influence illicit drug addiction is important 
for the development of successful intervention protocols. One of the major obstacles in drug 
rehabilitation is the phenomenon of relapse, which is often related to of intense cravings 
triggered by exposure to drug-associated cues such as drug related paraphernalia or locations 
where drugs were taken.1-4 Aerobic exercise has been proposed as a potential component of 
rehabilitation treatment for drug abuse to help curb drug-cue induced relapses.5, 6 Exercise 
invokes changes in the brain reward pathway similar to those observed with drug use5-10 and 
incorporating exercise in laboratory animal behavioral models of drug addiction have 
demonstrated that it can decrease drug-seeking behavior.5, 11-13 Here, we use a preclinical 
behavioral model termed conditioned place preference (CPP) to study drug-to-context 
associations and measure the rewarding effects of cocaine.14, 15 CPP is considered a form of 
classical Pavlovian conditioning where the animal is trained to associate a particular 
environmental stimulus with a drug. In our experiments, mice were trained to associate a 
particular floor texture with cocaine. Preference testing is performed by placing the animals in a 
dual-floor texture chamber and tracking the amount of time the mouse spends on the floor 
texture they were trained to associate with the drug (the cocaine-paired context).16 In previous 
experiments, animals that were housed with a running wheel after training spent significantly 
less time on the cocaine-paired context when tested in a dual-context chamber, indicating their 
preference for the cocaine-paired context was reduced.17-19 While this behavior is robust, the 
biochemical changes underlying the running-induced extinction of CPP is not well understood. 
One mechanism by which running accelerates the extinction of CPP may be differential 
expression of signaling peptides. To explore this possibility, tissue extracts were taken from the 
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dentate gyrus region of the hippocampus to measure peptide changes induced by running and 
cocaine conditioning. The dentate gyrus was chosen for sampling because it is a known site of 
neurogenesis (the birth of new neurons)20, 21 and neurogenesis is part of a cascade of 
physiological changes induced by exercise that increase neural plasticity in the hippocampus.22, 23 
We utilized two mass spectrometry (MS)-based methods to measure peptide changes in the 
hippocampus associated with the phenomenon of running-induced extinction of conditioned 
place preference (CPP) for cocaine. 
MS-based quantitation has emerged as a useful tool in the study of peptide dynamics in 
brain tissue as it provides information on the presence and structure of multiple molecular targets 
simultaneously without prior knowledge of the peptide complement.24-27 As long as it falls within 
the linear dynamic range of the detector, MS signal intensity has been shown to be proportional 
to the peptide amount.28 However, quantitative measurements with MS are complicated by 
differences in sampling, heterogeneity in ionization, and unpredictable suppression effects that 
can arise when working with a complex mixture.26 To address these complications, a number of 
different approaches have been developed to use MS-based measurements to calculate relative 
peptide amounts in two or more samples.29 30The two most common methods can be broadly 
categorized as stable isotopic labeling or label-free techniques. With stable isotopic labeling, two 
(or more) samples of interest are chemically modified with isotopic tags that contain different 
heavy and light isotopes then the samples are combined and analyzed together in a single MS 
run.25, 31, 32 The ratio of observed peak intensities of the different isotopic forms is then used to 
calculate the relative abundance of a peptide in the labeled samples. This technique has been 
used previously to determine peptide changes in samples of different genetic33, 34 and 
behavioral35, 36 phenotypes. The major advantage of this technique is the reduction in systematic 
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error that comes from analyzing the samples simultaneously, this tends to provide a higher 
precision and accuracy of quantitation compared to label-free methods.37 However, the chemical 
labeling requires additional handling and sample processing, which can perturb the sample 
composition and lead to non-uniform losses among the samples, especially for mass-and volume 
limited samples. To control for sample dilution and loss due to the addition of labeling reagents 
and extra processing steps, larger pooled samples are often used for isotopic labeling analysis.35, 
36, 38 Also, the multiplexing capabilities of this method is limited by the number of isotopic forms 
of the tag available. 
 Label-free techniques have been developed as an alternative to isotopic labeling. In this 
approach, relative amounts are measured by directly comparing the peak intensity of a specific 
peptide across multiple MS experiments.39, 40 We have developed a matrix-assisted laser 
desorption/ionization (MALDI) MS label-free technique, which has been used to study 
differences in peptide amount in different brain regions41 and with exposure to drugs.42, 43 This 
technique provides several advantages over isotopic labeling and other relative quantitation 
methods. The low sample volume requirements, decreased demand for sample processing along 
with high sensitivity allows for the probing of small samples individually, thus preserving 
individual features and allowing for exploration of the individual variability of samples. 
However, MS measurements are made in parallel (and not simultaneously), which raises the 
chance for systematic errors due to run-to-run variability. One other advantage compared to 
labeling approaches is that many of the common isotopic tags label free amine groups, limiting 
the detection of important peptides that have N-terminal modifications such as acetylation or 
pyroglutamate formation. Additionally, there is no limit to the number of samples that can be 
directly compared with this method. 
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 We hypothesize that due to distinct selectivity of MALDI and ESI ionization, and 
different advantages of the two quantitation approaches used, peptide dynamics associated with 
exercise-induced extinction of CPP could be evaluated more comprehensively. The two 
independent measurements on the same set of samples also yields insight into the success of each 
individual method for relative quantitation of peptide changes. 
 
3.3 Experimental  
3.3.1 Chemicals 
All chemicals were obtained from Sigma Aldrich (St Louis, MO) unless otherwise stated. 
The peptide standards for matrix-assisted laser desorption/ionization time-of-flight mass 
spectrometry (MALDI TOF MS) calibrations were supplied by Bruker (Billerica, MA). Heavy 
(D4) succinic anhydride was purchased from C/D/N Isotopes (Pointe-Claire, Quebec, Canada). 
3.3.2 Animals and Conditioned Place Preference 
 Male C57BL/6J mice (n=48) were obtained at 5 weeks of age from the Jackson 
Laboratory (Bar Harbor, ME). All procedures were approved by the University of Illinois 
Institutional Animal Care and Use Committee and adhered to NIH guidelines and measures were 
taken to minimize the number of animals used and the pain and suffering of the mice. The 
training and testing schedule for mice is depicted in Figure 3.1A. CPP training and testing were 
performed using chambers with interchangeable floor textures as described in previous studies 
and shown in Figure 3.1B.17, 44, 45 The CPP procedure is adapted from Cunningham et al.16 
Cocaine hydrochloride was dissolved in 0.9% saline and administered at a dose of 10 mg/kg via 
intraperitoneal (i.p.) injections in a volume of 10 ml/kg for conditioning trials. Dose was chosen 
based on the literature.36, 44 Conditioning trials were conducted to establish cocaine-to-context 
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associations by giving the animal a dose of cocaine and placing it in a chamber of a single floor 
texture (hole or grid). As a control, trials were also performed by giving the same animal an 
injection of saline and placing it in a chamber of the alternate floor texture. In the conditioning 
phase, each animal underwent 2 trials per day, one with the drug and one with saline, for four 
days. Following conditioning, the animals were placed individually in cages either with or 
without running wheels, to create two groups: runner mice (housed with a running wheel, n =25) 
and sedentary mice (housed without a running wheel, n=23). One trial of CPP testing was 
performed following 30 days of individual housing with or without a running wheel in 
accordance with previous experiments.17 Mice were tested individually for their preference using 
a dual-floor texture (hole and grid) chamber. The distance traveled and location of mice within 
the conditioning chamber were tracked and recorded to assess the strength of CPP.  
The day after CPP testing, animals were either re-exposed to the CPP texture they had 
been conditioned to associate with cocaine (n=24) or the CPP texture they had been conditioned 
to associate with vehicle (n=24) for 30 min. All animals were weighed, injected i.p. with 10 
ml/kg saline, and placed into the center of a single floor texture chamber. Mice were not placed 
in the dual-texture chamber to isolate the effect of the drug-to-context associations. Animals 
underwent context re-exposure the day after CPP testing because this was the time point where 
the runner and sedentary groups were divergent in CPP in previous results.17 With the different 
context re-exposures, there were four behavioral groups created: n = 11 sedentary mice re-
exposed to the vehicle-paired context, n = 12 sedentary mice re-exposed to the cocaine-paired 
context, n = 13 runner mice re-exposed to the vehicle-paired context, and n =12 runner mice re-
exposed to the cocaine-paired context. 
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3.3.3 Tissue Sampling and Peptide Extraction  
Immediately following the 30 min context re-exposure session, mice were anesthetized 
with 150 mg/kg sodium pentobarbital (i.p.) and then perfused transcardially with ice-cold saline. 
Their brains were carefully removed and immediately flash-frozen in liquid nitrogen for 
preservation and stored at -80° C. The next day, frozen brains were mounted using distilled water 
on a cryostat. Samples of the bilateral dentate gyrus of the hippocampus were isolated via biopsy 
punches of 1.25 mm diameter (World Precision Instruments, Sarasota, FL). Coordinates of the 
punches taken were determined according to the mouse brain atlas46 and were: from -1.94 to -
2.94 bregma. Tissue samples from both hemispheres of the dentate gyrus of the hippocampus 
were placed into 14 µL 0.25% acetic acid extraction solution and incubated for 24 hours at 4°C. 
The tissue was then homogenized by sonication in a water bath for 10 minutes followed by 
centrifugation to separate the extract and tissue pellet. The extraction process was repeated with 
another 10 µL of 0.25% acetic acid. Both extractions were combined.  
3.3.4 Analysis of Peptide Profiles by MALDI MS 
 For MALDI MS analysis of samples, a small portion of peptide extract (5 µL) was mixed 
with 2 µL of a 10 µM solution of an internal standard (acidic peptide from Aplysia californica, 
MW 2960). Next, 0.7 μL of the spiked sample was co-crystallized with 0.7 μL of α-cyano-4-
hydroxycinnamic acid (CHCA) matrix (13 mg/ml in 60% acetonitrile (ACN)) on a gold-coated 
MALDI target (Bruker, Bremen Germany). Samples were spotted as five technical replicates for 
each animal to total 240 sample spots. Positive ion mass spectra for each sample spot were 
acquired in the m/z 600-5,000 range on an MALDI-time-of-flight mass spectrometer 
(Ultraflextreme, Bruker) in reflectron mode with high-precision calibration. Spectra were 
acquired by automated run that sampled from the spot in a random walk fashion and utilized 
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dynamic termination, where data collection for a spot concluded when two individual peaks 
reached a summed intensity of 1x104. Collection settings were determined as optimal according 
to S/N, peak height and resolution for this sample type in pilot measurements. 
3.3.5 Statistical Analysis of MALDI MS Peptide Profiles 
The raw MALDI MS spectra were imported into ClinProTools 2.2 software (Bruker). 
Detected peaks were smoothed and de-isotoped using the Savitzky-Golay algorithm at a width of 
1.0 m/z over 4 cycles. The Quick Classifier algorithm in ClinProTools was used to rank peaks 
based on their variation between samples and select putative candidate peaks likely to differ 
significantly between treatment groups. Peaks considered for statistical analysis were restricted 
to a signal-to-noise ratio of 3:1. Intensity values of putative candidate peaks were normalized 
relative to the intensity of internal standard observed in the individual sample using SAS (version 
9.2) statistical software. Spectra in which the internal standard was not detected were omitted 
from the analysis, but in no animal sample did all 5 technical replicates fail to show peaks of the 
internal standard peptide peaks, so all animals were included in the analysis. All peak intensity 
values were then transformed to log(intensity) + 0.5 in order to normalize the intensities. 2x2 
between-within ANOVA tests were run on the peptide peak expression levels for each putative 
candidate peak to test for significant changes, where treatment group (runner or sedentary) and 
context at re-exposure (vehicle or cocaine) were between-groups factors and iteration (i.e. 
sample spot) was a within-subjects variable (5 per animal).  
3.3.6 Isotopic Labeling of Peptide Extracts 
Pooled samples for quantitative peptidomic measurements were created by combining the 
unused portions of the individual extracts from 3 animals of a specific behavioral group. Two 
pooled samples were created for each of the behavioral groups: sedentary mice re-exposed to the 
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cocaine-paired context, sedentary mice re-exposed to the vehicle-paired context, runner mice re-
exposed to the cocaine-paired context, and runner mice re-exposed to the control context. The 
remaining peptide extracts were combined (without regard to treatment group) into samples for 
peptide sequencing by MS/MS. Peptides in the pooled samples were covalently modified with 
H4- or D4-succinic anhydride (SA), which cause a mass shift of 100.01 Da and 104.02 Da, 
respectively, following the procedure described in Hou et al.28 Briefly, the pH of the sample was 
first adjusted to ~9 using 1.5M sodium phosphate buffer and 2M NaOH if needed. Then, 3 μL of 
4M of H4- or D4-SA in dimethyl sulfoxide was added to label the primary amine groups of 
peptides in the sample. After vortexing, centrifuging, and incubation at 22°C for 10 min, the pH 
was again adjusted to 9 with 2M NaOH. The labeling reagent was added six times with 
subsequent pH adjustment. Excess labeling reagent was reacted with 30 μL of 2.5M glycine. 
Samples from the different treatment groups were labeled and combined as diagramed in Figure 
3.2: sedentary mice re-exposed to the cocaine-paired context (H4-SA) with runner mice re-
exposed to the cocaine-paired context (D4-SA) and runner mice re-exposed to the control context 
(H4-SA) with sedentary mice re-exposed to the control context (D4-SA). The samples used for 
peptide identification were also labeled with H4-SA. Combined isotope-labeled samples were 
filtered through a 10kDa molecular weight cutoff filter (Millipore, Milford, MA). To remove the 
label from tyrosine, threonine, and serine residues, 2.5 M hydroxylamine in DMSO was added to 
all samples. The samples were desalted with PepClean™ C18 spin columns (Thermo Scientific) 
and eluted with 50% and 70% acetonitrile. The eluent was concentrated with a vacuum 
concentrator (Savant Speed Vac SVC-100H, Thermo Fisher Scientific, Waltham, MA) and 
reconstituted in 10 µL of 95/5 (v/v) H2O/ ACN with 0.1% formic acid (FA). 
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3.3.7 LC-ESI-MS Measurements of Labeled Peptides 
 The mass spectrometric platform utilized for quantitative measurements was a 
quadrupole time-of flight (QTOF) MS (MaXis Impact, Bruker) with the CaptiveSpray source 
(Bruker). Each of the combined labeled samples was loaded as a 1 µL sample onto a trap column 
(200 µm i.d. x 20 mm length, Acclaim™ Pepmap™ C18 100, 5µm, 100 Å; Thermo Scientific, 
Rockwood, TN, USA) at 20 µL/min with a nanoHPLC system (Ultimate3000, Dionex, 
Sunnyvale, CA, USA). Analytical separation was performed at 300 nL/min with a reverse phase 
C18 column (100 µm i.d. x 15 cm length Magic C18, 3 µm, 200 Å; Michrom Bioresources, 
Auburn, CA, USA). The solvents used were H2O with 0.1% FA for solvent A and 20/80 
H2O/ACN with 0.1% FA for solvent B. The gradient used was 0-10 min, 4-25%B; 10-20 min, 
25-30%B; 20-50 min, 30-60%B; 50-55 min, 60-75%B; 55-59 min, 75-90%B; 59-69 min, 90%B; 
69 min 90-20%B; 69-73 min 20-4%B;73-115 min 4% B. MS spectra were collected for a m/z 
range of 290-3000. Each sample was analyzed twice in MS mode for 2 technical replicates per 
sample. 
3.3.8 MS Data Analysis for Peptide Quantitation 
 Labeled peptide pairs were manually identified based on their common charge, retention 
time, and mass match using DataAnalysis 4.2 (Bruker). After detecting a labeled pair at a 
particular time point in the LC-ESI-MS analysis, extracted ion chromatograms (EIC) were 
created for the monoisotopic peak of the light and heavy species. The peaks observed in the EIC 
were integrated to create an averaged spectrum over the ions’ elution time. For each peptide, 
relative quantitative measurements were performed comparing the summed intensity of the first 
four isotopes for the light and heavy forms in the averaged spectrum. Fold changes between the 
summed intensities were calculated by log2-transforming the intensities and taking the difference 
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between light and heavy forms. Fold changes were averaged across technical replicates and 
Student’s t-tests were used to determine which peaks showed statistically significant changes. 
Adjustment for multiple hypothesis testing was controlled by applying the false discovery rate 
(FDR) correction.47  
3.3.9 Peptide Identification by MS/MS 
 For peptide identification, the platform utilized was the same nanoLC system (Ultimate 
3000, Dionex) coupled to the QTOF MS (MaXis Impact, Bruker) and chromatographic 
conditions were kept consistent with peptide quantitation measurements. The MS/MS precursor 
ion selection was set for the three ions of highest intensity per MS scan, and active exclusion of 
previously fragmented ions was enabled. MS and MS/MS spectra were collected for a m/z range 
of 290-3000. After data collection, the MS/MS spectra were exported as an .mzXML file and 
searched against an in-house mouse neuropeptide database and the whole mouse proteome 
downloaded from UniProtKB48 using PEAKS Studio 7 (Bioinformatics Solutions, Inc. Waterloo, 
ON, Canada). The search parameters used in the software were as follows: no enzyme, variable 
post-translational modifications (N-terminal pyro-Glu, acetylation, C-terminal amidation, 
phosphorylation, oxidation of methionine, methylation, and the addition of succinic anhydride), 
mass tolerance of 0.1 Da for the precursor ion and 0.1 Da for fragment ions. Peptide assignments 
were judged on the -10logP score (where >20 equates to p<0.01).  
 
3.4 Results 
3.4.1 Peptide Markers Found with MALDI MS Profiling and Statistical Analysis 
Peptide profiles were collected via MALDI MS for individual animals and the collected 
spectra show a high degree of reproducibility as demonstrated in Figure 3.3, which shows five 
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technical replicates collected from a single animal. The coefficient of variance (CV) within 
technical replicates averaged for all 48 samples was 12.9. Within treatment group, the CV 
averaged for all 4 treatment groups was 26.9. In total, 50 peaks were detected at a S/N greater 
than 3 in the averaged MALDI MS spectrum for each of the four treatment groups. Fifteen peaks 
were found to differ significantly (p<0.05) between the runner and sedentary groups, 
independent of context re-exposure. All of the fifteen peaks had measured ratios that signaled a 
higher amount in the sedentary mice as reported in Table 3.1. There were no peaks that were 
found to change significantly with context re-exposure in either the runner or the sedentary 
group. 
3.4.2 Relative Quantitation of Peptide Changes with Exercise using Stable Isotopic 
Labeling 
To isolate the effects of wheel running, context re-exposure was controlled for by making 
the comparison between sedentary and runner groups for the cocaine context re-exposed animals 
and saline-context re-exposed animals separately. The chromatographic separation prior to MS 
analysis yielded a higher number of observed peptides than MALDI MS measurements. In total, 
129 labeled peptide pairs were detected in the analysis of all the biological replicates (n=4) and 
statistical analysis was performed for all the peptides that were consistently detected. Applying 
the false discovery rate (FDR) correction and the criteria that FDR <0.1, only 2 peptides were 
found to differ between the runner and sedentary groups: calculated unlabeled mass 2119.94 Da 
and 2176.97 Da. Twelve other peptides showed significant differences at an unadjusted p < 0.05. 
The list of candidate peptides that differed between runner and sedentary mice is included in 
Table 3.1. A list of the labeled peptides that were not found to have significant changes between 
runner and sedentary mice is included in Table 3.2. 
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Of the fifteen peaks that were found to differ between the runner and sedentary groups 
with MALDI MS, eight are detected and show similar ratios between groups in the stable 
isotopic labeling experiments. Table 3.1 exhibits how the measured ratios compare between 
quantitative methods. 
 
3.5 Discussion 
Two quantitative MS methods were utilized to measure peptide changes with exercise 
and cocaine conditioning in mice in a CPP experiment. The behavioral results correspond well to 
what was reported in previous work.17 Both runner and sedentary mice show significant CPP for 
cocaine, but runner mice had significantly lower than CPP of sedentary animals. Using MALDI 
MS, the major peptide changes observed between the four treatment groups were found to be 
associated with the access to a running wheel. Due to this result, stable isotopic labeling and LC-
ESI-MS experiments were designed to measure the relative abundance of peptides in sedentary 
and runner mice, while keeping context re-exposure consistent. In comparing the ratios measured 
with the two MS-based quantitation methods, it is important to note that the isotopic labeling 
experiments were performed with pooled samples containing the extracts of 3 animals while the 
MALDI MS profiling experiments were performed with individual extracts; thus, while both 
used a similar number of animals, the MALDI MS data has a larger number of biological 
samples. There are several possible reasons why not all of the candidate peaks from MALDI MS 
measurements were observed in the isotopic labeling measurements. First, the different 
ionization processes could lead to different peptides being detected from the same sample. The 
use of both ESI-MS and MALDI MS has been shown to expand proteome coverage in a single 
sample because unique peptides are observed by each analysis.49 In addition, some of the 
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peptides could have an N-terminal post-translational modification (such as acetylation) that 
prevented their modification with succinic anhydride. Also, relative quantitation with stable 
isotopic labeling requires the ions of interest to be labeled and within the dynamic range of the 
MS instrument in both samples in order to calculate the H4-SA/D4-SA ratio between samples. 
Many of the peaks found to differ between extracts from sedentary and runner mice are 
shortened forms of different isoforms of myelin basic protein (MBP), a major constituent of the 
myelin sheath, which covers the axons of neurons and enhances transmission of action potentials 
along the length of the axons. Several potential roles of MBP-derived peptides in cell-to-cell 
signaling have also been proposed.43, 50 Seven of the 8 overlapping peaks between the MS-based 
quantitation methods are MBP-derived peptides and 2 other MBP-derived peptides were found to 
have significantly higher abundance in the samples from sedentary mice compared to runner 
mice in the isotopic labeling experiments. Exercise has been shown to increase the volume of 
gray matter, which is mostly unmyelinated, in the hippocampus.51 This change in the 
composition of the hippocampus seems to fit with our observation of more MBP-related peptides 
in sedentary animals. Myelination is a component of neural plasticity and appears to play roles in 
how animals behave in learning and memory tasks.52 A study in middle aged mice (age: 11-13 
months) performed by Latimer et al53 found that the levels of full-length MBP decreased in mice 
that ran on a running wheel when they were investigating the effects of exercise on the biology 
of middle age mice. The mice used in our experiment were young adults, but we observed a 
similar pattern of decreased levels of MBP-derived peptides in runner mice. 
 The runner and sedentary animals have a distinct behavioral pattern in the CPP 
experiment and accordingly, there are distinct peptide differences detected between the two 
exercise treatment groups. While MALDI MS did not find peptides that differed with context re-
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exposure, the changes associated with exercise still give insight into the mechanisms driving 
running-induced extinction of CPP for cocaine. Exercise has been shown to induce other 
morphological changes and increase several markers of neuroplasticity in the hippocampus 
including growth factors: brain-derived neurotrophic factor (BDNF), insulin-like growth factor-1, 
and vascular endothelial growth factor.54-57 Furthermore, exercise-induced changes in the brain 
have demonstrated strong correlations with improvements in cognitive function, similar to the 
extinction of CPP.58, 59 Our efforts have yielded identified and unknown candidate peptides that 
change in a specific brain region in runner and sedentary animals used in a CPP experiment. The 
findings yield insight into the biochemical mechanisms driving the extinguishment of CPP with 
wheel running. 
 
3.6 Conclusions 
We have used two MS-based quantitation methods: label free MALDI MS profiling and 
stable isotopic labeling with LC MS detection to provide enhanced measures of peptide changes 
in runner versus sedentary mice. By first performing MALDI MS measurements and statistical 
analysis with a small portion of peptide extracts, we were able to collect peptide profiles from 
individual animals and determine the important trends between treatment groups. Those results 
were expanded using stable isotopic labeling with LC-ESI-MS detection, and for those peptides 
detected in both approaches, the similar trends validated the measurement approaches. The use 
of two MS-based quantitation methods generated increased numbers of peptides that could be 
quantified with each technique generating unique candidate peptides that changed with wheel 
running. Together, the combined measurements yielded 27 peptides, many of which are derived 
from MBP, that showed significant changes in relative amount between sedentary and runner 
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mice. Because of the limited ability of our specific MALDI MS platform for the sequencing 
peptides and the fact that several of the MALDI MS detected peptides were not observed with 
our specific LC-ESI-MS platform, a number of peaks that had significant differences between 
treatments remain unidentified. Future work will aim to identify these peaks. Biologically, these 
results demonstrate that 30 days of running is sufficient to affect peptide signal intensity levels in 
the dentate gyrus of the hippocampus and suggest biochemical changes in this important brain 
region in response to wheel running.  
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3.8 Figures and Tables 
 
 
 
Figure 3.1 A) Schematic diagram of the animal conditioning and testing for conditioned place 
preference. Mice underwent four days of conditioning followed by 30 days housed in cages with 
or without running wheels. Following that, one day of CPP testing was performed to assess 
exercise effects on conditioning. The context re-exposure was performed with one of the two 
contexts (cocaine or vehicle) and sacrifice occurred immediately after context re-exposure.  
B) Picture of the single and dual floor texture chambers used in the CPP experiment. C) Picture 
of where hippocampal sampling from a frozen brain. 
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Figure 3.2 Scheme showing the labeling strategy used in the isotopic labeling experiments to 
compare runner and sedentary mice. Pooled samples were created for each treatment group by 
combining the peptide extracts from 3 animals. 
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Figure 3.3 Representative MALDI MS spectra collected for the peptide extract collected from an 
individual animal. Each spectrum represents the technical replicates from 5 spots generated with 
the peptide extract spiked with the internal standard (MW 2960 Da) co-crystallized with α-
cyano-4-hydroxycinnamic acid (CHCA) matrix.  
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Figure 3.4 Comparison of the number of overlapping and unique peptides found to differ 
between sedentary and runner animals using label-free MALDI MS peptide profiling and stable 
isotopic labeling with LC-ESI-MS detection 
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CHAPTER 4 
CHANGES IN ENDOGENOUS PEPTIDES INDUCED BY EXPOSURE TO A 
COCAINE-ASSOCIATED CONTEXT MEASURED VIA MS-BASED  
QUANTITATIVE PEPTIDOMICS 
 
4.1 Notes and Acknowledgments 
 This chapter focuses on measuring peptide changes via mass spectrometry-based 
quantitative peptidomics in the amygdala of mice re-exposed to a context they were trained to 
associate with cocaine. This chapter is adapted from a manuscript in preparation co-authored by 
Martina L. Mustroph, Elena V. Romanova, Bruce R. Southey, Heinrich Pinardo, Justin S. 
Rhodes, and Jonathan V. Sweedler. My contribution to this work was designing and performing 
MS-related experiments, followed by data analysis and interpretation. Justin Rhodes and 
Jonathan Sweedler initiated this project and provided useful advice throughout. Martina L. 
Mustroph performed the behavioral studies essential to the experiment and collected tissue 
samples for peptidomics work. Heinrich Pinardo assisted in animal training and collection as 
well as the analysis of behavioral data. Other members of the Rhodes laboratory also assisted 
with animal care and dissection. Elena V. Romanova provided guidance in experimental design 
and advice throughout the project. Bruce R Southey aided in statistical analysis of the 
quantitative peptidomics data. The project was supported by the National Institute on Drug 
Abuse under Award no. P30DA018310. The content of this chapter is solely the responsibility of 
the authors and does not necessarily represent the official views of NIDA or the National 
Institutes of Health. 
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4.2 Introduction 
Drug addiction is a complex disease and relapse presents a major obstacle in recovery. 
One factor that can lead to relapse even in recovered drug abusers is re-exposure to drug-related 
cues (e.g. drug-related paraphernalia, places where drug were taken, or people drugs were taken 
with), which trigger powerful cravings.1-4 Finding interventions that help mediate or extinguish 
the cravings induced by drug-paired cues is a critical step in designing more effective 
rehabilitation treatments. There is evidence that incorporating aerobic exercise can improve the 
long-term addiction rehabilitation outcomes.5-8 Exercise-induced changes in the brain could be 
used to alter or extinguish associations between contextual cues and drug reward.   
Both exercise and drugs of abuse activate areas of the brain associated with reward 
learning, including the dopamine and opioid systems.9-11 Within the brain, exercise leads to 
physiological changes including increases in neurogenesis in the hippocampus12, 13 and changes 
in synaptic plasticity in several brain regions.14-17 To study the relationship of exercise and drugs 
of abuse, different behavioral models of drug abuse and reward with lab have been used with 
rodents. Voluntary exercise can be introduced and measured by housing the animal with a 
running wheel. The physiological results of wheel-running activity in rodents closely parallel 
that of aerobic exercise in humans.18 Using a self-administration model that measures drug 
seeking and drug taking behavior, different laboratories have observed that rats with a running 
wheel had a substantially decreased amount of self-administration of heroin,19 
methamphetamine,8 and cocaine20, 21 compared to rats that did not have access to a running 
wheel. Similarly, studies have shown that exercise can facilitate the extinction of conditioned 
place preference (CPP) for cocaine in mice.22-24 CPP is a behavioral paradigm used to model 
drug-context associations and measure the rewarding effects of drugs by tracking the amount of 
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time an animal spends in a place they have been trained to associate with the drug.25, 26 In our 
experimental set-up, mice are trained to associate a particular floor texture with getting a dose of 
cocaine. Runner mice, those that were housed with a running wheel for thirty days after they are 
trained to make context associations, spend significantly less time on the cocaine-associated 
context during preference testing.22-24 Based on these previous results showing an extinction of 
CPP in the runner group, we are investigating the biochemical changes that arise in animals re-
exposed to a context they were trained to associate with cocaine to learn more about the 
mechanism driving the extinction of CPP with exercise. Since exercise and drug abuse both 
induce peptide changes in the brain reward pathway,10, 27 altered expression of cell-to-cell 
signaling peptides may be involved in the recognition of a drug-associated context and play a 
role in the extinction of CPP with wheel running.  
Signaling peptides are small, protein-derived cell-to cell signaling molecules that have 
been implicated in many behaviors and conditions, including drugs of abuse.28, 29 Mass 
spectrometry (MS) was chosen to investigate peptide changes in this study because it is an 
information-rich tool that allows for untargeted, unambiguous identification of the peptides 
present in a sample.30-33 Our laboratory and others have utilized this technology to measure 
peptide changes in animals of different genetic34, 35 and behavioral phenotypes.36, 37 MS-based 
measurements of peptide changes with different drugs of abuse have also been reported.38-42 This 
study investigated peptide changes with drug-paired cues using two behavioral phenotypes that 
were designated by their final context re-exposure: exposure to the cocaine-paired context or 
exposure to a non-drug or vehicle-paired context. The amygdala was chosen as the brain region 
from which to sample for peptides because it is a brain center that controls emotional 
responses.43 Re-exposure to drug-related cues has been shown to cause increases in blood 
 71 
 
flow,44, 45 glucose metabolism,2 Fos expression,46 and dopamine release47, 48 in the amygdala. 
Interrupting the actions of the amygdala has demonstrated that it is required for acquisition and 
reconsolidation of the context cues used in CPP.49, 50 These previously observed changes in the 
amygdala make it a clear candidate brain region for examining peptide changes with drug-paired 
context re-exposure. 
To investigate the role of signaling peptides in drug-to-context associations, a group of 
mice were trained and conditioned for CPP as outlined in Mustroph et al.23 Following 
conditioning, half of the mice were housed with a running wheel to investigate if similar peptide 
changes were observed with different context re-exposures in the runner group. Unlike previous 
quantitative peptidomic studies where comparisons involve a fairly large perturbation in 
physiological state such as a genetic manipulation or administration of a drug, here we examined 
what is expected to be a subtle change. Within the runner and sedentary groups, all animals 
received identical treatment in the training phase, including the number of total cocaine 
conditioning trials, and a single trial of CPP testing; the only point of differentiation is in the 
final context exposure. While changes in dopaminergic and glutamatergic signaling with drug-
related craving and seeking have been measured,47, 51, 52 the role of signaling peptides has not 
been fully examined. Knowledge of specific peptides up or down-regulated in response to a 
context previously associated with cocaine will allow for future targeting of those peptides in the 
search for effective interventions for drug addiction. 
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4.3 Experimental  
4.3.1 Chemicals 
All chemicals were obtained from Sigma Aldrich (St Louis, MO) unless otherwise stated. 
Heavy (D4) succinic anhydride was purchased from C/D/N Isotopes (Pointe-Claire, Quebec, 
Canada). Cocaine hydrochloride (Sigma Aldrich, St. Louis, MO) was dissolved in 0.9% saline 
and administered at a dose of 10 mg/kg via intraperitoneal (i.p.) injections in a volume of 10 
ml/kg. Dose was chosen based on the literature and was prepared according to the salt not the 
base form.53, 54 
4.3.2 Animals and Conditioned Place Preference 
Procedures were performed with two sets of male C57BL/6J mice (acquired at 5 weeks of 
age from the Jackson Laboratory (Bar Harbor, ME)); the first set consisted of 40 animals and the 
second set had 48 animals. The resources for housing, training, and testing for CPP limited the 
number of animals per training set. All procedures were approved by the University of Illinois 
Institutional Animal Care and Use Committee and adhered to NIH guidelines and measures were 
taken to minimize the number of animals used and the pain and suffering of the mice.  
In each set of mice, all animals underwent conditioning trials for four days that included 
four conditioned stimulus trials (cocaine injection paired with one floor texture) and four control 
trials (saline injection paired with the alternate floor texture). Following the conditioning phase, 
half of the animals (the runner group, n=20 in set 1 and n=25 in set 2) were housed with a 
running wheel. The rotations of the running wheel were monitored continuously in 1 min 
increments via magnetic switches. The other half of the animals (n=20 in set 1 and n=23 in set 2) 
assigned as the sedentary group were housed without running wheels and their random physical 
activity was kept to a minimum. Testing took place 31 days after the final conditioning session. 
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For testing, each mouse was injected with 10 ml/kg saline (i.p.) and placed in the center of a dual 
floor texture. CPP was determined by measuring the duration of time spent on each floor texture. 
The day after CPP testing, each animal underwent a 30 min session of re-exposure to a single 
context by placement in one of the single floor texture chambers used in the conditioning phase. 
In both the running and sedentary groups, half of the animals (Set 1: n = 10 runner mice, n=10 
sedentary mice; Set 2: n=12 runner mice and n= 12 sedentary mice) were re-exposed to the floor 
texture they had been conditioned to associate with cocaine and the other half (Set 1: n = 10 
runner mice, n=10 sedentary mice; Set 2: n=13 runner mice and n= 11 sedentary mice) were re-
exposed to the texture they had been trained to associate with the vehicle (saline). Mice were 
deliberately not placed in the dual-floor texture chamber to isolate the effect of the drug-related 
conditioning. Animals underwent a 30 min context re-exposure the day after CPP testing because 
this was the time point where previously the runner and sedentary groups showed the greatest 
divergence in CPP.23 
4.3.3 Tissue Sampling, Peptide Extraction, and Stable Isotopic Labeling 
Immediately following the 30 minute context re-exposure session, mice were 
anesthetized with 150 mg/kg sodium pentobarbital (i.p.) and then perfused transcardially with 
ice-cold saline. Their brains were carefully removed and immediately flash-frozen in liquid 
nitrogen for preservation and stored at -80° C. For sampling, frozen brains were mounted using 
distilled water on a cryostat and tissue from the bilateral basolateral amygdala was isolated via 
biopsy punches of 1.25 mm diameter (World Precision Instruments, Sarasota, FL). Coordinates 
of the punches taken were from 0.94 to -1.94 bregma, determined according to the mouse brain 
atlas.55 Tissue samples from both hemispheres were placed together into 19 µL 0.25% acetic acid 
extraction solution and incubated for 24 hours at 4°C. The tissue was then homogenized by 
 74 
 
sonication in a water bath for 10 minutes followed by centrifugation to separate the extract and 
tissue pellet. The extraction process was repeated with another 15 µL of 0.25% acetic acid. Both 
extractions were combined. Pooled samples were created from the extracts of three animals that 
had undergone identical treatment (i.e., runner mice re-exposed to the cocaine-paired context). 
The two independent sets of animals that yielded three samples per behavioral group, for six 
samples total per treatment group (sedentary or runner) and context re-exposure (cocaine-paired 
context or vehicle-paired context). The remaining 12 peptide extracts were combined (without 
regard to treatment group) in 3 samples to be used for peptide sequencing.  
 Peptides in the pooled samples for quantitative measurements were covalently modified 
with H4- or D4-succinic anhydride (SA) for relative quantitation following the procedure 
described in Hou et al.56 The same comparison of context re-exposure was performed with both 
the sedentary and runner groups, as diagramed in Figure 4.1. The samples were labeled and 
combined as follows: sedentary mice re-exposed to the cocaine-paired context (H4-SA) with 
sedentary mice re-exposed to the vehicle-paired context (D4-SA) and runner mice re-exposed to 
the cocaine-paired context (H4-SA) with runner mice re-exposed to the control context (D4-SA). 
The samples set aside for peptide identification were also labeled with H4-SA. 
4.3.4 Peptide Measurement and Quantitation by LC-MS 
 Each of the labeled samples was diluted 5-fold in water with 0.1% formic acid (FA) and a 
1 µL sample was loaded onto a trap column (200 µm i.d. x 20 mm length, Acclaim™ Pepmap™ 
C18 100, 5µm, 100 Å; Thermo Scientific, Rockwood, TN, USA) at 20 µL/min with an 
nanoHPLC system (Ultimate3000, Dionex, Sunnyvale, CA, USA). Analytical separation was 
performed at 300 nL/min with a reverse phase C18 column (100 µm ID by 15 cm length, Magic 
C18, 3 µm, 200 Å; Michrom Bioresources, Auburn, CA). The LC solvents were water with 
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0.1%FA for solvent A and 80% ACN with 0.1%FA for solvent B. The gradient used was 0-10 
min, 4-25%B; 10-20 min, 25-30%B; 20-50 min, 30-60%B; 50-55 min, 60-75%B; 55-59 min, 75-
90%B; 59-69 min, 90%B; 69 min 90-20%B; 69-73 min 20-4%B;73-115 min 4% B. Eluting 
peptides were analyzed in MS mode on a QTOF MS (MaXis Impact, Bruker, Bremen, Germany) 
with the CaptiveSpray source (Bruker) for a m/z range of 290-3000. Each sample was injected 
and analyzed twice for 2 technical replicates per sample. 
4.3.5 MS Data Analysis and Statistical Analysis 
Labeled peptide pairs were selected based on their charge, retention time, and mass 
match using DataAnalysis 4.2 (Bruker). The addition of H4-SA causes a 100 Da mass shift and 
D4-SA a shift of 104 Da, therefore, the mass difference between labeled peptides is 4 Da per 
label and the calculated unlabeled mass of a pair of peptides should be equal. After detecting a 
labeled pair at a particular time point in the LC-MS analysis, extracted ion chromatograms (EIC) 
were created for the monoisotopic peak of the light and heavy species. An average mass 
spectrum was created for the full width of the peaks of the EIC that was used for quantification. 
For each peptide, intensities were obtained by summing the intensity of the first four isotopes in 
the spectrum for the light and heavy forms. The summed intensities were then log2-transformed 
and the difference between light and heavy forms was used to calculate fold changes between 
treatment groups. Fold changes were averaged between technical replicates and compared across 
the six biological samples generated by the two sets of animals. Student’s t-tests were used to 
determine which peaks showed fold changes significantly different from zero. Adjustment for 
multiple hypothesis testing was controlled by applying the False Discovery Rate (FDR) 
correction.57  
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4.3.6 Peptide Identification by MS/MS 
For peptide identification, conditions were kept consistent with quantitative 
measurements by LC-MS. The same nanoHPLC system (Ultimate 3000, Dionex) with an 
identical gradient coupled to the QTOF MS (MaXis Impact, Bruker) was used with MS/MS data 
collection. The MS/MS precursor ion selection was set for the three ions of highest intensity per 
MS scan and active exclusion of previously fragmented ions was enabled. MS and MS/MS 
spectra were collected for an m/z range of 290-3000. After data collection, the chromatogram 
analysis was exported as an .mzXML file and searched against an in-house mouse neuropeptide 
database and the whole mouse proteome downloaded from UniProtKB58 using PEAKS Studio 7 
(Bioinformatics Solutions, Inc. Waterloo, ON, Canada). The search parameters used in the 
software were as follows: no enzyme digestion, variable post-translational modifications 
(including N-terminal pyro-Glu, acetylation, C-terminal amidation, phosphorylation, oxidation of 
methionine, and the addition of succinic anhydride), and a mass tolerance of 0.1 Da for the 
precursor ion and 0.1 Da for fragment ions. Peptide assignments were judged on the -10logP 
(>20) score and mass error. 
 
4.4 Results 
4.4.1 Peptide Identification 
 Peptide identification was performed by analyzing labeled samples with tandem MS/MS. 
Using labeled samples allowed for an enhanced confidence in identifications because the 
observed ions, retention time, and charge states could be correlated with the quantitative 
analysis. Most of the identified peptides were from cytosolic proteins, but two peptides were 
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derived from prohormone precursors: somatostatin and proSAAS. A list of the identified 
peptides is presented in Table 4.1. 
4.4.2 Quantitative Peptidomics 
 Differential isotopic labeling and MS analysis were used to measure peptide changes 
between mice that were re-exposed to a context they were trained to associate with cocaine and 
mice re-exposed to a vehicle-paired context separately for sedentary and runner groups. While 
many labeled peptide pairs were detected in each individual analysis, only 39 labeled peptide 
pairs were consistently detected in samples from both sets of the runner mice and 36 labeled 
peptide pairs were consistently detected in samples from both sets of the sedentary mice. While 
attempts were made to keep all conditions between sample sets consistent, the animals were 
acquired and sampled at different times of the year. This discrepancy in timing could have led to 
some peptides being unique to one set of animals. Variability in the peptides detected in the 
different pooled samples may also be artifacts of sampling, with certain peaks being detected in 
only 1 or 2 samples. Looking at the peptides identified by MS/MS, a lot of the peptides detected 
were from structural proteins like myelin basic protein (MBP) and actin (ACTB) and many of 
these were the peaks that showed the high variation between different pooled samples and fold 
changes did not seem to correlate with context re-exposure.  
In the analysis of runner mice, only one peptide was found to have a significant change in 
abundance (FDR < 0.1) between animals re-exposed to the cocaine-paired context and animals 
re-exposed to the control context. The peptide is derived from β-hemoglobin and comes from the 
C-terminal of the protein. Three other peptides, all derived from α-hemoglobin, showed 
significant differences at an unadjusted p < 0.05. All four peptides show a higher abundance in 
the animals re-exposed to the cocaine-paired context compared to the control context (Figure 
 78 
 
4.3). These four peptides showed significant differences based on context re-exposure only in the 
runner group, not in the sedentary group (Figure 4.3).  
When making the same comparison of animals re-exposed to the different contexts in the 
sedentary group, no peptides had a statistically significant (FDR < 0.1) change. Two peptides 
showed significant differences between treatment groups at an unadjusted p < 0.05. The peptides, 
one of which is a fragment of actin (sequence FAGDDAPRAVFPSIVGRPRHQG) and the other 
could not be identified (calculated unlabeled MW: 927.43 Da) are both decreased in the animals 
re-exposed to the cocaine-paired context compared to the animals re-exposed to the control 
context. The observed log2-based fold change for the actin-derived peptide between the context 
re-exposures (cocaine-paired context – vehicle paired context) was -1.33± 0.80 (Mean ± std 
error). The mass spectrum of this peptide is shown as an example in Figure 4.2. A graph 
depicting the average fold changes of the peaks of interest in the runner and sedentary groups is 
presented in Figure 4.3.  
 
4.5 Discussion 
 This study aimed to discover peptide changes using MS-based quantitative peptidomics 
in the amygdala of mice when they were re-exposed to a context they had previously been 
trained to associate with cocaine. Behavioral results indicate significant CPP at testing in both 
sedentary and runner animals. Furthermore, CPP of the runner mice was already decreased 
relative to the CPP of sedentary mice on the CPP test day. We know from previous studies23, 24 
that the CPP of runner mice extinguishes faster than the CPP of sedentary mice, and that the CPP 
diverged the most on the second day of testing. Instead of a second day of CPP testing, we opted 
to re-expose mice to a single context (either drug-paired or vehicle-paired) in order to assess 
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subtle peptide changes in response to context in animals that we know to show divergent CPP, 
which has, to our knowledge, never been attempted. 
While many peptides were observed in the quantitative peptidomic experiments, only 
four were found to differ with context re-exposure in runner mice and only two peptides were 
found to differ with context re-exposure in sedentary animals. Importantly, these peaks did not 
exhibit the same changes in both runner and sedentary animals, indicating that the chemistry of 
the amygdala was changed along with the observed behavior in the two groups. The other 
peptides detected were not statistically different with context re-exposure, which is expected for 
such a subtle change. 
 In active mice, the peptides that show a higher relative abundance in animals re-exposed 
to the cocaine-paired context compared to the control context are derived from α- and β-
hemoglobin. The α- and β-subunits of hemoglobin are expressed in neuronal cells59, 60 and 
several hemoglobin-derived peptides have been found to be unique to the brain.61 Hemoglobin-
derived peptides have been proposed as non-classical neuropeptides because they are derived 
from cytosolic proteins, but may play a signaling role because of their interactions with cell to 
cell signaling receptors.62-64 To date, there are two classes of hemoglobin-derived peptides whose 
roles as signaling peptides have been extensively explored. The first class of peptides, called 
hemopressins, is derived from α-and β-hemoglobin and interacts with cannabinoid receptors.62, 64, 
65 The second class named hemorphins consists of several β-hemoglobin derived peptides that 
interact with opioid receptors.62, 66 MS-based peptidomics studies have detected and identified 
the hemopressin and hemorphin peptides as well as other peptides derived from α-and β-
hemoglobin in the brain.61, 63, 67, 68 Intriguingly, the hemoglobin-derived peptides identified in this 
study are not hemopressin or hemorphin peptides. Therefore, their peptide-receptor actions are 
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not known. The β-hemoglobin derived peptide comes from the C-terminal of the sequence and a 
previous study by the Fricker laboratory identified this particular peptide in extracts from both 
the brain and in blood of mice.61 Prior to tissue sampling, the animals were perfused with saline 
to remove blood from the brain; therefore, peptides that are products of blood protein 
degradation should be limited. However, if degradation of blood hemoglobin is the source of our 
β-hemoglobin derived peptide, its observed increase with re-exposure to the cocaine-paired 
contexts correlates well with previous studies that saw an increase in blood flow in the amygdala 
with drug-paired cues.44, 45 However, one of the hemopressin peptides was also detected in both 
blood and brain tissue61 and therefore, the presence of the β-hemoglobin C-terminal peptide in 
blood samples does not disqualify it as a potential signaling peptide. The α-hemoglobin-derived 
peptides identified in this study as having higher abundance in runner mice re-exposed to a 
cocaine-paired context than in runner mice re-exposed to a vehicle-paired context originate from 
the same region of the protein and correlate to residues 107-123, 110-123, and 107-128. None of 
these peptides were detected in the peptidomic analysis of the blood,61 but the largest peptide 
(residues 107-128) has been observed in peptide extracts from the brain.63, 69 As this peptide 
appears to be distinct to the brain, its relative increase with cocaine-context re-exposure is likely 
unrelated to the increase in cerebral blood flow in the amygdala.  
 In the sedentary group, a peptide derived from the structural protein actin was found to 
significantly differ between the groups re-exposed to different contexts. Actin is responsible for 
the remodeling of the cytoskeleton of neurons and changes in actin dynamics have been linked 
memory consolidation and retrieval with drugs of abuse.70-72 Interestingly, other actin-derived 
peptides show a high degree of variability in calculated fold changes in the different pooled 
samples and the observed decrease with re-exposure to the cocaine context in sedentary mice is 
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unique to this particular actin-derived peptide. The peptide sequence is too short to determine 
from which actin isoform that it originated. It could be another example of a peptide that is 
produced from an intercellular protein that functions in cell-cell signaling63 or could be related to 
a change in actin dynamics in the amygdala. Since it is lower in the animals re-exposed to the 
cocaine-paired context compared to those re-exposed to the vehicle-paired context, the peptide 
may play a role in suppressing signals associated with drug-cue induced cravings.  
 
4.6 Conclusions and Future Directions 
In this study, we used stable isotopic labeling with MS detection to measure relative 
amounts of peptides in the amygdala of animals re-exposed to a cocaine-paired context 
compared to those re-exposed to a vehicle-paired context. The comparison was made with both 
sedentary mice and runner mice, which had been given access to a running wheel for 30 days 
between conditioning and CPP testing. Previous observations show that the preference for the 
cocaine-paired context is diminished in runner mice and our results suggest distinct biological 
processes occurring in this behavioral group. Re-exposure to the cocaine-paired context 
correlated with relative increases in four hemoglobin-derived peptides in runner mice. With 
sedentary animals, the peptide profiles were highly variable and only two peptides were found to 
differ significantly (unadjusted p < 0.05) with context re-exposure. These results represent 
correlation between context re-exposure and peptide levels, not necessarily causation. Future 
studies will be needed to further examine the role of these peptides in the brain and their 
relationship with context-induced drug cravings. 
The goal of this study was to determine a very subtle change, peptides that were up or 
down-regulated in the amygdala based on environmental context in a relatively short time frame 
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of 30 min. While previous measurements in neurochemical changes in the brain with exposure to 
a drug-paired cue focused on neurotransmitters whose actions are almost immediate,47 here, we 
probed for changes in endogenous peptide levels. While we hoped to measure changes in 
neuropeptides from the secretory pathway, instead we found peptides whose role is not yet 
characterized. Future work can explore whether a different exposure time changes the peptides 
detected in the amygdala and other brain regions can also be investigated to get a complete 
picture of peptide changes with CPP for cocaine. 
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4.8 Figures and Tables 
 
 
 
Figure 4.1 Scheme showing the labeling strategy used in the relative quantitation experiments. 
Samples for the cocaine and vehicle context were created by pooling the peptide extracts from 3 
animals.  
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A) 
 
B) 
 
Figure 4.2 Representative chromatogram and mass spectrum of a succinic anhydride (SA)-
labeled peptide from the basolateral amygdala of sedentary mice. A) Extracted ion 
chromatograms of the light (m/z 613.32) and heavy (m/z 614.33) species in the labeled peptide 
pair (MW 2349.13 plus one label, charge state +4). B) Representative mass spectrum of the 
labeled peptide pair. Peptide extracts from animals re-exposed to the cocaine-paired context were 
labeled with H4-SA and peptide extracts from animals re-exposed to the vehicle context were 
labeled with D4-SA.  
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Figure 4.3 Graphical representation of the fold changes observed in peptides of interest in the 
runner and sedentary groups. Fold changes are calculated by subtracting log2-transformed 
intensity sum for the first four isotopes of the heavy labeled peptide (corresponding to the 
vehicle-context re-exposure) from the log2-transformed intensity sum for the first four isotopes 
of the light labeled peptide (corresponding to the cocaine-context re-exposure). Values are the 
average fold change for n=6 biological samples, with the exception of HBA 110-123 where n=4, 
and error bars represent standard error. * unadjusted p-values <0.05, indicating fold changes are 
significantly different from zero based on Student’s T-test **FDR<0.1 
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Table 4.1: List of peptides identified from the amygdala by MS/MS and database searching. 
Precursor Peptide Sequence z #T Obs. 
Mass 
Mass 
Error 
(ppm) 
Aconitate 
hydratase 
766-774 W.FRAGSALNR.M 2 1 990.54 -60.6 
Aconitate 
hydratase 
154-175 F.LATAGAKYGVGFWRPG 
SGIIHQ.I 
3 2 2285.21 -50.2 
Actin   169-176 G.YALPHAIL.R 1 1 896.51 -51.4 
Actin   169-177 G.YALPHAILR.L 2 1 1052.61 -52.5 
Actin   95-104 L.RVAPEEHPVL.L 2 1 1145.62 -47.4 
Actin   169-178 G.YALPHAILRL.D 2 1 1165.70 -59.3 
Actin   32-42 F.PSIVGRPRHQG.V 3 1 1202.66 -51.3 
Actin   21-33 G.FAGDDAPRAVFPS.I 2 1 1348.64 -41.1 
Actin   21-36 G.FAGDDAPRAVFPSIVG.R 2 1 1617.82 -26.7 
Actin   91-104 F.YNELRVAPEEHPVL.L 2 1 1664.85 -26.5 
Actin   357-372 W.ISKQEYDESGPSIVHR.K 2 2 1843.91 -48.4 
Actin   357-373 W.ISKQEYDESGPSIVHRK.C 2 3 1972.00 -59.8 
Actin   21-39 G.FAGDDAPRAVFPSIVGRPR.H 3 1 2027.07 -27.1 
Actin   356-373 M.WISKQEYDESGPSIVHRK.C 3 3 2158.08 -69.4 
Actin   21-40 G.FAGDDAPRAVFPSIVGRPRH.Q 4 1 2164.13 -28.1 
Actin   22-42 F.AGDDAPRAVFPSIVGRPRHQG.V 4 1 2202.14 -40.8 
Actin   21-42 G.FAGDDAPRAVFPSIVGRPRHQG.V 4 1 2349.21 -38.5 
Actin   21-46 G.FAGDDAPRAVFPSIVGRPRHQG 
VMVG.M 
4 1 2735.41 -28.1 
Actin   21-52 G.FAGDDAPRAVFPSIVGRPRHQGV 
MVGMGQKDS.Y 
4 2 3381.68 -31.4 
ADP/ATP 
translocase 1 
13-30 F.LAGGIAAAVSKTAVAPIE.R 2 2 1637.94 -64.9 
ADP/ATP 
translocase 1 
12-30 D.FLAGGIAAAVSKTAVAPIE.R 2 2 1785.00 -58.3 
ADP/ATP 
translocase 1 
12-31 D.FLAGGIAAAVSKTAVAPIER.V 2 2 1941.10 -54.2 
ADP/ATP 
translocase 1 
13-33 F.LAGGIAAAVSKTAVAPIERVK.L 3 3 2021.20 -72.8 
ADP/ATP 
translocase 1 
13-34 F.LAGGIAAAVSKTAVAPIERVKL.L 3 3 2134.28 -68.8 
ADP/ATP 
translocase 1 
12-33 D.FLAGGIAAAVSKTAVAPIERVK.L 2 3 2168.27 -61.9 
ADP/ATP 
translocase 1 
12-34 D.FLAGGIAAAVSKTAVAPIERVKL.L 2 3 2281.35 -58.5 
ADP/ATP 
translocase 1 
12-35 D.FLAGGIAAAVSKTAVAPIER 
VKLL.L 
3 3 2394.44 -56.3 
α-hemoglobin 111-123 L.ASHHPADFTPAVH.A 3 1 1385.65 -32.9 
α-hemoglobin 110-123 T.LASHHPADFTPAVH.A 3 1 1498.73 -31.9 
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Table 4.1 (continued) 
Precursor Peptide Sequence z #T Obs. 
Mass 
Mass 
Error 
(ppm) 
α-hemoglobin 35-47 F.ASFPTTKTYFPHF.D 2 2 1542.75 -57.4 
α-hemoglobin 107-121 L.LVTLASHHPADFTPA.V 2 1 1575.80 -35.9 
α-hemoglobin 34-47 M.FASFPTTKTYFPHF.D 2 2 1689.82 -58.1 
α-hemoglobin 108-123 L.VTLASHHPADFTPAVH.A 3 1 1698.85 -40.5 
α-hemoglobin 107-123 L.LVTLASHHPADFTPAVH.A 3 1 1811.93 -25.0 
α-hemoglobin 107-124 L.LVTLASHHPADFTPAVHA.S 3 1 1882.97 -32.5 
α-hemoglobin 111-128 L.ASHHPADFTPAVHASLDK.F 3 2 1899.92 -48.4 
α-hemoglobin 110-128 T.LASHHPADFTPAVHASLDK.F 3 2 2013.01 -45.7 
α-hemoglobin 107-126 L.LVTLASHHPADFTPAVHASL.D 3 1 2083.09 -29.3 
α-hemoglobin 107-128 L.L(+100.07)VTLASHHPADFTPA 
VHASLDK(+100.07).F 
3 2 2326.21 -39.0 
ATP synthase 
subunit alpha 
76-88 L.SIGDGIARVHGLR.N 3 1 1349.75 -40.4 
ATP synthase 
subunit alpha 
76-89 L.SIGDGIARVHGLRN.V 3 1 1463.80 -37.4 
ATP synthase 
subunit alpha 
69-88 L.EETGRVLSIGDGIARVHGLR.N 4 1 2134.16 -34.7 
ATP synthase 
subunit alpha 
69-89 L.EETGRVLSIGDGIARVHGLRN.V 4 1 2248.20 -25.8 
ATP synthase 
subunit alpha 
64-88 D.TSVDLEETGRVLSIGDGIARVH 
GLR.N 
4 1 2649.42 -26.6 
ATP synthase 
subunit alpha 
64-89 D.TSVDLEETGRVLSIGDGIARVH 
GLRN.V 
4 1 2763.46 -25.7 
ATP synthase 
subunit alpha 
59-89 R.ILGADTSVDLEETGRVLSIGDGIAR 
VHGLRN.V 
4 1 3232.72 -18.5 
ATP synthase 
subunit beta  
50-64 Q.ASAAPKAGTATGRIV.A 2 2 1369.77 -59.5 
ATP synthase 
subunit beta  
98-110 L.EVAQHLGESTVRT.I 2 1 1425.72 -38.4 
ATP synthase 
subunit beta  
50-65 Q.ASAAPKAGTATGRIVA.V 2 2 1440.80 -55.9 
ATP synthase 
subunit beta  
48-65 A.AQASAAPKAGTATGRIVA.V 2 2 1639.90 -49.8 
ATP synthase 
subunit beta  
50-72 Q.ASAAPKAGTATGRIVAVIG 
AVVD.V 
2 2 2094.18 -37.2 
ATP synthase 
subunit delta 
71-84 L.ASHVPTLQVLRPGL.V 2 1 1486.86 -42.1 
ATP synthase 
subunit delta 
124-137 D.MLDLGAARANLEKA.Q 2 2 1471.78 -68.8 
ATP synthase 
subunit delta 
71-92 L.ASHVPTLQVLRPGLVVVH 
TEDG.T 
3 1 2323.26 -24.2 
ATP synthase 
subunit delta 
71-95 L.ASHVPTLQVLRPGLVVVHTED 
GTTT.K 
3 1 2626.41 -27.5 
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Table 4.1 (continued) 
Precursor Peptide Sequence z #T Obs. 
Mass 
Mass 
Error 
(ppm) 
ATP synthase 
subunit delta 
71-95 L.ASHVPTLQVLRPGLVVVHTED 
GTTT.K 
3 1 2626.41 -27.5 
ATP synthase 
subunit O  
24-33 P.FAKLVRPPVQ.V 2 2 1153.70 -68.5 
ATP synthase 
subunit O  
24-34 P.FAKLVRPPVQV.Y 2 2 1252.77 -70.0 
ATP synthase 
subunit O  
24-36 P.FAKLVRPPVQVYG.I 2 2 1472.85 -54.8 
ATP synthase 
subunit O  
27-42 K.LVRPPVQVYGIEGRYA.T 3 1 1816.00 -56.2 
ATP synthase 
subunit O  
24-42 P.FAKLVRPPVQVYGIEGRYA.T 3 2 2270.31 -51.2 
β-hemoglobin C terminal K.VVAGVAAALAHKYH 2 2 1405.78 -63.0 
Clathrin coat 
assembly 
protein 
80-93 L.VTTHHLMVHGNERF.I 4 1 1676.82 -40.1 
Clathrin coat 
assembly 
protein 
73-93 W.VVVFKALVTTHHLMVHGNERF.I 4 2 2433.31 -40.1 
Claudin-11 191-207 F.Y(+100.07)YSSGSSSPTHAK(+100.07) 
SAHV 
2 1 1715.93 -33.6 
Elongation 
factor 1-alpha 
1 
344-354 Q.VIILNHPGQIS.A 2 1 1189.68 -46.7 
Elongation 
factor 1-alpha 
2 
344-352 Q.VIILNHPGQ.I 2 1 989.57 -54.2 
Elongation 
factor 1-alpha 
2 
344-354 Q.VIILNHPGQIS.A 2 1 1189.68 -46.7 
Elongation 
factor 1-alpha 
2 
344-359 Q.VIILNHPGQISAGYSP.V 2 1 1664.89 -38.1 
Elongation 
factor 1-alpha 
2 
344-360 Q.VIILNHPGQISAGYSPV.I 2 1 1763.96 -26.2 
Fructose-
bisphosphate 
aldolase  
211-223 L.AAVYKALSDHHVY.L 2 2 1472.74 -67.2 
Glucose-6-
phosphate 
isomerase 
2-10 M.A(+42.01)ALTRNPQF.Q 2 0 1058.55 -9.4 
Glucose-6-
phosphate 
isomerase 
2-11 M.A(+42.01)ALTRNPQFQ.K 1 0 1186.61 1.1 
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Table 4.1 (continued) 
Precursor Peptide Sequence z #T Obs. 
Mass 
Mass 
Error 
(ppm) 
Glucose-6-phosphate 
isomerase 
2-12 M.A(+42.01)ALTRNPQFQK.L 2 1 1314.70 -43.3 
Glucose-6-phosphate 
isomerase 
2-13 M.A(+42.01)ALTRNPQFQKL.L 2 1 1427.79 -31.7 
Glucose-6-phosphate 
isomerase 
14-25 L.LEWHRANSANLK.L 2 1 1537.82 -68.4 
Glucose-6-phosphate 
isomerase 
2-21 M.A(+42.01)ALTRNPQFQKL 
LEWHRANS.A 
3 1 2421.27 -33.5 
Isocitrate 
dehydrogenase 3 
(NAD+) beta 
371-384 D.FIKSVIGHLHPHGG 3 2 1497.82 -61.4 
Macrophage migration 
inhibitory factor 
84-94 L.LSDRLHISPDR.V 3 1 1307.69 -44.6 
Macrophage migration 
inhibitory factor 
5-17 F.IVNTNVPRASVPE.G 2 1 1394.75 -31.2 
Macrophage migration 
inhibitory factor 
83-94 G.LLSDRLHISPDR.V 3 1 1420.78 -40.8 
Macrophage migration 
inhibitory factor 
5-18 F.IVNTNVPRASVPEG.F 2 1 1451.77 -38.2 
Macrophage migration 
inhibitory factor 
30-46 Q.ATGKPAQYIAVHVVPDQ.L 2 2 1792.95 -46.7 
Macrophage migration 
inhibitory factor 
28-46 L.AQATGKPAQYIAVHVV 
PDQ.L 
2 2 1992.04 -41.0 
Macrophage migration 
inhibitory factor 
27-46 Q.LAQATGKPAQYIAVHVV 
PDQ.L 
3 2 2105.13 -48.4 
Macrophage migration 
inhibitory factor 
24-46 L.TQQLAQATGKPAQYIAVHV 
VPDQ.L 
3 2 2462.29 -40.4 
Malate dehydrogenase 43-52 L.LLKNSPLVSR.L 2 2 1125.69 -77.9 
Malate dehydrogenase 27-41 K.VAVLGASGGIGQPLS.L 2 1 1324.74 -51.3 
Malate dehydrogenase 25-40 N.AKVAVLGASGGIGQPL.S 2 2 1436.84 -61.5 
Malate dehydrogenase 27-42 K.VAVLGASGGIGQPLSL.L 2 1 1437.82 -47.7 
Malate dehydrogenase 43-55 L.LLKNSPLVSRLTL.Y 2 2 1452.90 -55.3 
Malate dehydrogenase 25-41 N.AKVAVLGASGGIGQPLS.L 2 2 1523.87 -53.4 
Malate dehydrogenase 25-42 N.AKVAVLGASGGIGQPLSL.L 2 2 1636.95 -49.0 
Malate dehydrogenase 224-258 L.ATLTGRIQEAGTEVVKAKA 
GAGSATLSMAYAGARF.V 
4 3 3453.80 -65.6 
Myelin basic protein 212-220 T.QDENPVVHF.F 2 0 1083.50 -1.0 
Myelin basic protein 158-168 R.HGFLPRHRDTG.I 3 1 1291.65 -37.2 
Myelin basic protein 156-166 H.ARHGFLPRHRD.T 3 1 1360.72 -44.8 
Myelin basic protein 224-237 N.IVTPRTPPPSQGKG.G 2 2 1433.80 -61.7 
Myelin basic protein 157-168 A.RHGFLPRHRDTG.I 4 1 1447.75 -42.4 
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Table 4.1 (continued) 
Precursor Peptide Sequence z #T Obs. 
Mass 
Mass 
Error 
(ppm) 
Myelin basic protein 155-166 D.HARHGFLPRHRD.T 4 1 1497.78 -40.8 
Myelin basic protein 207-219 S.QHGRTQDENPVVH.F 3 0 1515.72 -1.7 
Myelin basic protein 156-168 H.ARHGFLPRHRDTG.I 4 1 1518.79 -43.2 
Myelin basic protein 155-167 D.HARHGFLPRHRDT.G 4 1 1598.83 -28.8 
Myelin basic protein 154-166 M.DHARHGFLPRHRD.T 4 1 1612.81 -37.8 
Myelin basic protein 155-168 D.HARHGFLPRHRDTG.I 4 1 1655.85 -36.9 
Myelin basic protein 154-167 M.DHARHGFLPRHRDT.G 4 1 1713.86 -35.6 
Myelin basic protein 154-168 M.DHARHGFLPRHRDTG.I 4 0 1770.88 1.2 
Myelin basic protein 154-168 M.DHARHGFLPRHRDTG.I 4 1 1770.88 -33.9 
Myelin basic protein 153-166 T.M(+42.01)DHARHGFLPR 
HRD.T 
4 0 1785.86 -6.7 
Myelin basic protein 224-240 N.IVTPRTPPPSQGK(+42.01) 
GGRD.S 
3 1 1803.96 -30.9 
Myelin basic protein 153-167 T.MDHARHGFLPRHRDT.G 4 0 1844.90 -12.7 
Myelin basic protein 153-167 T.M(+42.01)DHARHGFLPRHR 
DT.G 
4 0 1886.91 2.4 
Myelin basic protein 153-168 T.MDHARHGFLPRHRDTG.I 4 0 1901.92 1.9 
Myelin basic protein 153-168 T.M(+42.01)DHARHGFLPRHR 
DTG.I 
4 0 1943.93 2.8 
Myelin basic protein 152-168 S.TMDHARHGFLPRHRDTG.I 4 0 2002.97 -14.0 
Myelin basic protein 152-168 S.TMDHARHGFLPRHRDTG.I 4 1 2002.97 -31.3 
Myelin basic protein 202-219 S.LPQKSQHGRTQDENPVVH.F 4 1 2069.04 -33.8 
Myelin basic protein 151-168 A.STMDHARHGFLPRHRDTG.I 4 1 2090.00 -28.7 
Myelin basic protein 154-171 M.DHARHGFLPRHRDTGILD.S 4 1 2112.07 -29.5 
Myelin basic protein 154-171 M.DHARHGFLPRHRDTGILD.S 4 1 2112.07 -29.5 
Myelin basic protein 154-171 M.DHARHGFLPRHRDTGILD.S 4 1 2112.07 -29.5 
Myelin basic protein 201-219 G.SLPQKSQHGRTQDENPVVH.F 3 2 2156.07 -42.3 
Myelin basic protein 154-172 M.DHARHGFLPRHRDTGILDS.I 4 1 2199.10 -36.3 
Myelin basic protein 153-171 T.M(+42.01)DHARHGFLPRHRD 
TGILD.S 
4 0 2285.12 -11.2 
Myelin basic protein 201-220 G.SLPQUSQHGRTQDENPVVHF.F 3 2 2303.14 -45.4 
Myelin basic protein 198-220 T.HYGSLPQKSQHGRTQDENP 
VVHF.F 
4 1 2660.28 -35.8 
Neurogranin 52-76 C.GRKGPGPGGPGGAGGARGGAG 
GGPS.G 
3 1 1944.96 -42.8 
Peptidyl-prolyl cis-
trans isomerase  
135-148 Y.AYGATGHPGIIPPH.A 2 1 1386.70 -26.5 
Peptidyl-prolyl cis-
trans isomerase  
134-148 D.YAYGATGHPGIIPPH.A 2 1 1549.77 -36.0 
Peptidyl-prolyl cis-
trans isomerase 
134-151 D.YAYGATGHPGIIPPHATL.V 2 1 1834.94 -23.4 
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Table 4.1 (continued) 
Precursor Peptide Sequence z #T Obs. 
Mass 
Mass 
Error 
(ppm) 
Phosphoglycerate 
kinase 1 
61-75 L.MSHLGRPDGVPMPDK.Y 2 2 1635.79 -61.8 
Phosphoglycerate 
kinase 1 
348-366 A.FARGTKSLMDEVVKATSRG.C 3 3 2052.08 -59.6 
Phosphoglycerate 
mutase 1 
208-217 E.LNLPTGIPIV.Y 1 1 1039.65 -41.0 
Phosphoglycerate 
mutase 1 
208-218 E.LNLPTGIPIVY.E 1 1 1198.70 -43.4 
Phosphoglycerate 
mutase 1 
9-21 L.IRHGESAWNLENR.F 3 1 1580.78 -30.0 
Phosphoglycerate 
mutase 1 
26-47 W.YDADLSPAGHEEAKRGGQA 
LRD.A 
2 2 2355.12 -40.4 
ProSAAS 62-82 R.AVPRGEAAGAVQELARALAHL.L 3 1 2099.16 -27.8 
Somatostatin 25-47 G.APSDPRLRQFLQKSLAAATGKQE.L 3 3 2511.36 -53.0 
Synapsin-2  186-205 L.IRQHAFGMAENEDFRHLVIG.M 4 1 2339.16 -30.9 
Synapsin-2  26-79 D.LQRPEPQQPPPAPGPGAATASA 
ATSAASPGPERRPPPAQAPAPQPA 
PQPAPTPS.V 
4 1 5215.66 -16.9 
Tubulin  53-64 F.FSETGAGKHVPR.A 2 2 1284.66 -71.3 
Tubulin  53-65 F.FSETGAGKHVPRA.V 2 2 1355.69 -69.6 
UCHL1 51-62 L.LLFPLTAQHENF.R 2 1 1428.74 -35.1 
UCHL1 50-62 L.LLLFPLTAQHENF.R 2 1 1541.82 -36.4 
UCHL1 92-105 G.TIGLIHAVANNQDK.L 2 2 1492.80 -65.6 
V-type proton 
ATPase subunit 
G 2 
105-114 C.EVRPQVHPNY.R 2 1 1237.62 -43.3 
V-type proton 
ATPase subunit 
G 2 
105-115 C.EVRPQVHPNYR.V 3 1 1393.72 -32.7 
V-type proton 
ATPase subunit 
G 3 
105-116 C.EVRPQVHPNYRV.T 3 1 1492.79 -38.8 
Peptide identifications are based on MS/MS of labeled samples. (.) indicates cleavage site; (_) indicates 
the site of isotopic labeling; Obs. mass: observed monoisotopic mass (after subtraction of the isotopic 
label; z the charge state of peaks used for relative quantitation in LC-MS measurements; #T, the number 
of succinic anhydride labels covalently bonded to the peptide after labeling. 
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CHAPTER 5 
INVESTIGATING ALTERNATIVE NEUROPEPTIDE PROCESSING  
IN A TRANSFECTED CELL LINE 
 
5.1 Notes and Acknowledgments  
This chapter details the work performed in developing sampling protocols and MS-based 
approaches for detecting and sequencing a novel neuropeptide from a transfected cell line. This 
project was performed in collaboration with Professor Barbara Kofler’s lab from the University 
Hospital at Paracelsus Medical University in Salzburg, Austria. I was responsible for the MS 
studies from designing and performing experiments to data analysis and interpretation. 
 I would like to acknowledge the following people for their help with this study: Xiaowen 
Hou and Jonathan Sweedler from the University of Illinois as well as Barbara Holub and Barbara 
Kofler from Paracelsus Medical University. I would like to thank Xiaowen Hou for her guidance 
with the initial stages of this project. Barbara Holub was responsible for culturing the different 
cell lines and collecting supernatant for our MS studies. I must also thank Jonathan Sweedler and 
Barbara Kofler for initiating the collaboration and their thoughtful suggestions throughout the 
project. This study was supported by the National Institute on Drug Abuse under Award no. 
P30DA018310. The content of this chapter is solely the responsibility of the authors and does not 
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5.2 Introduction 
 Alternative posttranslational splicing of gene products is an important pathway for 
increasing proteomic diversity. One example of alternative splicing, which is of particular 
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interest for this study, is the neuropeptide alarin. Alarin is a splice variant of galanin-like peptide 
(GALP), a hypothalamic neuropeptide belonging to the galanin family of peptides.1-3 The mRNA 
encoding alarin was first discovered in ganglioneuroma and neuroblastoma tissues.1 Sequencing 
of the mRNA of the splice variant revealed an approximately 280 base pair sequence that was 
missing exon 3 of the GALP preprohormone. The exclusion of exon 3 leads to a frame shift in 
the original GALP sequence and yields a novel peptide sequence with a stop codon after 49 
amino acids.4 Figure 5.1 is a schematic drawing of the GALP gene and its splice variants.3 Since 
the proteolytic cleavage site of GALP is conserved in the splice variant, the predicted sequence 
of alarin is a 25 amino acid peptide. The synthetic version of the peptide has exhibited effects on 
biological systems4-8 and alarin-like immunoreactivity implicates alarin in metabolism and 
reproduction.9-13 However, the endogenous processing and secretion of the peptide have not been 
observed. The effects of alarin do not appear to be regulated by any of the known galanin 
receptors and the actual sequence of alarin is important in determining the mechanism behind its 
effects. 
 Due to its localization and a perceived function in the skin,4, 14 our collaborators selected 
a human keratinocyte cell line to elucidate the structure of the endogenously expressed form of 
alarin. Two types of human keratinocyte cell lines (HaCaT) were investigated: one transfected 
with a vector encoding human preproalarin and the other mock transfected as a control. 
Expression of the vector is stimulated by the addition of doxycycline and the supernatant was 
collected for mass spectrometry (MS) analysis. A three stage strategy was developed to study the 
release of alarin from the overexpressing cell lines. First, the appropriate MS platforms for alarin 
identification were selected using synthetic alarin. A major challenge in sequencing the 
expressed peptide in the supernatant was its low concentration in a complex growth medium that 
 98 
 
includes components that generate intense MS signals. Therefore, the second stage in the 
strategy was to optimize a sampling protocol to isolate alarin from the components of the cell 
growth medium. The final stage was to apply the improved sample clean up to the supernatants 
collected from the overexpressing cells and analyze the samples on the appropriate MS 
platforms. Despite the successes with the first two stages in the alarin discovery strategy, a 
definitive alarin peptide could not be identified in the supernatants from the overexpressing cell 
lines.  
 
5.3 Experimental 
5.3.1 Chemicals 
 All chemicals were obtained from Sigma Aldrich (St Louis, MO) unless otherwise stated. 
The peptide standards for matrix-assisted laser desorption/ionization (MALDI) time-of-flight 
(TOF) MS calibration were supplied by Bruker (Billerica, MA). Synthetic forms of alarin 
peptides were supplied by the Kofler group from Paracelsus Medical University. Alarin is 
defined as a 25 amino acid peptide of sequence APAHRSSTFPKWVTKTERGRQPLRS. Several 
other alarin-related peptides (ARPs) were also tested. Peptide standards were created for the full 
length alarin peptide (MW 2894.3), a c-terminal amidated version of the full peptide (MW 
2893.3), residues 3-25 (MW 2726.1), residues 3-25 with the c-terminal amidated (MW 2725.1), 
and residues 3-19 (MW 1988.24).  
5.3.2 HaCaT Cell Lines and Sample Collection 
 Two types of human keratinocyte cell lines (HaCaT) were produced: one transfected with 
a vector encoding human preproalarin (named A9) and the other mock transfected as a control 
(named TE19). The T-Rex™ system (Life Technologies, Carlsbad, CA) was used to allow for 
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the inducible expression of alarin by the addition of doxycycline. Prior to the induced expression 
of alarin, the cells were washed 2-3 times with phosphate buffered saline and seeded in serum-
free and supplement-free Epilife Keratinocyte Growth Medium (Life Technologies, Carlsbad, 
CA). TE19 cells were supplemented with Blasticidin and A9 cells were supplemented with 
Blasticidin and Zeocin. After addition of 100 ng/mL doxycycline, the supernatants of the TE19 
and A9 cell lines were collected at 2, 8, 12, and 24 hours in fresh supplement-free medium. 
Immunoblot analysis of supernatant estimates an alarin concentration of 100-500 fmol/mL after 
induced expression for 24 h. The cell pellets were saved.  
 Due to difficulties with the high complexity of the cell culture medium, new samples 
were prepared that had the supernatant of the overexpressing cells collected in phosphate 
buffered saline (PBS). However, the immunoprecipitation of alarin from the supernatant of the 
overexpressing cells from this set of samples was not successful. Alarin was not reproducibly 
precipitated with the antibody even in samples spiked with synthetic alarin. A third set of 
samples were prepared in Dermalife® K medium (Lifeline Cell Technology, Frederick, MD) 
plus supplements. Immunoprecipitation was not performed with this set of samples. In these 
subsequent sets of samples, all supernatants were collected after 24 h of induced expression with 
doxycycline. 
5.3.3 Isolation of the alarin peptide in the cell culture medium 
 Supernatants from the A9 and TE19 cell lines were first concentrated with a vacuum 
concentrator (Savant Speed Vac SVC-100H, Thermo Fisher Scientific, Waltham, MA) and then 
reconstituted in a solution of 95/5 (v/v) % H2O/acetonitrile (ACN) with 0.1% formic acid (FA) 
and 0.01% trifluoroacetic acid (TFA). Pierce™ C18 spin columns (Thermo Scientific, Waltham, 
MA) were utilized to remove salt and isolate the peptide from the components of the culture 
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medium. After the sample was loaded onto the column, it was washed with 95/5 H2O/ACN with 
0.1% FA and 0.01% TFA twice. Due to the complexity of the culture medium, 6-8 additional 
washing steps with 90/10 H2O/ACN with 0.1% FA and 0.01% TFA were performed and 
collected for further analysis. To isolate the part of the sample containing the peptide of interest, 
fractions of gradually increasing organic content (H2O/ACN with 0.1% FA and 0.01% TFA from 
80/20 to 70/30 to 50/50) were collected from the spin column. Fractions were concentrated via a 
vacuum concentrator (Savant Speed Vac SVC-100H, Thermo Fisher Scientific, Waltham, MA) 
and reconstituted in 95/5 H2O/ACN with 0.1% FA and 0.01% TFA for further analysis. 
5.3.4 Mass Spectrometry Measurements 
 Two mass spectrometry platforms were selected for the detection and identification of 
alarin. Methods were optimized with synthetic alarin. A MALDI TOF MS (Bruker 
Ultraflextreme, Bremen, Germany) was used to detect and screen for the peptide in the 
supernatant of overexpressing cells. For analysis, 0.5 µL of sample was spotted on a gold-coated 
MALDI plate and co-crystallized with 0.5 µL of concentrated 2,5-dihydroxybenzoic acid matrix 
(prepared as 50 mg/mL in 1:1 water: acetone). Positive ion mass spectra were acquired in the 
500-5000 m/z mass range in reflectron mode with external calibration. 
For tandem MS-based identification, the electrospray ionization (ESI)-Ion Trap MS 
(AmaZon ETD, Bruker) was selected for its ability to utilize multiple fragmentation methods: 
collision induced dissociation (CID) and electron transfer dissociation (ETD). Sequencing of the 
synthetic alarin standard was first performed via direct injection with a syringe pump. Tandem 
MS fragmentation was controlled by TrapControl software (Bruker) with alternating 
fragmentation (CID and ETD) performed in a data dependent manner, with the three ions of 
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highest intensity selected for fragmentation. The scan ranges for the MS and MS/MS scans were 
400-2000 m/z and 150-3000 m/z, respectively.  
For analysis of standards and samples in cell culture medium, a chromatographic 
separation of the sample was performed prior to MS analysis. A 5 µL volume of sample was 
loaded onto a trap column (200 µm i.d. x 20 mm length, Acclaim™ Pepmap™ C18 100, 5µm, 
100 Å; Thermo Scientific, Rockwood, TN, USA) at 20 µL/min with an Ultimate3000 HPLC 
system (Dionex, Sunnyvale, CA, USA). Analytical separation was performed at 3 µL/min with a 
reverse phase C18 column (300 µm i.d. x 150 mm length Acclaim™ Pepmap™ RSLC, 3 µm, 
100 Å; Thermo Scientific, Rockwood, TN, USA). The solvents used were water with 0.1%FA 
for solvent A and 100% ACN with 0.1%FA for solvent B. The gradient used was 0-5 min, 4% B; 
5-40 min, 4-50%B; 40-43 min, 50-90%B; 43-47 min, 90%B; 47 min, 90-4%B; 47-60 min, 4%B. 
Eluting peptides were analyzed in positive mode with alternating fragmentation on the ESI-Ion 
Trap MS (AmaZon ETD, Bruker). MS spectra were collected for a m/z range of 400-2000 and 
MS/MS spectra were collected for a m/z range of 150-3000. Precursor ions were selected in a 
data dependent manner with the three ions of highest intensity selected for fragmentation. The 
observed ions of the synthetic alarin standard were listed as preferred ions for fragmentation.  
5.3.5 MS/MS Data Analysis 
 For identification of alarin-like species from the supernatant of overexpressing cells, the 
MS/MS spectra were exported as an .mzXML file and searched against the alarin prohormone 
using PEAKS Studio 7 software (Bioinformatics Solutions, Inc. Waterloo, ON, Canada). The 
search parameters used in the software were as follows: no enzyme, variable post-translational 
modifications (acetylation, C-terminal amidation, and phosphorylation), mass tolerance of 0.3 Da 
for the precursor ion and 0.5 Da for fragment ions. Since it is a larger peptide, scores were 
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improved when basing the mass tolerance on the average mass rather than the monoisotopic 
mass. Peptide assignments were judged on the -10logP score and mass error.  
MS/MS spectra were also converted into .mgf files (Mascot generic file) and searched 
against the full alarin sequence with BioTools 3.2 software (Bruker Daltonics). This software 
was used to confirm identifications and measure sequence coverage.  
 
5.4 Results 
5.4.1 Selection of MS Platforms 
The predicted alarin sequence contains 25 amino acids, several of which are basic amino 
acids (K, R, and H). Based on immunoprecipitation of alarin from the supernatant of 
overexpressing cells, the expected concentration of the peptide in the supernatant was 100-500 
fmol/mL after induced expression for 24 h. Taking into consideration the expected size of alarin 
and its low abundance in the chemically complex culture medium, two MS platforms were 
selected for analysis: MALDI TOF MS (Bruker Ultraflextreme, Bremen, Germany) and ESI-Ion 
Trap (Bruker AmaZon ETD, Bremen, Germany). The capabilities of these instruments to detect 
and sequence alarin were validated using synthetic alarin standards. MALDI TOF MS was able 
to detect the full alarin peptide at the expected concentration and was chosen for the initial 
screening of biological samples to look for alarin-like peptides. Interestingly, the alarin peptide 
was detected as both a +1 and +2 ion (Figure 5.2) with MALDI TOF MS.  
Synthetic alarin is highly charged when ionized using ESI (Figure 5.2). Due to the 
formation of multiply charged ions, ETD was utilized for sequencing along with the more 
traditional CID. ETD is a gentler fragmentation method and works well for sequencing large, 
highly charged peptides and identification of weakly bonded post-translation modifications.15, 16 
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Comparing the two fragmentation methods using the full sequence alarin standard, ETD 
performed better and yielded up to 20% more sequence coverage than CID for the highly 
charged (z > 4) ions. Figure 5.3 shows the MS/MS spectrum of the +5 ion of synthetic alarin 
collected with ETD fragmentation sequenced with high confidence. The retention time of 
synthetic alarin spiked in cell culture medium and separated by reverse phase HPLC was ~25 
min.  
5.4.2 Optimization of Sampling Protocol 
The supernatants of the different cell lines were collected in a cell culture medium 
designed for epidermal cells, which is a complex mixture containing amino acids, vitamins, trace 
minerals, inorganic salts and other organic compounds. MS signals from the components of the 
growth medium overwhelm the signal generated from the alarin standard. The ion of highest 
intensity is m/z 1329.7 and likely corresponds to the [M-CN+H]+ ion of vitamin B12.17 Using 
medium spiked with synthetic alarin (MW 2893.4 Da), a variety of sampling protocols were 
attempted to try and isolate the peptide from the medium. The most successful approach utilized 
Pierce™ C18 spin columns with extra washing steps and a gradual elution of the peptide with 
fractions of increasing organic content. The synthetic alarin peptide was detected in the 80/20 
H2O/ACN with 0.1%FA and 0.01% TFA and 70/30 H2O/ACN with 0.1%FA and 0.01% TFA 
fractions. Compared to a standard protocol for removing salts with the C18 spin column, this 
modified method intensified the MS signal for the peptide more than 10 fold and lowered the 
number of interfering compounds (Figure 5.4).  
5.4.3 Investigation of the Supernatant of Overexpressing Cells 
 After selecting the appropriate MS platforms and optimizing the sampling protocol with 
synthetic alarin, the methodology was applied to the supernatant from the cell lines. Based on 
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estimates from immunoprecipitation in the first set of samples, the supernatant of the A9 cell line 
collected after 24 h of induced expression was expected to have the highest amount of alarin. 
After applying the sampling protocol to the supernatant of the A9 and TE19 cell lines, the 
fractions were analyzed by MALDI TOF MS. No species were observed that corresponded to the 
predicted mass of the full sequence of alarin or to the mass of the shortened sequence of amino 
acids 3-25. A putative peak that could be alarin-related was observed around m/z 1988.01 and 
matches the mass of alarin residues 3-19 (monoisotopic mass 1987.04 Da). This peak is unique 
to the spectra collected from the A9 cell line and was not observed in MALDI TOF MS spectra 
of the mock transfected cell line, TE19 (Figure 5.5). The peak is relatively low in intensity, 
which was expected based on the predicted concentration of the peptide in the supernatant. 
While the mass of the peak matches a shortened sequence of alarin, that criteria is not enough to 
conclude that the peak is alarin-related. Further analysis using LC-ESI-Ion Trap MS was 
necessary to confirm the structure of the candidate peak.  
 When analyzing fractions of the supernatant collected from the A9 and TE19 cell lines 
via LC-ESI-Ion Trap MS, the 10%, 20%, and 30% ACN fractions generated from the C18 spin 
column were combined. The putative alarin peak was observed by MALDI TOF MS in all of 
these fractions and combining them increased the likelihood of it being detected with the second 
MS platform. Based on the increase of sequence coverage observed when using ETD 
fragmentation for the alarin standard, alternating CID and ETD fragmentation was utilized for 
peptide sequencing in the supernatant samples. Expected ions of the shortened 3-19 sequence as 
well as the full length (1-25) sequence of alarin were listed as preferred precursor ions for 
MS/MS fragmentation. The supernatant of the A9 cell line was more complex than that of the 
TE19 cell line and generated more MS/MS compounds. Database searching of the generated 
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MS/MS spectra to see if any showed homology with the alarin prohormone yielded no alarin-
related peptides in the supernatant of the A9 or TE19 cell lines. Manual inspection of the LC-MS 
chromatogram of the supernatant from the A9 cell line did reveal the detection and fragmentation 
of ions that matched the m/z of charge states expected for the full alarin sequence: m/z 724.46 
(+4) and m/z 579.99 (+5). The MS/MS spectrum generated for m/z 724.46 (+4) is presented in 
Figure 5.6. While the MS/MS spectra of these ions did have a few of the expected product ions, 
not enough could be assigned to confidently identify the species as alarin.  
 
5.5 Discussion 
 This study aimed to elucidate the structure of the bioactive form alarin using a 
keratinocyte cell line transfected with a vector encoding the human alarin prohormone. Despite 
success developing sampling protocols and MS-based approaches for detection and identification 
of synthetic alarin in the cell culture medium, we were not able to unambiguously identify 
human alarin in the supernatant of the transfected cells. Analysis of the supernatant of the 
transfected cell line A9 with MALDI TOF MS and LC-ESI-Ion Trap MS both yielded peaks that 
were unique to this cell line, but did not generate high quality MS/MS spectra that could be 
confidently identified as alarin.  
 There are a few possible explanations for why alarin was not detected in our experiments. 
The first explanation is that the amount of alarin in the supernatant was much lower than 
predicted by immunoprecipitation and could not be detected even after using the optimized 
sampling protocol. Our collaborators told us that the antibody used for the immunoprecipitation 
experiments did not yield consistent results and false positives with the mock transfected TE19 
cell line were observed. A second explanation is that the peptide is in a form that different than 
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what was predicted. The inclusion of an unusual PTM would have made matching the peptide to 
the prohormone sequence unlikely with our database search parameters. A third explanation is 
that the keratinocyte cells lack the correct peptide-processing enzymes to generate the mature 
bioactive form of alarin in a detectable level. While the mRNA of alarin has been found in 
murine skin and has been shown to have vasoactive properties,4 the peptide itself has not been 
isolated from skin. This last explanation was proposed looking at the peak that was proposed to 
be alarin 3-19. The shortened sequence ends in a glycine residue, which would likely undergo α-
amidation at the C-terminal by the peptidyl-glycine alpha-amidating monooxygenase (PAM) 
enzyme in neuronal and endocrine tissues.18 The candidate peak matches the mass of the 3-19 
ARP sequence with a glycine at the C-terminal.  
 
5.6 Conclusions and Future Directions 
Neuropeptides are gene products that become biologically active only after a number of 
post-translational processing events. Even with genomic knowledge, the final bioactive form of a 
peptide is difficult to predict. Alarin mRNA has been detected in the brain, skin, and thymus of 
rodents.4 Sequencing of the mRNA yielded a predicted sequence for the alarin peptide, but the 
peptide itself has never been isolated and sequenced. Immunohistochemistry staining for alarin-
like immunoreactivity corresponds well with the localization of alarin mRNA12 and points to a 
role of alarin in metabolism and reproduction.19 Knowledge of the bioactive form of alarin is 
important for determining the mechanism behind alarin’s effects especially because the effects of 
alarin do not appear to be regulated by any of the known galanin receptors. Interestingly, a 
shortened form of alarin, residues 6-24, was shown to have limited bioactivity and actually acts 
as an antagonist to the effects of the full length (residues 1-25) peptide.20 Unfortunately, our 
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study was not able to elucidate the bioactive form of the novel peptide alarin. We developed a 
sampling protocol that worked well to isolate the peptide in the cell culture medium and and 
boost its MS signal for detection and identification. MS analysis of the supernatant of 
overexpressing cells transfected with the alarin prohormone yielded a few putative alarin peaks, 
but nothing could be unambiguously identified as alarin. If this study were to be repeated, a 
different cell line would be recommended for transfection with the preproalarin vector.  
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5.8 Figures 
 
 
 
 
 
 
 
 
Figure 5.1 Schematic of the organization of the preproGALP gene and the post-transcriptional 
splice variant, alarin. PreproGALP is encoded by exons 2-6 and the mature peptide (GALP) is 
encoded by exons 2-5. Post transcriptional splicing leads to the exclusion of exon 3 and a frame 
shift, creating a novel precursor protein. The novel protein, named Pro-alarin, shares the signal 
peptide sequence and the first five amino acids of the mature GALP peptide. Based on this 
shared sequence homology, the predicted sequence of mature alarin is a 25 amino acid peptide 
with the sequence APAHRSSTFPKWVTKTERGRQPLRS. Figure is adapted from Lang et al.3 
with permission from Elsevier © 2007. 
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Figure 5.2 MS spectra of alarin 1-25 (MW 2892.56 Da) standard collected on MALDI TOF MS 
(A) and ESI-Ion trap MS via direct infusion (B). Alarin contains several basic residues and is 
easily charged with both ionization approaches.  
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Figure 5.3 ESI-Ion Trap MS/MS spectrum of the +5 ion (m/z 579.97) of alarin 1-25 
(monoisotopic mass: 2892.56 Da). Fragmentation was performed with electron transfer 
dissociation (ETD). 
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Figure 5.4 MALDI TOF MS spectra of synthetic alarin 1-25 (monoisotopic mass: 2892.56 Da) 
spiked in Epilife Keratinocyte Growth Medium (Life Technologies, Carlsbad, CA). A) MS 
spectrum of peptide spiked in medium after using a standard sample clean-up protocol with a 
C18 spin column. B) MS spectrum of the peptide spiked in medium after altering the sample 
clean-up protocol. The spectrum is collected from a 20% acetonitrile fraction collected from a 
C18 spin column. The observed intensity of the peak of interest is increased ~10 fold with the 
improved sampling protocol.  
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Figure 5.5 MALDI TOF MS spectra of the supernatant collected from the TE19 (A) and A9 (B) 
cell lines after 24 h of induced expression utilizing the optimized sample protocol. Highlighted in 
the inserts is a putative alarin peak, m/z 1988.01, unique to the supernatant of the A9 cell line, 
which was transfected with human pre-proalarin. This small peak matches the mass of alarin 
residues 3-19 (monoisotopic mass 1987.04 Da). 
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Figure 5.6 ESI-Ion Trap MS/MS spectrum of a putative alarin peak from the supernatant of the 
overexpressing A9 cell line induced with doxycycline for 24 hours. The precursor ion was m/z 
724.36 (+4). The ions highlighted in red correspond to charge states or fragments of alarin 1-25 
(MW 2894.3). There were not enough ions to confidently assign this species as alarin. 
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CHAPTER 6 
ASSESSING THE EFFECT OF HEATING, COOLING, AND BLOOD REMOVAL ON 
NEUROPEPTIDE DETECTION 
 
6.1 Notes and Acknowledgments 
 This chapter presents a study examining how different sample collection and processing 
procedures affect the peptides measured by mass spectrometry. Elena Romanova initiated this 
project and aided in collecting samples, analyzing them with MALDI MS, and interpreting the 
data. Justin Rhodes and members of his laboratory assisted in animal sacrifice and brain region 
isolation. Beyond the actual data presented here, Xiaowen Hou, Stanislav Rubakhin, and Bora 
Kim are acknowledged for their assistance in testing and developing the methods used in this 
chapter. I would also like to thank Jonathan Sweedler for his insight and advice throughout this 
project. This project was supported by the National Institute on Drug Abuse under Award no. 
P30DA018310. The content of this chapter is solely the responsibility of the authors and does not 
necessarily represent the official views of NIDA or the National Institutes of Health. 
 
6.2 Introduction 
Neuropeptides are protein-derived signaling molecules used by neurons for cell-to-cell 
communication and regulate a variety of biological functions and behaviors. The detection of 
neuropeptides in the brain presents a unique analytical challenge due to their low endogenous 
concentrations, broad dynamic range, and diverse chemical properties.1 Mass spectrometry 
(MS)-based peptidomics has emerged as a preferred technique to biochemical probe for 
neuropeptides characterization because it is untargeted and easily multiplexed to identify 
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multiple neuropeptides in complex samples.2, 3 Sample collection and preparation is a critical 
stage and requires significant consideration for a successful peptidomics experiment. The 
detection of neuropeptides from mammalian tissue samples can be improved significantly by 
preventing the actions of proteolytic enzymes postmortem.4 Degradation products of abundant 
proteins generate intense mass spectrometry (MS) signals, which complicate the mass spectrum 
in the typical neuropeptide mass range (500-5000 Da) and overwhelm the signals of 
neuropeptides. Without any treatment to prevent post mortem degradation, analysis of freshly 
sacrificed brain tissue yields intense MS signals from protein fragments from blood proteins like 
hemoglobin or structural proteins like actin.5-7  In addition, the enzymes degrade the endogenous 
neuropeptides, which also hinders their characterization.  
A prevalent strategy for enhancing the detection of neuropeptides and preventing the 
degradation of abundant proteins after sacrifice is to denature proteolytic enzymes by applying 
heat to the tissue.8-13 Several studies have found focused microwave irradiation an effective 
technique for preventing protein degradation and improving the detection of neuropeptides from 
tissue samples.14-18 Despite the success of focused microwave irradiation for peptide recovery, 
the method has significant drawbacks. The microwave device is costly and the sacrifice 
conditions place the animals in a restraining device, which causes stress and can change brain 
chemistry. Technology introduced by Svensson et al.19 and commercially available as the 
Stabilizor™ system (Denator, Gotenburg, Sweden) is an automated instrument that combines 
heat and pressure under vacuum to increase tissue temperature rapidly and uniformly for tissue 
samples. Since heating is applied to tissue samples, standard animal sacrifice procedures can be 
used and the need to place animals in the restraining device used with microwave irradiation is 
eliminated. The peptide profile for a tissue sample using this technology is comparable to tissue 
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collected with animal sacrifice by focused microwave irradiation and has been applied to 
characterize the neuropeptidome of different animal models.20-22 While promising, this 
technology is not widely available due to relatively high cost. Another alternative strategy for 
applying heat to a tissue sample to halt proteolytic degradation is a conventional microwave.23 In 
contrast to the focused microwave irradiation device or the Stabilizor™ system, a conventional 
microwave costs $100 or less and is widely available. Che and Fricker et al.23 demonstrated that 
a few seconds of heating with conventional microwave oven is sufficient to heat the brain to 
80°C and prevent the postmortem degradation of proteins. The Fricker laboratory has utilized 
this technique for studying neuropeptides and enzymes involved in peptide processing.24-28 A 
limitation to the use of the conventional microwave for the irradiation of tissue samples is that it 
is difficult to achieve uniform and reproducible heating and as the brain is heated, there is a 
change in tissue elasticity and if heating exceeds 90°C, much of the brain morphology is lost.23 
The loss in morphology complicates, and in some cases prevents, dissection of specific brain 
regions. In this chapter, we compared the different peptides and their relative levels detected 
after heating tissue samples with a conventional microwave to brain cooling via perfusion of cold 
physiological saline.  
 Perfusion of the animal with ice-cold physiological saline is an alternative strategy for 
preventing proteolytic degradation by cooling the tissue and removing blood. While in the 
microwave heating treatment, enzymes are denatured, with this approach, peptidases are 
removed or slowed. Many peptidase enzymes are present in blood29-31 and removing the blood 
after sacrifice prevents them from degrading proteins and peptides during tissue homogenization 
and peptide extraction. The deliberately induced cooling is used to slow the actions of other 
proteolytic enzymes. Perfusion of an animal with saline and a fixative is often used for imaging 
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experiments like electron microscopy and immunocytochemistry.32 In this chapter, perfusion was 
performed with ice cold saline and cold 2,5-dihydroxybenzoic acid (DHB). DHB is typically 
used as a matrix from MALDI MS, but DHB can also be used for efficient peptide extraction 
from tissue and for long term preservation of samples.33 The perfusion technique has the 
advantage over microwave irradiation via a commercial microwave in that distinct features of the 
brain are preserved, making it easier to isolate specific brain regions for later study. We 
hypothesized that the removal of blood and cooling of the brain by cold saline perfusion would 
reduce postmortem degradation of abundant proteins and ultimately, aid in the detection of 
neuropeptides. 
To test our hypothesis, we measured the peptide levels detected in tissue extracts via MS 
after using the two techniques, microwave irradiation and cooling with saline perfusion, both 
separately and together with microwave irradiation following saline perfusion. Due to the loss in 
morphology induced by heating, two large and distinct brain regions were selected for isolation, 
the hypothalamus and the striatum. For analysis, the two brain regions were isolated from the 
brain after treatment and peptides were extracted in DHB following a one-step extraction 
procedure developed in our laboratory.33 In contrast to previous studies looking at the effects of 
microwave heating on detected peptides,10-12, 23 the tissue samples used in this experiment were 
never frozen. Peptide profiles for each sample were measured using matrix-assisted laser 
desorption/ionization (MALDI) MS and compared using principal component analysis (PCA) to 
correlate the differences in observed chemical species with sample treatment. This methodology 
was used previously by our laboratory to find neural adaptations rats and mice with different 
drugs of abuse.34-36 In addition, differential isotopic labeling with liquid chromatography (LC) 
coupled to electrospray ionization (ESI) MS detection was used to verify the differences in 
 119 
 
peptides detected in the striatum when comparing the sample treatments. The results of our 
analyses echo that of previous studies,23, 24 which report heating the tissue sample after sacrifice 
does significantly alter the number of peptides detected by mass spectrometry and leads to the 
recovery of more neuropeptides. Applying perfusion with ice cold saline and DHB did lead to 
the detection of a few more neuropeptides in the averaged spectrum of peptide extracts compared 
to that of the extracts from untreated samples. However, these peptides were not detected in all 
of the samples perfused with saline and DHB and their intensities were not found to be 
significantly different from untreated samples, making it difficult to conclude that including 
perfusion with saline and DHB aids in neuropeptide recovery.  
 
6.3 Experimental 
6.3.1 Chemicals 
 All chemicals were obtained from Sigma Aldrich (St Louis, MO) unless otherwise stated. 
The peptide standards for matrix-assisted laser desorption/ionization time-of-flight mass 
spectrometry (MALDI TOF MS) calibrations were supplied by Bruker (Billerica, MA). Heavy 
(D4) succinic anhydride was purchased from C/D/N Isotopes (Pointe-Claire, Quebec, Canada).  
6.3.2 Animals, Sample Treatments, and Peptide Extraction 
 In our study of the effects of tissue heating on sampling of peptides from the mammalian 
brain in conjunction with brain cooling via perfusion, four different sample treatments were 
used: no heating or perfusion, perfusion with saline and DHB, heating of the head with a 
commercial microwave, or perfusion with physiological saline followed by microwave heating 
(Figure 6.1). Twenty C57BL/6J mice were sacrificed and subjected to 1 of the 4 sample 
treatments. For the first group, referred to as the control or no treatment group (n=5), there was 
 120 
 
no perfusion and no microwaving. The animals were anesthetized with 150 mg/kg sodium 
pentobarbital (i.p.) and sacrificed by decapitation. The second group (n=5) were perfused 
transcardially with cold physiological saline and then a cold DHB solution (15 mg/mL DHB in 
H2O) at ~4 mL/min. The animals were anesthetized with perfused with saline, perfused with 
DHB, and then decapitated. The third group (n=5) were not perfused, but the head was heated 
with a 700 watt commercial microwave (GE microwave model JES0736). The animals were 
anesthetized, sacrificed by decapitation, and then the head was heated in the microwave for 6 sec 
at 70% power. The power and time settings were chosen to try and replicate the conditions used 
in a published study.23 Despite using identical settings on the microwave, equal heating was 
difficult to control and there was a good deal of variation in the observed temperatures of the 
skull and brain of individual animals. For the five animals in this treatment group, the average 
temperature of the skull was 118.7 ± 6.6°C and that of the brain was 116.2 ± 12.4°C. In samples 
that were heated in the microwave, the brain consistency was changed, making it harder to 
remove from the skull and difficult to dissect even simple brain regions. The fourth group (n=5) 
were perfused transcardially with cold saline at a rate of ~4 mL/min prior to heating of the head 
with the microwave. The animals were anesthetized, perfused with saline, then decapitated, and 
the head was heated in the microwave for 6 sec at 70% power. For the five animals in this 
treatment group, the average temperature of the skull was 114.4 ± 4.3°C and that of the brain was 
118.3 ± 9.3°C. From every animal, the hypothalamus and striatum were isolated and placed in an 
individual vial containing 100 uL DHB (15 mg/mL in H2O) for the hypothalamus and 300 uL 
DHB for the striatum. For one of the samples with microwave heating, the head was heated to 
the most extreme of our temperatures (130°C) and had portions of the brain missing and the 
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hypothalamus could not be isolated. All samples were incubated in DHB solutions for 4 days at 
4°C for peptide extraction. 
6.3.3 Peptide Profiling by MALDI MS 
 Sampling for peptide profiles were performed as previously described.33-36 Briefly, 
peptide extracts from each individual sample were analyzed in triplicate where 0.5 µL of extract 
was mixed 1:1 with freshly prepared concentrated DHB (50 mg/mL dissolved in 1:1 
acetone:H2O). Calibration spots were created using 0.3 µL of the Bruker peptide standard mix 
and 0.5 µL of concentrated DHB and were dispersed among the sample spots. Positive ion mass 
spectra for each sample spot were acquired in the m/z 650-6,000 range on an MALDI time-of-
flight (TOF) mass spectrometer (Ultraflextreme, Bruker, Bremen, Germany) in reflectron mode 
with high-precision calibration. Spectra were collected manually with 5000-5500 laser shots per 
spot.  
6.3.4 Statistical Analysis of MALDI MS Peptide Profiles 
Statistical analysis of the raw MALDI MS spectra was performed with ClinProTools 2.2 
software (Bruker). Spectra were normalized to total ion count with a built in algorithm. Detected 
peaks were smoothed using the Savitzky-Golay algorithm at a width of 1.0 m/z over 4 cycles to 
smooth the isotopic envelope. The peptide profiles of the mean spectra of the four groups were 
compared using PCA. Peak picking for PCA calculation was limited to peaks with a signal-to-
noise ratio of 6 or higher. The detected peaks were evaluated with the Anderson-Darling 
normality test and ANOVA or Kruskal–Wallis tests were performed to establish significance in 
normal and non-normally distributed data, respectively. The Benjamini-Hochberg p-value 
adjustment was automatically applied to correct for multiple hypothesis testing.  
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6.3.5 Isotopic Labeling and Analysis of Striatum Peptide Extracts 
 To test how each approach affected peptides levels, the extracted peptides were 
covalently modified with a stable isototopic tag for relative quantitation. Prior to investigating 
the biological samples, the labeling procedure described by Hou et al37 was tested for peptides 
dissolved in aqueous DHB (15 mg/mL) using peptide standards. Five neuropeptide standards: 
bradykinin 1-7, NPSSFVRIamide, bradykinin, angiotensin I, and neurotensin were dissolved in 
aqueous DHB mixed together to generate peptide mixtures of the five peptides at known 
concentrations to control the expected ratios of H/D-labeled peptides (1:1, 1:12, 3:1, 1:6, 1:2, 
etc.). One mixture was labeled with H4-succinic anhydride (SA) and the other with D4-SA as 
described in Hou et al.37 The mixtures were combined and the relative abundance of the peptide 
standards was measured with a QTOF MS (MaXis 4G, Bruker) via the CaptiveSpray source 
(Bruker). 
For labeling of peptide extracts from the striatum samples, each sample was first divided 
in half by volume. One half of the extract was reacted with H4-SA, while the other half was 
reacted with D4-SA. The differentially labeled samples of two different treatments were then 
combined. For each comparison, there were two technical replicates referred to as forward and 
reverse labeling with the H/D labeling of sample treatments reversed in the two replicates. The 
use of technical replicates in this fashion controls for potential artifacts that would result from 
unequal reactivity of the labeling reagents.23 One biological replicate was used to perform the 
comparisons between the following treatments: control versus microwave heating, control versus 
perfused with saline and DHB, and perfused with saline and DHB versus perfused with saline 
and microwaved. Two biological replicates were used to compare peptide levels between a 
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mouse striatum that underwent microwave heating and one that was perfused with saline prior to 
microwave heating. 
For LC-ESI-MS analysis of labeled samples, samples were diluted 1:1 with 100% H2O 
with 0.1%FA and a 1 µL injection was loaded onto a trap column (200 µm i.d. x 20 mm length, 
Acclaim™ Pepmap™ C18 100, 5µm, 100 Å; Thermo Scientific, Rockwood, TN, USA) at 20 
µL/min with an Ultimate3000 nanoHPLC system (Dionex, Sunnyvale, CA, USA). Analytical 
separation was performed at 300 nL/min with a reverse phase C18 column  (100 µm i.d. x 15 cm 
length Magic C18, 3 µm, 200 Å; Michrom Bioresources, Auburn, CA, USA). The solvents used 
were H2O with 0.1%FA for solvent A and 80% ACN with 0.1%FA for solvent B. The gradient 
used was 0-10 min, 4-15%B; 10-58 min, 15-50%B; 58-61 min, 50-90%B; 61-69 min, 90%B; 69-
70 min, 90-4%B; 70-90 min, 4%B. Eluting peptides were analyzed in MS mode for a m/z range 
of 290-3000. 
For relative quantiation of peptides between labeled samples, labeled peptide pairs were 
detected manually in the LC-ESI-MS chromatogram based on their charge, retention time, and 
mass match using DataAnalysis (Bruker). After detecting a labeled pair at a particular time point 
in the LC-ESI-MS analysis, extracted ion chromatograms (EIC) were created for the 
monoisotopic peak of the light and heavy species. The peaks of the EIC were integrated to create 
a combined mass spectrum that was used for quantification. For each peptide, quantitative 
information was obtained by summing the intensity of the first four isotopes in the spectrum for 
the light and heavy forms. Ratios between samples were calculated using these summed 
intensities.  
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6.3.6 Peptide Identification by LC-ESI-MS 
 Peptide identification was performed with pooled samples for both the hypothalamus and 
striatum that contained peptide extracts from four animals, one from each treatment group. The 
one-step DHB extraction protocol33 used here is not directly compatible with LC due to the 
excess amount of DHB. Therefore, extra sample clean-up was needed to remove most of the 
DHB while maintaining the peptide complement in the sample. The solid phase extraction (SPE) 
procedure used was described previously in Romanova et al36 to remove a substantial amount of 
the DHB from the sample. 
Following clean up and removal of the DHB by SPE, the sample was fractionated using a 
microbore HPLC System (Breeze 2, Waters, Milford, MA) with a C18 reverse phase column (4.6 
mm i.d. x 150 mm length , 2 µm, 100 Å; Thermo Scientific, Rockwood, TN, USA) at a 0.5 
mL/min flow rate over a 65 minute run. A five step linear solvent gradient was generated mixing 
solvent A (95/5 H2O/ACN (v/v) with 0.1% FA and 0.01% heptafluorobutyric acid (HFBA)) and 
solvent B (5/95 H2O/ACN (v/v) with 0.1% FA and 0.01% HFBA) as follows: 5-20%B in 0-15 
min; 20-25%B in 15-20 min; 25-60%B in 20-40 min; 60-80%B in 40-50 min; isocratic 80%B in 
50-60 min; and 80-5%B in 60-65 min. Fractions were collected for 2 minute intervals for a 1 mL 
final volume and then concentrated with a vacuum concentrator (Savant Speed Vac SVC-100H, 
Thermo Fisher Scientific, Waltham, MA) and reconstituted in a solution of 95/5 (v/v) H2O/ACN 
with 0.1% FA. The peptide content in the fractions was evaluated by MALDI MS 
(Ultraflextreme, Bruker).  
Fractions containing peptides of interest were subjected to a second stage separation 
using a capillary HPLC system (Ultimate 3000, Dionex, Sunnydale, CA) equipped with a C18 
reverse phase column (300 µm i.d. x 150 mm length Acclaim™ Pepmap™ RSLC, 2 µm, 100 Å; 
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Thermo Scientific, Rockwood, TN, USA). The solvents used were water with 0.1%FA for 
solvent A and 100% ACN with 0.1%FA for solvent B. The gradient used was 0-7 min, 4-15% B; 
7-57 min, 15-55%B; 57-60 min, 55-90%B; 60-65 min, 90%B; 65-70 min, 90-4%B; 70-90 min, 
4%B. Eluting peptides were detected and fragmented via electrospray ionization (ESI)-Ion Trap 
MS (AmaZon ETD, Bruker). MS spectra were collected for a m/z range of 200-2800 and MS/MS 
spectra were collected for a m/z range of 100-3x the precursor m/z. MS/MS ion precursor 
selection was performed in a data-dependent manner with the 3 ions of highest intensity being 
selected for fragmentation with active exclusion of previously fragmented precursor ions limited 
to 3 spectra per minute.  
After data collection, the chromatogram analysis was exported as an .mzXML file and 
searched against an in-house mouse neuropeptide database and the whole mouse proteome 
downloaded from the UniProt knowledgebase38 using PEAKS Studio 7 (Bioinformatics 
Solutions, Inc. Waterloo, ON, Canada). The search parameters used in the software were as 
follows: no enzyme digestion, up to 3 variable post-translational modifications (including N-
terminal pyro-Glu, acetylation, C-terminal amidation, phosphorylation, oxidation of methionine, 
and methylation), and a mass tolerance of 0.3 Da for the precursor ion and 0.5 Da for fragment 
ions. Peptide assignments were judged on the -10logP score, where a score of 20 equates to a p-
value of 1%, and mass error (<1000 ppm). 
 
6.4 Results 
6.4.1 Treatment Differences in Hypothalamic Peptide Profiles  
 Sample MALDI MS spectra for hypothalamic peptide extracts from the different 
treatment groups are presented in Figure 6.2. As depicted in the diagrams in Figure 6.3, the 
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spectra collected from samples that were heated (microwave heating and perfused with saline 
and microwaved) have a greater overlap in detected peptides, with 57% of peaks shared between 
the sample treatments. Peak picking was limited to those with a signal to noise ratio of 6 or more 
in the average spectrum created for each treatment group. These spectra are distinct compared to 
the unheated samples (control-no treatment and perfused with saline and DHB). The unheated 
samples also a great deal of homology with 50% of detected peptides shared by the two 
treatments (Figure 6.3). There were 12 peaks that were detected in the individual averaged 
spectrum for all of the sample treatments. When examining the number of prohormone-derived 
peptides tentatively identified by mass matching with each sample treatment, there were 5 shared 
in the spectra of all sample treatments: vasopressin, neurotensin, big LEN, little SAAS, and PEN. 
These neuropeptides have previously been detected and identified in peptide extracts from the 
hypothalamus.23, 25, 35 An additional 5 prohormone-derived peptides were detected in the two 
treatments that included microwave heating: substance P and four peptides from the 
proopiomelanocortin (POMC) prohormone: α-melanocyte stimulating hormone (α-MSH), 
diacetyl-MSH (DiAc-MSH), J-peptide, and corticotrophin-like intermediate peptide (CLIP). Two 
of the POMC-derived peptides, J-peptide and CLIP were also detected in the spectra from 
samples that were perfused with saline and DHB. These samples also uniquely detected a 
shortened form of the CLIP peptide. The hypothalamic POMC-derived peptides are especially 
sensitive to postmortem changes, so their detection is an important indicator of the success of the 
different sample treatments in preventing proteolytic degradation.23, 39 The samples that were 
subjected to microwave heating without perfusion had a few unique prohormone-derived 
peptides detected, which included phosphorylated CLIP, C-terminal flanking peptide from 
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protachykinin and three peptides from proenkephalin: heptapeptide, octapeptide, and 
phosphorylated 239-262. 
PCA shows clear separation of the heated and unheated samples by principal component 
(PC) 1, which accounts for >75% of the variance in the samples (Figure 6.4). The PCA plot 
illustrates that the peptide profiles collected for the individual heated samples are highly variable, 
as demonstrated by their relative positions in the plot. The unheated samples are tightly clustered 
in the PCA plot, indicating a low degree of variability between individual samples. The relative 
MS intensities of a subset of peptides that contribute highly in the PCA loading plot are also 
plotted in Figure 6.3. Two of the POMC-derived peptides (J-peptide and CLIP), along with the 
neuropeptide little SAAS derived from the proSAAS prohormone, were found to statistically 
differ between treatments as measured by Kruskal-Wallis one-way analysis of variance 
(ANOVA) (Figure 6.4). Overall, 58 MS peaks were found to significantly differ between the 
heated and unheated samples by Kruskal-Wallis one-way ANOVA (p<0.05). There were no 
peaks that significantly differed when comparing the extracts from control animals and the 
extracts from the animals perfused with saline and DHB. There were also no peaks that 
significantly differed when comparing the extracts from the microwave heating group and the 
extracts from the group perfused with saline and microwaved. 
It is important to note that the time delay between sacrifice and microwave irradiation 
introduced by perfusion with cold saline did not significantly alter the observed intensity of 
POMC-derived peptides compared to samples that were microwaved immediately after 
decapitation. Similar to the POMC-derived peptides, there was not a significant difference in the 
amount of proSAAS-derived peptides detected in the extracts from samples perfused with saline 
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and microwaved compared to the extracts of samples that were microwaved immediately after 
decapitation (Figure 6.4). 
6.4.2 Treatment Differences in Striatal Peptide Profiles  
 Similar to the hypothalamic peptide profiles, the spectra collected from striatal peptide 
extracts that were heated (microwave heating and perfused with saline and microwaved) are 
distinct compared to those from the unheated samples (control-no treatment and perfused with 
saline and DHB) (Figure 6.5). Spectra from heated samples show a 55% overlap in detected 
peaks; unheated samples show a 64% overlap in detected peaks. Compared to hypothalamic 
extracts, the degree of overlap between all sample treatments is much less in extracts from the 
striatum, with only 6 peptide peaks being shared in the averaged spectra for all treatments. PCA 
of the peptide profiles show the heated and unheated samples being separated by PC 1, which 
accounts for ~68% of the variance in the samples (Figure 6.6). Similar to the hypothalamic 
extracts, the unheated samples are tightly clustered in the PCA plot while the heated samples 
have a greater spatial distribution in the plot. In total, 74 peaks were found to significantly differ 
in observed intensity when comparing the heated and unheated samples by Kruskal-Wallis one-
way ANOVA (p<0.05). Of the 74 peaks, 16 high intensity peaks (normalized intensity >3) had a 
significantly higher average intensity in the samples that were not heated compared to the 
samples that were heated. There were 18 high intensity peaks that had a significantly higher 
average intensity in the samples that were heated compared to the samples that were not heated; 
the most intense of those peaks matches the mass of thymosin β-4. PC 3,which accounts for ~8% 
of the variance, appears to separate the peptide profiles of extracts from samples heated by 
microwave and the extracts from samples perfused with saline prior to microwave heating. 
However, isolated testing between these two sample treatments groups found no peptides to have 
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significant differences in abundance between the groups. There were also no peaks that 
significantly differed when comparing the extracts from control animals and the extracts from 
the animals perfused with saline and DHB. 
To validate the results found with MALDI MS, a relative quantitation experiment was 
performed with stable isotopic labeling and LC-ESI-MS detection. First, the labeling procedure 
previously described by our laboratory37 was tested to confirm the reaction would proceed with 
peptides dissolved in DHB. Labeling of peptide standards in aqueous DHB proved successful as 
demonstrated by Figure 6.7, where the difference between the expected and observed ratios was 
less than 10%. The labeling was performed to make comparisons of striatal peptide extracts 
subjected to the sample treatments as diagramed in Figure 6.1. One biological replicate was used 
to perform each of the comparisons and a second biological replicates was used in the 
comparison of detected peptide levels between extracts from tissue that underwent microwave 
heating and tissue that was perfused with saline prior to microwave heating. The relative 
abundance of peptides in each comparison was determined by the ratio of peak intensities 
between light and heavy labeled peptides. One of the limitations when using stable isotopic 
labeling for relative quantitation is that it requires the ions of interest to be present and within the 
dynamic range of the MS in both samples in order to calculate the ratio. Over 100 labeled pairs 
were detected when comparing the two unheated sample treatments: no treatment versus 
perfused with saline and DHB. Over 70 labeled peptide pairs were detected when comparing the 
heated sample treatments: microwave heating versus perfused with saline and microwaved. The 
number of labeled pairs detected was lower when comparing unheated and heated treatments 
than the comparison of more similar treatments. In the comparison of the control and the 
microwave heating treatments, only 30 labeled pairs were detected. In the comparison of the 
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perfused with saline and DHB versus the perfused with saline and microwaved treatments, 35 
labeled pairs were detected. With the comparisons of the heated to unheated treatments, there 
were several peptides that appear to be present in extracts from a single treatment. To confirm 
this pattern, it was necessary to compare the MS spectra from the forward and reverse labeled 
samples to be sure the ions represented the same peptide. Table 6.1 shows how the ratios 
detected with MALDI MS compare to those detected with isotopic labeling and LC-ESI-MS for 
select peptides. Since there were limited samples used for calculating the relative abundance in 
peptide extracts via isotopic labeling and LC-ESI-MS, the significance of the detected ratios 
could not be established. 
Unlike in the hypothalamic extracts, there were not a distinct set of neuropeptides to 
measure the efficiency of each sample treatment for neuropeptide detection in the striatum. The 
ProSAAS-derived neuropeptide, little SAAS was sequenced by MS/MS in striatal peptide 
extracts, but it was not detected in the unheated samples by MALDI MS or LC-ESI-MS (Table 
6.1). However, the peptide was seen in the comparison of microwave irradiated samples with 
samples perfused with saline and microwaved via MALDI MS and LC-ESI-MS (Table 6.1). 
Interestingly, the relative amount detected appears to be higher, but does not reach significance, 
in the samples perfused with saline prior to microwave heating than those that were only 
microwaved. An easier comparison of how each sample treatment affected peptide detection was 
compare the relative levels of two myelin basic protein (MBP) derived peptides with MW 1589.9 
Da and MW 1770.8 Da. The relative levels of these peptides were significantly higher in the 
unheated samples compared to the heated samples, but not significantly different in the control 
group compared to samples that were perfused with saline and DHB (Table 6.1). Although a 
significant difference in relative abundance was not measured when comparing the two 
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treatments that incorporated microwave irradiation, the average relative intensity in MALDI MS 
observed for the comparison and confirmed with isotopic labeling and LC-ESI-MS suggests 
higher relative amounts of the MBP-derived peptides were detected in the samples perfused prior 
to microwave heating. The MBP-derived peptides could be products of postmortem degradation, 
but more experimentation is needed to definitely classify them as such. If they are degradation 
products, the relative levels suggest that postmortem degradation is decreased in heated samples 
and less in samples that were microwaved immediately, likely due to the time delay introduced 
between sacrifice and heating introduced by saline perfusion. 
One of the observations in the previous study of heating with a commercial microwave 
on peptide detection23 was that several peptides were considerably more abundant in the 
unheated samples, the majority of which were hemoglobin-derived peptides. To compare with 
this result, the relative levels of hemoglobin-derived peptides detected with the different sample 
treatments were also quantified. MS/MS sequencing of peptide extracts from the striatum 
identified two peptides derived from α-hemoglobin (HBA), HBA 111-123 (MW 1385.7) and 
HBA 35-47 (MW 1542.8). These two peptides were not detected by MALDI MS, but were 
detected with isotopic labeling and LC-ESI-MS. As shown in Figure 6.8, when comparing 
untreated samples and those perfused with saline and DHB, the larger of the HBA-derived 
peptides, HBA 35-47, was detected only in the untreated sample extracts, indicating that it was 
not present in samples perfused with saline and DHB. A similar result was observed when 
comparing the untreated and microwave heating sample treatments, HBA 35-47 was only 
detected in the untreated samples. The smaller HBA-derived peptide, HBA 111-123, was also 
detected in a higher amounts in the untreated samples compared to samples that were perfused or 
microwaved (Table 6.1). When comparing a sample that was perfused with saline and DHB to a 
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sample that was perfused with saline and subjected to microwave heating, HBA 111-123 was 
detected only in the sample that was perfused with saline and DHB and HBA 35-47 was not 
detected in either sample. In comparing samples that were microwaved with samples perfused 
with DHB and microwaved, HBA 111-123 was detected only in the peptide extract from the 
sample that was microwaved without perfusion, but HBA 35-47 had a slightly higher amount 
detected in the sample perfused with saline and microwaved (Table 6.1). When HBA 35-47 was 
detected in this particular comparison, the labeled peptide pair was low in intensity (<1000 
counts) and close to the baseline and because it was so close to the limit of detection, there is less 
confidence in the observed ratio and more replicates of the comparison are needed to confirm the 
relative amount of HBA 35-47. The origin of these HBA-derived peptides is debatable since α-
and β-hemoglobin are expressed by neurons.40-42 Our preliminary results show a decrease in 
these HBA-derived peptides with perfusion and microwave heating compared to untreated 
samples. If these peptides are a product of degradation of full hemoglobin proteins in blood, the 
results suggest that perfusion with saline does aid in reducing the amount of these degradation 
products observed in MS measurements from tissue extracts. 
 
6.5 Discussion 
Sample collection is a critical stage in MS peptidomic measurements that must be 
optimized to reproducibly detect neuropeptides from brain tissue. Peptides and proteins are 
known to be degraded by enzymes during the postmortem period. Microwave irradiation can be 
used to denature enzymes and prevent degradation, leading to the detection of higher number of 
labile molecules like neuropeptides by MS.15-18 In this study, we tested how microwave 
irradiation with a commercial microwave contributed to the peptides detected by MS compared 
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with brains that were cooled by perfusion with cold physiological saline and DHB. Our results 
show the incorporation of microwave irradiation was the major factor separating the peptide 
profiles for our four sample treatment groups in both the hypothalamus and striatum. Isotopic 
labeling with LC-ESI-MS detection also found big differences between samples that were and 
were not heated.  
In hypothalamic and striatal peptide profiles, the detection of known neuropeptides was 
used to assess the success of the sample treatment. We observed that microwave irradiation was 
necessary for consistent, high intensity detection of several neuropeptides, including POMC-
derived peptides in the hypothalamus. However, as shown on the PCA plots (Figures 6.4 and 
6.6), the heated samples are greatly variable in their peptide profiles. There are a few potential 
sources for this variability. The observed variation in peptide profiles from individual samples 
that underwent microwave heating limits the application of this approach in quantitative peptide 
studies that are often looking for subtle changes in peptide levels. While it is possible that the 
differences are a product of animal to animal variation, the close clustering of the samples that 
were not heated indicates that should not be a major contribution. Similarly, the extraction 
techniques were identical for all samples and if that were a source of variability in the peptides 
detected in heated samples, the unheated samples should show a comparable spatial distribution 
on the PCA plot. The most likely explanation for the variability in peptide profiles collected for 
heated samples is due to uneven heating. Heating with the commercial microwave was difficult 
to control, leading to a large variability in the temperature of the skull and the brain. The 
observed temperatures were higher than had been used previously23 and as the temperature 
increased, the heated tissue had a change in elasticity that made the isolation of even large brain 
regions difficult. In one of the samples that was microwaved without perfusion, parts of the brain 
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disintegrated during the heating, despite using identical duration and power settings on the 
microwave. In samples that included perfusion with saline prior to microwave heating, brain 
morphology was slightly better preserved and the isolation of specific brain regions was easier 
than samples that were microwaved immediately. Even with perfusion prior to microwave 
irradiation, dissection of small, distinct brain regions or nuclei would be impossible. Heating via 
microwave irradiation with a commercial microwave would be advantageous in peptidomic 
studies looking to identify and characterize peptides in a whole brain sampling or large, distinct 
brain regions.  
In contrast, perfusion with saline and DHB would work better in quantitative studies 
involving small brain regions or distinct nuclei. As shown in the PCA plots (Figures 6.4 and 6.6), 
samples that underwent this sample treatment yielded more reproducible peptide profiles from 
individual animals. While the peptide profiles collected for the sample treatments were similar to 
those of control samples, there were more neuropeptides detected in samples that were perfused 
with saline and DHB (Figure 6.3). Comparison of the relative levels of these peptides between 
the samples that were perfused with saline and DHB versus control samples did not reach 
significance, likely due to the limited number of samples used in the experiment. Interestingly, 
the few prohormone-derived peptides that were exclusively detected in the samples that were not 
heated were shortened forms of longer neuropeptides. The one neuropeptide that was uniquely 
detected in the hypothalamic extracts of samples that were perfused with saline and DHB was a 
shortened form of the POMC-derived peptide CLIP. This peptide was found previously to be 
reduced in pituitary extracts with microwave heating23 and here, we detected it only in samples 
that were not heated. In the striatal extracts, a shortened form of little SAAS was detected by 
MALDI MS in the samples that were perfused with saline and DHB and in the control group. 
 135 
 
One possible explanation for the preferential detection of these peptides in unheated samples is 
that they are formed after secretion by extracellular peptidases, whose actions are halted when 
the sample is heated, but remain active in unheated samples. Further study into the formation of 
these shortened peptides might be beneficial in elucidating their role in cell-to-cell signaling. 
 
6.6 Conclusions  
In this study, we used PCA of MALDI MS peptide profiles and stable isotopic labeling 
with LC-ESI-MS detection to assess how different sample treatments affect the number and type 
of peptides detected from tissue extracts from the mouse hypothalamus and striatum. Overall, we 
found that microwave irradiation alone and following perfusion with cold physiological saline 
lead to the detection of more neuropeptides in the hypothalamus and striatum. The alternative 
strategy proposed to maintain the in situ levels of proteins and peptides, perfusion of the tissue 
with cold physiological saline and DHB to remove blood and cool the brain, did lead to the 
detection of more neuropeptides compared to untreated samples, but less than microwave 
irradiated samples. However, more trials are needed to establish the significance of this trend. 
Adding perfusion of the brain tissue with saline prior to microwave heating did not significantly 
change the amount or types of peptides compared to when the tissue was heated immediately. 
However, proenkephalin-derived peptides reached the threshold of detection only in the average 
spectrum of samples that were microwaved immediately. Similar to the peptides detected with 
perfusion of saline and DHB, this pattern needs to be scrutinized further with more samples to 
establish significance. Of note, the inclusion of saline perfusion prior to microwave heating led 
to better preservation of anatomical features and made the isolation of specific brain regions 
easier. Based on these preliminary results, incorporating saline perfusion prior to microwave 
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heating appears as a promising sample collection approach for preventing postmortem 
degradation by proteolytic enzymes and improving detection of neuropeptides from mammalian 
tissue for qualitative peptidomic studies of large brain regions or whole brain samples, where 
reproducible spectra are not needed. In quantitative peptidomic studies, when the aim is to 
measure subtle peptide changes, an approach that is better controlled and yield more 
reproducible measurements, like perfusion with saline and DHB would be a better choice, even if 
it leads to the detection of fewer neuropeptides. Ultimately, of the treatments tested, not one is 
ideal and the appropriate sample treatment should be selected depending on the study goals. 
 
6.7 Future Work 
Only a few trials were possible for relative quantitation with isotopic labeling and LC-
ESI-MS detection and this portion of the study would need to be repeated to increase the 
statistical power and make definitive conclusions. The incorporation of chromatographic 
separation prior to MS detection typically leads to the detection of more peaks compared to 
direct MALDI MS profiling and therefore, it is important to be able to establish the significance 
of differences in peptide abundance detected with isotopic labeling and LC-ESI-MS detection. 
The inclusion of four different sampling techniques limited the number of biological replicates 
for each comparison that can be performed with the current isotopic labeling strategy, in which 
only pairwise comparisons can be performed. To optimize the use of samples and increase the 
number of replicates for the comparisons in follow-up experiments, other options than the 
current isotopic labeling approach can be explored such as using a different isotopic tag that 
allows for multiplexed analysis. However, using a different tag would require one to optimize the 
labeling procedure and the analysis of the data would be more complicated. Another avenue that 
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can be explored to optimize the use of samples would be to try a label-free quantitation with LC-
ESI-MS and compare it to the results gathered with the ProfileAnalysis software package 
(Bruker, Bremen, Germany). This software can perform PCA or a T-test with LC-ESI-MS data, 
similar to how ClinProTools operates with MALDI MS data. Another label-free approach would 
be to use a triple quad MS and to perform absolute quantitation with a select number of ions via 
selected reaction monitoring.  
A full understanding of how microwave irradiation and perfusion with cold saline and 
DHB affect peptide levels will be beneficial for future neuropeptide studies using extracts from 
mammalian tissue. To really accomplish this goal, more of the detected peptides will need to be 
identified by tandem MS and database searching. A preliminary study exploring different 
strategies for removing more DHB while maintaining the peptide complement in DHB extracts 
has been performed. This study found that by slightly altering the SPE procedure used in these 
experiments34 and incorporating an extra rinse with 90/10 H2O/ACN (v/v) with 0.1% HFBA and 
0.01% H3PO4 improved the recovery of small peptides that would otherwise be discarded with 
the initial wash. Applying this method to a new set of tissue samples might lead to the 
identification of more of the peptides and greater insight into the efficacy of the different sample 
treatments to prevent postmortem proteolytic degradation.  
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6.9 Figures and Tables 
 
 
Figure 6.1 Scheme of the four sample treatment methods and the comparisons to be performed. 
 
 
 
 
 
Figure 6.2 Sample MALDI TOF MS spectra collected for peptide extracts from the 
hypothalamus with different sample handling treatments. (Right) Venn diagram showing the 
total number of peaks detected among 4 sample treatments and overlapping peaks detected in 
more than one sample treatment.  
  
 142 
 
 
 
 
 
 
 
 
Figure 6.3 Venn diagrams showing the total number of peaks detected (right) and the number of 
neuropeptides (left) among 4 sample treatments and overlapping peaks detected in more than one 
sample treatment from hypothalamic extracts.  
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Figure 6.4 (Top) PCA score and loading plots based on MALDI TOF MS analysis of 
hypothalamus extracts. PC1 accounts for 78% of the variance and PC2 accounts for 10%. 
(Bottom) Relative intensities of select peaks from the hypothalamus peptide profiles detected by 
MALDI MS. Treatment groups are color coded as indicated in the legend. Peptides are 
tentatively identified based on a match to the mass of a known brain peptide, except the 
ProSAAS-derived peptide Little SAAS, which was identified with MS/MS sequencing. *-p-
value <0.05 by Kruskal Wallis test. 
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Figure 6.5 (Right) Sample MALDI TOF MS spectra collected for peptide extracts from the 
striatum with different sample handling treatments. (Left) Venn diagram showing the total 
number of peaks detected among 4 sample treatments and overlapping peaks detected in more 
than one sample treatment from striatal extracts. (Bottom) Venn diagram showing the 
neuropeptides tentatively identified by mass matching detected with the different sample 
treatments. 
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Figure 6.6 PCA score and loading plots based on MALDI TOF MS analysis of striatum extracts. 
(Left) PCA score plot above the loading plot for PC1 and PC2. (Right) PCA score plot above the 
loading plot for PC1 and PC3. PC1 describes 68% of the variance, PC2 describes 12% of the 
variance, and PC3 describes 8% of the variance. 
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Figure 6.7 Mass spectra of peptide standards labeled with H4/D4-succinic anhydride while 
dissolved in DHB (15 mg/mL in water). Each of the standards has an observed ratio similar to 
the expected ratio based on the preparation. 
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Figure 6.8 (A) Effect of perfusion of cold saline and DHB on the relative level of α-hemoglobin 
derived peptide. Doubly charged ions at m/z 872.40 and 876.42 (monoisotopic peaks) correspond 
to di-H4-SA and di-D4-SA labeled α-hemoglobin peptide (ASFPTTKTYFPHF), respectively. 
The top spectrum was collected with the control sample extract labeled with H4-SA and the 
extract from the sample perfused with saline and DHB was labeled with D4-SA. The labels are 
reversed in the bottom spectrum. (B) MS/MS spectrum of the same α-hemoglobin peptide. 
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Table 6.1 Comparison of peptide amounts between treatments using MALDI MS and isotopic 
labeling with LC-ESI-MS detection.  
Observed Mass (Da) 
and Peptide Name 
Treatment Comparison Ratio in MALDI 
MS 
Isotopic Labeling and 
LC-ESI-MS Ratio 
1133.8 
Unknown 
N.T. : P. 0.91 ± 0.14 : 1 1.01 : 1 
N.T. : M. 0.41 ± 0.12 : 1* 15.8 : 1 
M. : P.M. 0.35 ± 0.22 : 1 0.24 : 1 
P. : P.M. 0.16 ± 0.09 : 1* 0.23 : 1 
1385.7 
HBA (111-123) 
N.T. : P.  n.d. 8.66 : 1 
N.T. : M. n.d. N.T. 
M. : P.M. n.d. M. 
P. : P.M. n.d. n.d. 
1542.8 
HBA (35-47) 
N.T. : P. n.d. N.T. 
N.T. : M. n.d. N.T. 
M. : P.M. n.d. 0.72 :1 
P. : P.M. n.d. P. 
1589.8 
MBP Isoform 4  
2-14 
N.T. : P. 0.80 ± 0.22 : 1 0.39 : 1 
N.T. : M. 5.32 ± 1.90 : 1* 43.8 : 1 
M. : P.M. 0.63 ± 0.42 : 1 0.53 : 1 
P. : P.M. 4.22 ± 2.62 : 1* 21.2 : 1 
1660.8 
Unknown 
N.T. : P. 0.80 ± 0.38 : 1 0.33: 1 
N.T. : M. 2.59 ± 1.43 : 1* 2.01: 1 
M. : P.M. 0.57 ± 0.45 : 1 0.53 :1 
P. : P.M. 1.85 ± 1.39 : 1 12.3 : 1 
1770.8 
MBP 154-168 
N.T. : P. 1.00 ± 0.78 : 1 2.23 : 1 
N.T. : M. 3.36 ± 2.04 : 1* 7.52 : 1 
M. : P.M. 0.72 ± 0.32 : 1 n.d. 
P. : P.M. 2.41 ± 1.60 : 1* 7.49 : 1 
1812.0 
Little SAAS 
N.T. : P. n.d. n.d. 
N.T. : M. n.d. n.d. 
M. : P.M. 0.87 ± 0.23 : 1 0.76 : 1 
P. : P.M. n.d. n.d. 
2420.4 
Unknown 
N.T. : P. 1.11 ± 0.29 : 1 n.d. 
N.T. : M. 0.34 ± 0.12 : 1* 0.43 : 1 
M. : P.M. 0.71 ± 0.27 : 1 0.64 : 1 
P. : P.M. 0.22 ± 0.06 : 1* P.M. 
Peptide identifications are based on tandem MS. Observed mass is observed monoisotopic mass (after 
subtraction of the isotopic label). Treatments are abbreviated as follows: N.T.: no treatment (control);  
P.: perfused with saline and DHB; M.: microwave heating; P.M.: perfused with saline and microwaved. 
MALDI MS ratios are reported as average ± standard deviation, n.d. indicates not detected. Isotopic 
labeling ratios are averaged between technical replicates for one biological sample, if a single treatment is 
listed, the peptide was only detected from the extract of that treatment. * p-value <0.05 by Kruskal Wallis 
ANOVA. 
  
 
149 
T
ab
le
 6
.2
 N
eu
ro
pe
pt
id
es
 id
en
tif
ie
d 
by
 M
S/
M
S 
an
d 
da
ta
ba
se
 se
ar
ch
in
g 
or
 m
as
s m
at
ch
 to
 k
no
w
n 
ne
ur
op
ep
tid
es
. 
Pr
ot
ei
n 
Pe
pt
id
e 
Se
qu
en
ce
 
M
as
s 
pp
m
 
-1
0l
gP
 
R
eg
io
ns
  
C
hr
om
og
ra
ni
n 
B
 
58
8-
59
7 
[S
FA
R
A
PQ
LD
L]
 
11
17
.0
0 
-2
42
 
 
S 
C
hr
om
og
ra
ni
n 
B
 
43
8-
45
4 
[L
LD
EG
H
Y
PV
R
ES
PI
D
TA
] 
19
11
.9
9 
-5
2.
3 
 
S 
C
hr
om
og
ra
ni
n 
B
 
57
0-
58
5 
[W
W
ER
R
PF
SE
D
V
N
W
G
Y
E]
 
21
56
.6
1 
14
4 
 
S 
PO
M
C
 
α-
M
SH
 
[A
c-
SY
SM
EH
FR
W
G
K
PV
-a
m
id
e]
 
16
64
.5
8 
-1
80
 
 
H
 
PO
M
C
 
D
iA
c-
α-
M
SH
 
[A
c-
A
c-
SY
SM
EH
FR
W
G
K
PV
-a
m
id
e]
 
17
06
.7
2 
-9
9.
5 
 
H
 
PO
M
C
 
J-
pe
pt
id
e 
[A
EE
EA
V
W
G
D
G
SP
EP
SP
R
E-
am
id
e]
 
19
40
.8
6 
-6
6.
9 
 
H
 
PO
M
C
 
C
LI
P 
fr
ag
m
en
t 
[R
PV
K
V
Y
PN
V
A
EN
ES
A
EA
FP
LE
] 
23
59
.2
0 
-1
78
 
 
H
 
PO
M
C
 
C
LI
P 
[R
PV
K
V
Y
PN
V
A
EN
ES
A
EA
FP
LE
F]
 
25
07
.0
6 
10
4 
 
H
 
PO
M
C
 
Ph
os
ph
or
yl
at
ed
  
C
LI
P 
[R
PV
K
V
Y
PN
V
A
EN
E-
ph
os
ph
o-
S-
A
EA
FP
LE
F]
 
25
86
.6
0 
-6
5.
7 
 
H
 
Pr
oe
nk
ep
ha
lin
 
H
ep
ta
pe
pt
id
e 
[Y
G
G
FM
R
F]
 
87
6.
40
 
-3
88
 
 
H
,S
 
Pr
oe
nk
ep
ha
lin
 
O
ct
ap
ep
tid
e 
[Y
G
G
FM
R
SL
] 
92
9.
73
 
-3
87
 
 
H
,S
 
Pr
oe
nk
ep
ha
lin
 
19
8-
20
9 
[S
PQ
LE
D
EA
K
EL
Q
] 
13
86
.1
8 
-2
16
 
 
S 
Pr
oe
nk
ep
ha
lin
 
21
9-
22
9 
[V
G
R
PE
W
W
M
D
Y
Q
] 
14
66
.4
6 
-1
09
 
 
H
,S
 
Pr
oe
nk
ep
ha
lin
 
Ph
os
ph
or
yl
at
ed
 2
39
-2
62
 
[F
A
ES
LP
-p
ho
sp
ho
-S
D
EE
G
EN
Y
SK
EV
PE
IE
] 
25
78
.5
6 
3.
88
 
 
H
,S
 
Pr
on
eu
ro
te
ns
in
 
N
eu
ro
te
ns
in
  
[p
yr
o-
EL
Y
EN
K
PR
R
PY
IL
] 
16
72
.7
3 
-1
31
 
 
H
,S
 
Pr
oS
A
A
S 
Li
ttl
e 
LE
N
 
R
.L
EN
PS
PQ
A
PA
.R
 
10
22
.5
0 
14
8 
26
.6
2 
H
 
Pr
oS
A
A
S 
SA
A
S 
fr
ag
m
en
t 
[A
SA
PL
V
ET
ST
PL
R
L]
 
14
53
.5
6 
-1
72
 
 
S 
Pr
oS
A
A
S 
42
-5
7 
R
.S
LS
A
A
SA
PL
V
ET
ST
PL
.R
 
15
42
.8
1 
-3
0.
6 
54
.6
2 
H
 
Pr
oS
A
A
S 
B
ig
 L
EN
 
[L
EN
PS
PQ
A
PA
R
R
LL
PP
] 
17
55
.8
7 
-9
6.
8 
 
H
,S
 
Pr
oS
A
A
S 
Li
ttl
e 
SA
A
S 
R
.S
LS
A
A
SA
PL
V
ET
ST
PL
R
L.
R
 
18
11
.9
9 
14
7 
31
.1
6 
H
,S
 
Pr
oS
A
A
S 
PE
N
 
[S
V
D
Q
D
LG
PE
V
PP
EN
V
LG
A
LL
R
V
] 
23
17
.6
3 
4.
31
 
 
H
 
Pr
ov
as
op
re
ss
in
 
V
as
op
re
ss
in
 
[C
Y
FQ
N
C
PR
G
-a
m
id
e]
 
10
83
.7
3 
26
8 
 
H
,S
 
Pr
ep
ro
ta
ch
yk
in
in
 A
 
Su
bs
ta
nc
e 
P 
[R
PK
PQ
Q
FF
G
LM
-a
m
id
e]
 
13
47
.3
5 
-2
30
 
 
H
 
Pr
ep
ro
ta
ch
yk
in
in
 A
 
C
-te
rm
in
al
 fl
an
ki
ng
 
 p
ep
tid
e 
[A
LN
SV
A
Y
ER
SA
M
Q
N
Y
E]
 
18
44
.8
5 
-1
08
 
 
H
 
SM
S 
89
-1
00
 
R
.S
A
N
SN
PA
M
(+
15
.9
9)
A
PR
E.
R
 
12
59
.5
6 
17
7 
35
.0
5 
H
 
(.)
 in
di
ca
te
s c
le
av
ag
e 
si
te
; [
 ] 
id
en
tif
ic
at
io
n 
ba
se
d 
on
 m
as
s m
at
ch
 o
nl
y;
 M
as
s:
 o
bs
er
ve
d 
m
on
oi
so
to
pi
c 
m
as
s o
r o
bs
er
ve
d 
av
er
ag
e 
m
as
s f
or
 m
as
s m
at
ch
es
; p
pm
: 
di
ffe
re
nc
e 
(in
 p
ar
ts
 p
er
 m
ill
io
n)
 b
et
w
ee
n 
th
e 
th
eo
re
tic
al
 a
nd
 o
bs
er
ve
d 
pe
pt
id
e 
m
as
s;
 -1
0l
gP
 in
di
ca
te
s c
on
fid
en
ce
 in
 th
e 
se
qu
en
ce
 a
ss
ig
nm
en
t, 
a 
-1
0l
gP
 sc
or
e 
of
 2
0 
is
 e
qu
iv
al
en
t t
o 
a 
p-
va
lu
e 
of
 0
.0
1;
 R
eg
io
ns
: b
ra
in
 re
gi
on
s i
n 
w
hi
ch
 p
ep
tid
es
 w
er
e 
de
te
ct
ed
, H
-h
yp
to
th
al
am
us
, S
-s
tri
at
um
. 
  
 
150 
T
ab
le
 6
.3
 P
ep
tid
es
 id
en
tif
ie
d 
by
 M
S/
M
S 
an
d 
da
ta
ba
se
 se
ar
ch
in
g.
 
Pr
ot
ei
n 
Pe
pt
id
e 
Se
qu
en
ce
 
M
as
s 
pp
m
 
-1
0l
gP
 
R
eg
io
ns
  
A
P1
80
 
89
1-
90
1 
D
.P
LA
D
LN
IK
D
FL
 
12
57
.7
0 
23
4 
53
.1
5 
S 
A
Q
P4
 
29
3-
30
3 
L.
IL
K
PG
V
V
H
V
ID
.I 
11
88
.7
2 
28
0 
35
.9
9 
S 
A
Q
P4
 
55
-6
9 
G
.S
TI
N
W
G
G
SE
N
PL
PV
D
.M
 
15
84
.7
4 
10
1 
59
.1
7 
S 
A
Q
P4
 
51
-6
9 
L.
LG
V
G
ST
IN
W
G
G
SE
N
PL
PV
D
.M
 
19
10
.9
4 
-3
2.
7 
29
.3
7 
S 
A
T1
A
1/
A
T1
A
2 
79
4-
80
4/
 
79
1-
80
1 
F.
IIA
N
IP
LP
LG
T.
V
 
11
20
.6
9 
24
6 
31
.2
7 
S 
A
T1
A
1/
A
T1
A
2 
78
1-
79
1/
 
77
8-
78
8 
L.
TS
N
IP
EI
TP
FL
.I 
12
30
.6
5 
10
9 
32
.1
2 
S 
A
T1
A
1/
A
T1
A
2 
79
4-
80
6/
 
79
1-
80
3 
F.
IIA
N
IP
LP
LG
TV
T.
I 
13
20
.8
0 
92
.6
 
55
.4
 
S 
A
T1
A
1/
A
T1
A
2 
78
1-
79
2/
 
77
8-
78
9 
L.
TS
N
IP
EI
TP
FL
I.F
 
13
43
.7
3 
14
6 
33
.4
7 
S 
A
T1
A
3 
86
7-
87
5 
N
.G
FL
PG
N
LV
G
.I 
87
2.
48
 
23
2 
28
.0
3 
S 
A
T1
A
3 
86
6-
87
5 
E.
N
G
FL
PG
N
LV
G
.I 
98
6.
52
 
33
.3
 
23
.1
2 
S 
A
T1
A
3 
78
7-
79
6 
A
.N
IP
LP
LG
TI
T.
I 
10
37
.6
1 
12
7 
33
.6
 
S 
A
T1
A
3 
78
6-
79
6 
M
.A
N
IP
LP
LG
TI
T.
I 
11
08
.6
5 
19
8 
33
.6
8 
S 
A
T1
A
3 
77
1-
78
1 
L.
TS
N
IP
EI
TP
FL
.L
 
12
30
.6
5 
10
9 
32
.1
2 
S 
A
T1
A
3 
77
1-
78
2 
L.
TS
N
IP
EI
TP
FL
L.
F 
13
43
.7
3 
14
6 
33
.4
7 
S 
A
T1
B
1 
59
-7
0 
L.
LT
IS
EL
K
PT
Y
Q
D
.R
 
14
06
.7
3 
99
.6
 
54
.3
6 
S 
A
T1
B
1 
71
-8
4 
D
.R
V
A
PP
G
LT
Q
IP
Q
IQ
.K
 
15
16
.8
7 
12
7 
48
.8
9 
S 
A
T1
B
1 
71
-8
5 
D
.R
V
A
PP
G
LT
Q
IP
Q
IQ
K
.T
 
16
44
.9
7 
14
4 
33
.6
2 
S 
A
T1
B
1 
71
-8
6 
D
.R
V
A
PP
G
LT
Q
IP
Q
IQ
K
T.
E 
17
46
.0
2 
12
.8
 
28
.5
2 
S 
A
T5
G
1 
79
-9
0 
G
.V
A
G
SG
A
G
IG
TV
F.
G
 
10
34
.5
4 
96
.7
 
39
.1
5 
S 
A
T5
G
1 
70
-9
0 
F.
IG
A
G
A
A
TV
G
V
A
G
SG
A
G
IG
TV
F.
G
 
17
31
.9
2 
-1
17
 
36
.6
6 
S 
A
TP
5I
 
2-
12
 
M
.V
PP
V
Q
V
SP
LI
K
.F
 
11
75
.7
3 
21
.1
 
48
.6
3 
S 
A
TP
5I
 
2-
13
 
M
.V
PP
V
Q
V
SP
LI
K
F.
G
 
13
22
.8
0 
19
7 
55
.9
3 
S 
A
TP
8 
58
-6
7 
K
.IY
LP
H
SL
PQ
Q
 
11
94
.6
4 
-4
2.
4 
34
.6
 
S 
A
TP
8 
34
-4
5 
F.
PL
A
PS
PK
SL
TT
M
.K
 
12
41
.6
7 
-1
2.
3 
23
.5
5 
S 
C
O
X
6C
 
2-
16
 
M
.S
(+
42
.0
1)
SG
A
LL
PK
PQ
M
R
G
LL
.A
 
16
08
.9
0 
85
.4
 
31
.1
1 
S 
EA
A
1 
45
6-
46
7 
L.
TS
V
G
LP
TD
D
IT
L.
I 
12
30
.6
3 
-3
.0
0 
22
.0
9 
S 
  
 
151 
T
ab
le
 6
.3
 (c
on
tin
ue
d)
 
Pr
ot
ei
n 
Pe
pt
id
e 
Se
qu
en
ce
 
M
as
s 
pp
m
 
-1
0l
gP
 
R
eg
io
ns
  
EA
A
1 
23
2-
24
6 
M
.V
PV
PG
SV
N
G
V
N
A
LG
L.
V
 
13
91
.7
8 
18
7 
48
.0
1 
S 
EA
A
1 
23
1-
24
6 
E.
M
V
PV
PG
SV
N
G
V
N
A
LG
L.
V
 
15
22
.8
2 
0.
90
 
20
.0
6 
S 
EA
A
1 
23
0-
24
6 
E.
E(
-1
8.
01
)M
V
PV
PG
SV
N
G
V
N
A
LG
L.
V
 
16
33
.8
5 
-3
7.
1 
43
.6
6 
S 
EA
A
1 
23
0-
24
6 
E.
EM
V
PV
PG
SV
N
G
V
N
A
LG
L.
V
 
16
51
.8
6 
88
.9
 
21
.1
1 
S 
EA
A
1 
23
0-
24
6 
E.
EM
(+
15
.9
9)
V
PV
PG
SV
N
G
V
N
A
LG
L.
V
 
16
67
.8
6 
-2
7.
8 
38
.6
7 
S 
EA
A
1 
42
9-
44
7 
T.
IS
IT
A
TA
A
SI
G
A
A
G
IP
Q
A
G
.L
 
16
68
.9
1 
72
.5
 
53
.4
4 
S 
EA
A
2 
10
2-
10
8 
L.
IT
G
LS
G
L.
D
 
65
9.
39
 
92
.5
 
28
.0
2 
S 
EA
A
2 
77
-8
5 
M
.L
IA
FP
G
D
IL
.M
 
95
7.
55
 
32
0 
39
.3
3 
S 
EA
A
2 
43
9-
45
0 
A
.A
SI
PS
A
G
LV
TM
L.
L 
11
58
.6
3 
50
.9
 
32
.9
3 
S 
EA
A
2 
43
4-
44
8 
L.
A
SI
G
A
A
SI
PS
A
G
LV
T.
M
 
13
13
.7
2 
36
4 
45
.2
 
S 
EA
A
2 
35
8-
37
1 
A
.L
G
TA
SS
A
G
TL
PV
TF
.R
 
13
20
.6
9 
21
7 
42
.9
8 
S 
EA
A
2 
25
2-
26
4 
F.
G
IA
M
G
K
M
G
EQ
A
K
L.
M
 
13
32
.6
9 
41
6 
23
.3
2 
S 
EA
A
2 
35
5-
37
0 
W
.IT
A
LG
TA
SS
A
G
TL
PV
T.
F 
14
58
.7
9 
12
5 
57
.0
4 
S 
EA
A
2 
35
5-
37
1 
W
.IT
A
LG
TA
SS
A
G
TL
PV
TF
.R
 
16
05
.8
6 
94
.5
 
53
.9
1 
S 
EN
O
A
 
13
8-
15
0 
L.
A
G
N
PE
V
IL
PV
PA
F.
N
 
13
22
.7
2 
55
.4
 
27
.3
5 
S 
EN
O
G
 
14
3-
15
0 
D
.L
IL
PV
PA
F.
N
 
86
8.
54
 
85
0 
37
.6
9 
S 
G
PM
6A
 
21
8-
22
7 
A
.L
A
G
A
G
A
A
V
IA
.M
 
81
2.
48
 
18
1 
25
.4
6 
S 
G
PM
6A
 
10
5-
11
3 
F.
FT
TG
A
IK
D
L.
Y
 
96
4.
52
 
17
.0
 
23
.9
8 
S 
H
2A
2C
/H
2A
2A
 
10
1-
11
4 
K
.V
TI
A
Q
G
G
V
LP
N
IQ
A
.V
 
13
79
.7
8 
14
5 
46
.2
5 
S 
H
2A
2C
/H
2A
2A
 
99
-1
13
 
L.
G
(+
42
.0
1)
K
V
TI
A
Q
G
G
V
LP
N
IQ
.A
 
15
35
.8
7 
-1
25
 
26
.1
9 
S 
H
2A
2C
/H
2A
2A
 
99
-1
14
 
L.
G
(+
42
.0
1)
K
V
TI
A
Q
G
G
V
LP
N
IQ
A
.V
 
16
06
.9
0 
67
.4
 
48
.3
5 
S 
H
2A
2C
/H
2A
2A
 
99
-1
14
 
L.
G
K
(+
42
.0
1)
V
TI
A
Q
G
G
V
LP
N
IQ
A
.V
 
16
06
.9
0 
85
.0
 
44
.7
8 
S 
H
B
A
 
35
-4
4 
F.
A
SF
PT
TK
TY
F.
P 
11
61
.5
7 
90
.6
 
37
.5
7 
S 
H
B
A
 
38
-4
7 
F.
PT
TK
TY
FP
H
F.
D
 
12
37
.6
1 
26
5 
37
.6
9 
S 
H
B
A
 
11
1-
12
3 
L.
A
SH
H
PA
D
FT
PA
V
H
.A
 
13
85
.6
5 
4.
10
 
46
.2
2 
S,
H
 
H
B
A
 
35
-4
7 
F.
A
SF
PT
TK
TY
FP
H
F.
D
 
15
42
.7
5 
10
4 
47
.8
4 
S 
H
B
B
1/
H
B
B
2 
34
-4
0 
L.
V
V
Y
PW
TQ
.R
 
89
1.
45
 
18
2 
21
.6
8 
S 
H
B
B
1/
H
B
B
2 
34
-4
2 
L.
V
V
Y
PW
TQ
R
Y
.F
 
12
10
.6
1 
11
6 
28
.1
8 
S 
  
 
152 
T
ab
le
 6
.3
 (c
on
tin
ue
d)
 
Pr
ot
ei
n 
Pe
pt
id
e 
Se
qu
en
ce
 
M
as
s 
pp
m
 
-1
0l
gP
 
R
eg
io
ns
  
K
A
P3
 
2-
12
 
M
.S
(+
42
.0
1)
IE
IP
A
G
LT
EL
.L
 
11
83
.6
3 
35
.8
 
34
.2
1 
S 
M
A
L 
46
-5
4 
L.
V
PL
PL
A
Q
G
W
.V
 
97
9.
55
 
10
0 
27
 
S 
M
A
L 
44
-5
3 
S.
SL
V
PL
PL
A
Q
G
.W
 
99
3.
59
 
11
9 
30
.3
8 
S 
M
A
L 
44
-5
4 
S.
SL
V
PL
PL
A
Q
G
W
.V
 
11
79
.6
7 
18
0 
48
.5
7 
S 
M
A
P6
 
84
4-
85
4 
D
.P
IIP
V
PL
K
G
Q
D
.P
 
11
75
.6
9 
62
.3
 
25
.0
5 
S 
M
B
P 
is
of
or
m
 4
 
10
6-
11
3 
Q
.D
EN
PV
V
H
F.
F 
95
5.
44
 
32
2 
22
.0
6 
S 
M
B
P 
is
of
or
m
 4
 
21
-2
9 
M
.D
H
A
R
H
G
FL
P.
R
 
10
48
.5
2 
-3
.9
0 
20
.6
7 
S 
M
B
P 
is
of
or
m
 4
 
10
5-
11
3 
T.
Q
(-1
7.
03
)D
EN
PV
V
H
F.
F 
10
66
.4
7 
-3
9.
3 
29
.2
1 
S 
M
B
P 
is
of
or
m
 4
 
34
-4
3 
D
.T
G
IL
D
SI
G
R
F.
F 
10
77
.5
8 
18
9 
47
.9
1 
S 
M
B
P 
is
of
or
m
 4
 
2-
14
 
M
.A
(+
42
.0
1)
SQ
K
R
PS
Q
R
SK
Y
L.
A
 
15
89
.8
6 
19
0 
22
.5
3 
S 
M
B
P 
is
of
or
m
 4
 
12
0-
13
5 
T.
PR
TP
PP
SQ
G
K
G
R
G
LS
L.
S 
16
46
.9
2 
47
.8
 
55
.6
9 
S 
M
B
P 
is
of
or
m
 4
 
12
0-
13
5 
T.
PR
TP
PP
SQ
G
K
G
R(
+1
4.
02
)G
LS
L.
S 
16
60
.9
4 
36
9 
31
.2
 
S 
M
B
P 
is
of
or
m
 4
 
11
7-
13
5 
N
.IV
TP
RT
PP
PS
Q
G
K
G
R
G
LS
L.
S 
19
60
.1
2 
19
7 
26
.9
7 
S 
M
D
H
M
 
43
-5
4 
L.
LL
K
N
SP
LV
SR
LT
.L
 
13
39
.8
2 
53
9 
33
.3
3 
S 
M
D
H
M
 
25
-4
1 
N
.A
K
V
A
V
LG
A
SG
G
IG
Q
PL
S.
L 
15
23
.8
7 
-1
05
 
30
.7
1 
S 
M
D
H
M
 
25
-4
2 
N
.A
K
V
A
V
LG
A
SG
G
IG
Q
PL
SL
.L
 
16
36
.9
5 
68
.9
 
50
.6
2 
S 
M
O
G
 
21
2-
22
2 
F.
V
IV
PV
LG
PL
V
A
.L
 
10
75
.7
0 
13
8 
28
.1
 
S 
M
Y
PR
 
20
8-
21
5 
Y
.G
V
LP
W
N
A
F.
P 
90
2.
47
 
17
8 
31
.5
 
S 
M
Y
PR
 
62
-6
9 
L.
IN
V
IH
A
FQ
.Y
 
94
0.
51
 
15
4 
38
.1
6 
S 
N
C
A
M
1 
52
0-
53
2 
Q
.F
D
EP
EA
TG
G
V
PI
L.
K
 
13
43
.6
6 
13
7 
50
.9
7 
S 
PG
A
M
1/
PG
A
M
2 
20
8-
21
7 
E.
LN
LP
TG
IP
IV
.Y
 
10
35
.6
3 
26
5 
35
.1
3 
S 
PG
A
M
1/
PG
A
M
2 
20
8-
21
8 
E.
LN
LP
TG
IP
IV
Y
.E
 
11
98
.7
0 
16
7 
33
.0
6 
S 
PG
A
M
1/
PG
A
M
2 
20
8-
21
9 
E.
LN
LP
TG
IP
IV
Y
E.
L 
13
27
.7
4 
14
4 
41
.9
6 
S 
PG
A
M
1/
PG
A
M
2 
20
8-
22
0 
E.
LN
LP
TG
IP
IV
Y
EL
.D
 
14
40
.8
2 
12
.9
 
20
.2
3 
S 
PG
K
1 
17
9-
18
9 
G
.V
N
LP
Q
K
A
G
G
FL
.M
 
11
42
.6
5 
86
.4
 
32
.8
5 
S 
PG
K
1 
40
3-
41
7 
L.
LE
G
K
V
LP
G
V
D
A
LS
N
V
 
15
09
.8
4 
58
.6
 
39
.1
8 
S 
PR
D
13
 
53
5-
55
9 
L.
SG
PA
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
IG
PA
EL
.G
 
19
76
.0
3 
-3
52
 
35
.9
8 
S 
PR
D
X
5 
51
-6
4 
A
.P
IK
V
G
D
A
IP
SV
EV
F.
E 
14
69
.8
1 
12
.9
 
27
.4
 
S 
  
 
153 
Ta
bl
e 
6.
3 
(c
on
tin
ue
d)
 
Pr
ot
ei
n 
Pe
pt
id
e 
Se
qu
en
ce
 
M
as
s 
pp
m
 
-1
0l
gP
 
R
eg
io
ns
  
PR
D
X
5 
50
-6
4 
M
.A
PI
K
V
G
D
A
IP
SV
EV
F.
E 
15
40
.8
5 
16
8 
59
.3
 
S 
PR
D
X
6 
91
-1
04
 
N
.G
ET
PT
EK
LP
FP
IID
.D
 
15
55
.8
1 
13
7 
38
.9
 
S 
SC
61
B
 
62
-7
5 
E.
D
SP
G
LK
V
G
PV
PV
LV
.M
 
13
75
.8
1 
16
7 
51
.4
7 
S 
SC
A
M
5 
2-
12
 
M
.A
(+
42
.0
1)
EK
V
N
N
FP
PL
P.
K
 
12
66
.6
6 
37
 
29
.5
7 
S 
SC
A
M
5 
2-
19
 
M
.A
(+
42
.0
1)
EK
V
N
N
FP
PL
PK
FI
PL
K
P.
C
 
20
90
.1
9 
19
2 
37
.7
9 
S 
SO
D
C
 
13
-2
1 
D
.G
PV
Q
G
TI
H
F.
E 
95
4.
49
 
20
2 
31
.2
4 
S 
SO
D
C
 
11
-2
1 
K
.G
D
G
PV
Q
G
TI
H
F.
E 
11
26
.5
4 
49
.5
 
24
.8
 
S 
SY
PH
 
7-
13
 
D
.M
(+
42
.0
1)
D
V
V
N
Q
L.
V
 
85
9.
41
 
51
5 
31
.1
6 
S 
SY
PH
 
71
-7
7 
E.
FE
Y
PF
R
L.
H
 
97
0.
49
 
14
5 
21
.9
8 
S 
SY
PL
1 
23
-3
5 
F.
Q
(-1
7.
03
)I
N
LN
PL
K
EP
LG
F.
I 
14
64
.8
0 
14
0 
53
.2
1 
S 
TB
B
6 
78
-9
0 
R
.S
G
PF
G
Q
LF
R
PD
N
F.
I 
14
80
.7
1 
95
.7
 
30
.3
5 
S 
T
hy
m
os
in
 β
-4
 
En
tir
e 
Pr
ot
ei
n 
[a
c-
SD
K
PD
M
A
EI
EK
FD
K
SK
LK
K
TE
TQ
 
EK
N
PL
PS
K
ET
IE
Q
EK
Q
A
G
ES
] 
49
64
.6
7 
22
8 
 
H
,S
 
TO
M
22
 
2-
19
 
M
.A
(+
42
.0
1)
A
A
V
A
A
A
G
A
G
EP
LS
PE
EL
.L
 
16
64
.8
3 
70
.5
 
55
.7
 
S 
TO
M
22
 
2-
20
 
M
.A
(+
42
.0
1)
A
A
V
A
A
A
G
A
G
EP
LS
PE
EL
L.
P 
17
77
.9
1 
-3
5.
2 
47
.6
1 
S 
U
B
B
/U
B
C
 
5-
15
 
F.
V
K
TL
TG
K
TI
TL
.E
 
11
73
.7
3 
11
2 
53
.1
4 
S 
U
B
B
/U
B
C
 
4-
15
 
I.F
V
K
TL
TG
K
TI
TL
.E
 
13
20
.8
0 
16
5 
35
.4
5 
S 
U
B
B
/U
B
C
 
28
-4
5 
K
.A
K
IQ
D
K
EG
IP
PD
Q
Q
R
LI
F.
A
 
20
95
.1
4 
97
.6
 
27
.0
1 
S 
V
A
TL
 
94
-1
04
 
L.
G
A
G
LS
V
G
LS
G
L.
A
 
92
9.
52
 
22
2 
42
.5
3 
S 
V
A
TL
 
94
-1
06
 
L.
G
A
G
LS
V
G
LS
G
LA
A
.G
 
10
71
.5
9 
33
8 
25
.0
9 
S 
V
A
TL
 
94
-1
07
 
L.
G
A
G
LS
V
G
LS
G
LA
A
G
.F
 
11
28
.6
1 
13
6 
51
.5
6 
S 
V
A
TL
 
94
-1
09
 
L.
G
A
G
LS
V
G
LS
G
LA
A
G
FA
.I 
13
46
.7
2 
10
4 
58
.9
5 
S 
V
A
TL
 
2-
14
 
M
.A
(+
42
.0
1)
D
IK
N
N
PE
Y
SS
F.
F 
14
25
.6
4 
82
.1
 
50
.0
2 
S 
V
G
LU
1 
35
3-
36
3 
T.
IIV
PI
G
G
Q
IA
D
.F
 
10
94
.6
3 
-1
2.
0 
31
.4
1 
S 
V
PP
1 
50
9-
51
8 
L.
Q
(-1
7.
03
)L
N
PA
IP
G
V
F.
G
 
10
37
.5
6 
16
3 
21
.2
7 
S 
V
PP
1 
51
2-
52
5 
N
.P
A
IP
G
V
FG
G
PY
PF
G
.I 
13
74
.7
0 
14
3 
21
.6
9 
S 
V
PP
1 
51
2-
52
7 
N
.P
A
IP
G
V
FG
G
PY
PF
G
ID
.P
 
16
02
.8
1 
77
.1
 
57
.0
3 
S 
(.)
 in
di
ca
te
s 
cl
ea
va
ge
 s
ite
; [
 ]
 id
en
tif
ic
at
io
n 
ba
se
d 
on
 m
as
s 
m
at
ch
 o
nl
y;
 M
as
s:
 o
bs
er
ve
d 
m
on
oi
so
to
pi
c 
m
as
s 
or
 o
bs
er
ve
d 
av
er
ag
e 
m
as
s 
fo
r 
m
as
s 
m
at
ch
es
; p
pm
: 
di
ffe
re
nc
e 
(in
 p
ar
ts
 p
er
 m
ill
io
n)
 b
et
w
ee
n 
th
e 
th
eo
re
tic
al
 a
nd
 o
bs
er
ve
d 
pe
pt
id
e 
m
as
s;
 -
10
lg
P 
in
di
ca
te
s 
co
nf
id
en
ce
 i
n 
th
e 
se
qu
en
ce
 a
ss
ig
nm
en
t, 
R
eg
io
ns
: b
ra
in
 
re
gi
on
s i
n 
w
hi
ch
 p
ep
tid
es
 w
er
e 
de
te
ct
ed
, H
-h
yp
to
th
al
am
us
, S
-s
tri
at
um
.  
